



REVIEW ARTICLE OPEN

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Yuan Cheng¹, Cai He¹, Manni Wang¹, Xuelei Ma¹, Fei Mo¹, Shengyong Yang¹, Junhong Han¹ and Xiawei Wei¹

Epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence. Epigenetic dysregulation is often linked to human disease, notably cancer. With the development of various drugs targeting epigenetic regulators, epigenetic-targeted therapy has been applied in the treatment of hematological malignancies and has exhibited viable therapeutic potential for solid tumors in preclinical and clinical trials. In this review, we summarize the aberrant functions of enzymes in DNA methylation, histone acetylation and histone methylation during tumor progression and highlight the development of inhibitors of or drugs targeted at epigenetic enzymes.

Signal Transduction and Targeted Therapy (2019)4:62; <https://doi.org/10.1038/s41392-019-0095-0>

INTRODUCTION

After the discovery of DNA and the double helix structure, classic genetics has long assumed that the sequences of DNA determine the phenotypes of cells. DNA is packaged as chromatin in cells, with nucleosomes being the fundamental repeating unit. Four core histones (H2A, H2B, H3, and H4) form an octamer and are then surrounded by a 147-base-pair (bp) segment of DNA. Nucleosomes are separated by 10–60 bp DNA. Researchers have gradually found organisms that share the same genetic information but have different phenotypes, such as somatic cells from the same individual that share a genome but function completely differently. The term epigenetics was first proposed and established in 1942 when Conrad Waddington tried to interpret the connection between genotype and phenotype.¹ Later, Arthur Riggs and his group interpreted epigenetics as inherited differences in mitosis and meiosis, which could explain the changes in phenotypes. They were both trying to find the link between genotype and phenotype. Epigenetics is usually referred to as a genomic mechanism that reversibly influences gene expression without altering DNA sequences. Holliday assumed that epigenetics was also mitotically and/or meiotically heritable without DNA sequence change. Aberrant DNA methylation could be repaired via meiosis, but some patterns are still transmitted to offspring.² This phenomenon covers a wide range of cellular activities, such as cell growth, differentiation, and disease development, and is heritable.³ Generally, epigenetic events involve DNA methylation, histone modification, the readout of these modifications, chromatin remodeling and the effects of noncoding RNA. The elements involved in different modification patterns can be divided into three roles, “writer,” “reader,” and “eraser”. The “writers” and “erasers” refer to enzymes that transfer or remove chemical groups to or from DNA or histones, respectively. “Readers” are proteins that can recognize the modified DNA or histones (Fig. 1). To coordinate multiple

biological processes, the epigenome cooperates with other regulatory factors, such as transcription factors and noncoding RNAs, to regulate the expression or repression of the genome. Epigenetics can also be influenced by cellular signaling pathways and extracellular stimuli. These effects are temporary and yet long-standing. Given the importance of epigenetics in influencing cell functions, a better understanding of both normal and abnormal epigenetic processes can help to understand the development and potential treatment of different types of diseases, including cancer.

The etiology of cancer is quite complicated and involves both environmental and hereditary influences. In cancer cells, the alteration of genomic information is usually detectable. Like genome instability and mutation, epigenome dysregulation is also pervasive in cancer (Fig. 2). Some of the alterations determine cell function and are involved in oncogenic transformation.⁴ However, by reversing these mutations by drugs or gene therapy, the phenotype of cancer can revert to normal. Holliday proposed a theory that epigenetic changes are responsible for tumorigenesis. The alteration of cellular methylation status by a specific methyltransferase might explain the differences in the probability of malignant transformation.⁵ In clinical settings, we noticed that although cancer patients share the same staging and grade, they present totally different outcomes. In tumor tissues, different tumor cells show various patterns of histone modification, genome-wide or in individual genes, indicating that epigenetic heterogeneity exists at a cellular level.⁶ Likewise, using molecular biomarkers is thought to be a potential method to divide patients into different groups. It is important to note that tumorigenesis is the consequence of the combined action of multiple epigenetic events. For example, the repression of tumor suppressor genes is usually caused by methylation of DNA CpG islands together with hypoacetylated and hypermethylated histones.⁷ During gene silencing, several hallmarks of epigenetic events have been

¹Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China

Correspondence: Xiawei Wei (xiaweiwei@scu.edu.cn)

These authors contributed equally: Yuan Cheng, Cai He

Received: 14 July 2019 Revised: 16 October 2019 Accepted: 24 October 2019

Published online: 17 December 2019




Fig. 1 Epigenetic regulation of DNA methylation, histone acetylation, and histone methylation. Gene silencing in mammalian cells is usually caused by methylation of DNA CpG islands together with hypoacetylated and hypermethylated histones. The “writers” (DNMTs, HATs, and HMTs) and “erasers” (DNA-demethylating enzymes, HDACs, and KDMs) are enzymes responsible for transferring or removing chemical groups to or from DNA or histones; MBDs and other binding proteins are “readers” that recognize methyl-CpGs and modified histones. DNMTs, DNA methyltransferases; MBDs, methyl-CpG binding domain proteins; HATs, histone acetylases; HDACs, histone deacetylases; HMTs, histone methyltransferases; KDMs, histone-demethylating enzymes.

identified, including histone H3 and H4 hypoacetylation, histone H3K9 methylation, and cytosine methylation.^{8,9}

Therefore, epigenetics enables us to investigate the potential mechanism underlying cancer phenotypes and provides potential therapy options. In this review, we focused and briefly expanded on three aspects of epigenetics in cancer: DNA methylation, histone acetylation and histone methylation. Finally, we summarized the current developments in epigenetic therapy for cancers.

DNA METHYLATION

The DNA methylation pattern in mammals follows certain rules. Germ cells usually go through a stepwise demethylation to ensure global repression and suitable gene regulation during embryonic development. After implantation, almost all CpGs experience de novo methylation except for those that are protected.¹⁰ Normal dynamic changes in DNA methylation and demethylation based on altered expression of enzymes have been known to be associated with aging.^{11,12} However, inappropriate methylation of DNA can result in multiple diseases, including inflammatory diseases, precancerous lesions, and cancer.^{13–15} Of note, de novo methylation of DNA in cancer serves to prevent reactivation of repressed genes rather than inducing gene repression.¹⁶ Because researchers have found that over 90% of genes undergoing de novo methylation in cancer are already in a repressed status in normal cells.¹⁷ Nevertheless, aberrant DNA methylation is thought to serve as a hallmark in cancer development by inactivating gene

transcription or repressing gene transcription and affecting chromatin stability.¹⁸

The precise mechanism by which DNA methylation affects chromatin structure unclear, but it is known that methyl-DNA is closely associated with a closed chromatin structure, which is relatively inactive.¹⁹ Hypermethylation of promoters and hypomethylation of global DNA are quite common in cancer. It is widely accepted that gene promoters, especially key tumor suppressor genes, are unmethylated in normal tissues and highly methylated in cancer tissues.²⁰ P16, a tumor suppressor encoded by CDKN2A, has been found to gain de novo methylation in ~20% of different primary neoplasms.²¹ Mutations in important and well-studied tumor-suppressive genes, such as P53 and BRCA1, are frequently identified in multiple cancers.^{22–24} Studies have found that the level of methylation is positively associated with tumor size. In support of this, a whole-genome methylation array analysis in breast cancer patients found significantly increased CpG methylation in FES, P2RX7, HSD17B12, and GSTM2 coincident with increasing tumor stage and size.²⁵ After analysis of long-range epigenetic silencing at chromosome 2q14.2, methylation of EN1 and SCTR, the first well-studied example of coordinated epigenetic modification, was significantly increased in colorectal and prostate cancers.^{26,27} EN1 methylation has also been observed to be elevated by up to 60% in human salivary gland adenoid cystic carcinoma.²⁸ Of note, only ~1% of normal samples exhibited EN1 CpG island hypermethylation.²⁶ Therefore, the significant difference between cancer cells and normal cells makes EN1 a potential cancer marker in diagnosis. In human pancreatic




Fig. 2 Epigenetic regulations in cancer. Alterations in epigenetic modifications in cancer regulate various cellular responses, including cell proliferation, apoptosis, invasion, and senescence. Through DNA methylation, histone modification, chromatin remodeling, and noncoding RNA regulation, epigenetics play an important role in tumorigenesis. These main aspects of epigenetics present reversible effects on gene silencing and activation via epigenetic enzymes and related proteins. DNMTs, DNA methyltransferases; TETs, ten-eleven translocation enzymes; HATs, histone acetylases; HDACs, histone deacetylases; HMTs, histone methyltransferases; HDMs, histone-demethylating enzymes. MLL, biphenotypic (mixed lineage) leukemia.

cancer, the APC gene, encoding a regulator of cell junctions, is hypermethylated by DNMT overexpression.²⁹ During an analysis of colorectal disease methylation patterns, researchers found several genes that showed significant changes between precancerous diseases and cancers, including RUNX3, NEUROG1, CACNA1G, SFRP2, IGF2 DMR0, hMLH1, and CDKN2A.³⁰ In the human colon cancer cell line HCT116, hMLH1 and CDKN2A always bear genetic mutation and hypermethylation of one allele, and this leads to inactivation of key tumor suppressors.³¹ It is known that p16, p15, and pax6 are usually aberrantly methylated in bladder cancer and show enhanced methylation in cell culture.³² Unlike gene promoter methylation, gene body methylation usually results in increased transcriptional activity.³³ This process often occurs in CpG-poor areas and causes a base transition from C to T.³⁴ The hypermethylation of specific CpG islands in cancer tissues is informative of mutations when the gene in normal tissues is unmethylated. One representative marker is glutathione S-transferase- π (GSTP1), which is still the most common alteration in human prostate cancer.³⁵ Recently, DNA methylation in cancer has generally been associated with drug resistance and predicting response to treatment.³⁶ For example, MGMT (O-6-methylguanine DNA methyltransferase) hypermethylation is still the best

independent predictor of response to BCNU (carmustine) and temozolomide in gliomas because hypermethylation of MGMT makes tumor cells more sensitive to treatments and is associated with regression of tumor and prolonged overall survival.^{37,38} Similarly, MGMT is also a useful predictor of response to cyclophosphamide in diffuse large B-cell lymphoma³⁹ (Table 1).

DNA methyltransferases (DNMTs)

DNA methylation is a covalent modification of DNA and is one of the best-studied epigenetic markers. It plays an important role in normal cell physiology in a programmed manner. The best-known type of DNA methylation is methylation of cytosine (C) at the 5th position of its carbon ring (5-mC), especially at a C followed by a guanine (G), so-called CpG sites. Non-CpG methylation, such as methylation of CpA (adenine) and CpT (thymine), is not common and usually has restricted expression in mammals.⁴⁰ CpG islands traverse ~60% of human promoters, and methylation at these sites results in obvious transcriptional regression.⁴¹ Meanwhile, among the ~28 million CpGs in the human genome in somatic cells, 60–80% are methylated in a symmetric manner and are frequently found in promoter regions.^{42,43} The process of DNA methylation is regulated by the DNA methyltransferase (DNMT)

Table 1. Key regulatory factors of DNA methylation in cancer.

Enzyme	Roles in cancer	Cancer type	Associated biological process (involved mechanism and molecules)
<i>DNA methyltransferases</i>			
DNMT1: DNMT1 is responsible for maintenance of DNA methylation and is expressed at high concentrations in dividing cells to guard existing methylated sites.			
	Promoter	AML, CML, cervical cancer, colorectal cancer, glioma, lung cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, breast cancer, esophageal cancer, bladder cancer, prostate cancer, thyroid cancer, ovarian cancer ^{92–100}	Promotes EMT phenotype, cell apoptosis, cell proliferation, migration, cancer stemness, and cisplatin sensitivity (β -catenin, E-cadherin, PTEN, p18, p27, P21, P16, miR-124, miR-148a, miR-152, miR-185, miR-506), DNMT1 is also upregulated by <i>Helicobacter pylori</i> CagA
	Suppressor	Prostate cancer, cervical cancer ^{101,102}	Cell migration, EMT and stem cell potential
DNMT3a: DNMT3a methylates unmethylated DNA de novo and is required for maternal imprinting at different methylated regions.			
	Promoter	Cervical cancer, CML, breast cancer, gastric cancer, prostate cancer, ovarian cancer, bone cancer, testicular cancer ^{52,103–107}	Promotes cell proliferation and invasion. (VEGFA, Wnt/ β -catenin signaling, miR-182, miR-708-5p)
	Suppressor	Lymphoma, AML, breast cancer, colorectal cancer, lung cancer ^{108–110}	Low level of DNMT3a is associated with the poor survival of cancer patients and promotes tumor progression but not initiation
DNMT3b: DNMT3b is also responsible for de novo methylation and is required for methylation of centromeric minor satellite repeats and CGIs in inactive X chromosomes.			
	Promoter	CML, AML, glioma, lung cancer, breast cancer, gastric cancer, colorectal cancer, prostate cancer, pancreatic cancer, bladder cancer, cervical cancer ^{52,94,111–113}	Promotes cell proliferation, and invasion and the chemotherapy effects of cisplatin; is associated with poor prognosis (E-cadherin, PTEN, P21, P16, miR-29b, miR-124, miR-506)
	Suppressor	AML, bladder cancer ^{109,114}	Downregulation of DNMT3a is associated with poor prognosis
<i>Methyl-CpG binding proteins</i>			
MeCP2	Promoter	Prostate cancer, colorectal cancer, breast cancer, gastric cancer ^{115,116}	Promotes cell proliferation, invasion, metastasis, apoptosis, cell cycle arrest in the G0/G1 phase, chemotherapy effects, regulation of estrogen receptor status, involves the MEK1/2-ERK1/2 signaling pathway (miR-638, miR-212)
	Suppressor	Pancreatic cancer ¹¹⁷	Decreased expression of MeCP2 contributes to cancer development
MBD1	Promoter	Pancreatic cancer, prostate cancer ^{118,119}	Promotes cell EMT, proliferation, invasion, and metastasis and the chemoradioresistance of cancer cells and induces an antioxidant response (E-cadherin)
MBD2	Promoter	Lung cancer, colon cancer, breast cancer, prostate cancer ^{94,120–122}	Promotes cell invasion and metastasis (p14)
MBD4	Promoter	Colon cancer, breast cancer ^{123,124}	Causes dominant negative impairment of DNA repair
KAISO (ZBTB33)	Promoter	Colon cancer, cervical cancer, prostate cancer, ovarian cancer, lung cancer, breast cancer, and chronic myeloid leukemia ^{125–128}	Silencing of tumor suppressor genes, EMT, apoptosis, migration and invasion (Wnt/ β -catenin, TGF β , EGFR, Notch, miR-4262, miR-31)
ZBTB4	Suppressor	Breast cancer, Ewing sarcoma, prostate cancer, bladder cancer ^{77,129–131}	Promotes cell growth and apoptosis and controls the cellular response to p53 activation, promoting long-term cell survival (miR-17-92/106b-25)
ZBTB38	Promoter	Bladder cancer ¹³²	Promotes cell migration and invasion (Wnt/ β -catenin pathway)
UHRF1	Promoter	Hepatocellular carcinoma, bladder cancer, renal cell carcinoma, lung cancer, retinoblastoma, intrahepatic cholangiocarcinoma, colon cancer, pancreatic cancer, gastric cancer, prostate cancer, melanoma, hepatoblastoma, esophageal squamous cell carcinoma, cervical cancer, breast cancer, thyroid cancer ^{133–138}	Promotes cell proliferation, EMT, and viability, increases hypoxia inducible factor (HIF)1 α , CSCs, taxane resistance correlates with poor pathological characteristics, human papillomavirus (HPV) contributes to overexpression of UHRF1 (miR-101, miR-124, PI3K/Akt signaling pathway, MEK/ERK pathway)
UHRF2	Promoter	Intrahepatic cholangiocarcinoma, hepatocellular carcinoma, colon cancer ^{139,140}	Promotes cell migration and invasion, and is associated with lower disease-free survival
	suppressor	Colon cancer, lung cancer, esophageal carcinoma ^{141,142}	Low level of UHRF2 is associated with shorter overall survival, vascular invasion and poor prognosis
<i>DNA demethylases</i>			
TET1: TET1 is highly expressed in mouse embryonic stem cells, the inner cell mass of blastocysts, and developing PGCs.			
	Promoter	MLL-rearranged leukemia, AML, breast cancer, ovarian cancer, lung cancer, renal cancer ^{143–147}	TET1-MLL fusion, cell migration, anchorage-independent growth, cancer stemness, and tumorigenicity, prevention of senescence via loss of p53, associated with a worse overall survival and sensitivity to drugs (PI3K-mTOR pathway)
	Suppressor	Hematopoietic malignancy, hepatocellular carcinoma, prostate cancer, colon cancer, gastric cancer, breast cancer, nasopharyngeal carcinoma cells, ovarian cancer ^{90,148,149}	Promotes EMT and increases cancer cell growth, migration, and invasion (miR-21-5p, Wnt/ β -catenin signaling pathway, AKT and FAK pathways)
TET2/TET3: TET2 and TET3 are present in multiple mouse adult tissues, whereas only TET3 is present in mouse oocytes and one-cell zygotes			
TET2	Suppressor	MDS, AML, CML, prostate cancer, gastric cancer, breast cancer, colorectal cancer, ovarian cancer, hepatocellular carcinoma, leukemia ^{87,150–153}	Promotes cell proliferation, colony formation, metastasis, is associated with reduced patient survival, pathologic stage, tumor grading, lymph node metastasis, and vascular thrombosis (caspase-4, ET2/E-cadherin/ β -catenin regulatory loop)
TET3	Promoter	Renal cell carcinoma ¹⁵⁴	Acts as an independent predictor of poor outcome
	Suppressor	Head and neck cancer, ovarian cancer, breast cancer ^{155,156}	Is associated with EMT, overall survival, disease-free survival (miR-30d)

AML acute myeloid leukemia, CML chronic myeloid leukemia, EMT epithelial-mesenchymal transition, VEGFR vascular endothelial growth factor receptor

family via the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to cytosine.⁴⁴ There are five members of the DNMT family: DNMT1, DNMT2, DNMT3a, DNMT3b, and DNMT3L. DNMT1 is responsible for the maintenance of methyl-DNA, recognizes hemimethylated DNA strands and regenerates the

fully methylated DNA state of DNA during cell division.⁴⁵ In a recent study, DNMT1 with Stella, a factor essential for female fertility, was responsible for the establishment of the oocyte methylome during early embryo development.⁴⁶ DNMT3a and DNMT3b are regarded as de novo methylation enzymes that

target unmethylated CpG dinucleotides and establish new DNA methylation patterns, but they have nonoverlapping functions during different developmental stages.^{47,48} DNMT2 and DNMT3L are not regarded as catalytically active DNA methyltransferases. DNMT2 functions as an RNA methyltransferase, while DNMT3L contains a truncated inactive catalytic domain and acts as an accessory partner to stimulate the de novo methylation activity of DNMT3A. The DNA methyltransferase-like protein DNMT3L can modulate DNMT3a activity as a stimulatory factor.⁴⁹

During aberrant DNA methylation, DNMTs play an important role. Compared with DNMT1 and DNMT3a, DNMT3b was significantly overexpressed in tumor tissues.⁵⁰ Overexpression of DNMT1, DNMT3a, and DNMT3b has been observed in multiple cancers, including AML, CML, glioma, and breast, gastric, colorectal, hepatocellular, pancreatic, prostate, and lung cancers. In cervical cancer patients, DNMT1 was expressed in more than 70% of cancer cells, whereas only 16% of normal cells expressed DNMT1. The higher level of DNMT1 expression was also associated with worse prognosis.⁵¹ The expression of DNMT1, DNMT3a, and DNMT3b has been observed to be elevated in acute myeloid leukemia (AML) and various solid cancers. These three methyltransferases do not show significant changes in the chronic phase of chronic myeloid leukemia (CML), but they are significantly increased during progression to the acute phase in CML.^{52,53} Notably, downregulation of DNMTs can also lead to tumorigenesis (Table 1).

Methyl-CpG recognition proteins

How DNA methylation leads to gene repression has been considered in many studies. Several hypotheses have been proposed. Three methyl-CpG binding domain protein (MeCP) families can read the established methylated DNA sequences and in turn recruit histone deacetylases, a group of enzymes responsible for repressive epigenetic modifications, to inhibit gene expression and maintain genome integrity.^{10,54} The first group is methyl-CpG binding domain (MBD) proteins, including MeCP2, MBD1, MBD2, and MBD4. MeCP1 is a complex containing MBD2, the histone deacetylase (HDAC) proteins HDAC1 and HDAC2, and the RbAp46 and RbAp48 proteins (also known as RBBP7 and RBBP4).⁵⁵ MBD3 is unlike the other four family members and is not capable of binding to methylated DNA but instead binds to hydroxymethylated DNA.⁵⁶ The zinc-finger and BTB domain-containing protein family is the second group and comprises three structurally different proteins, KAISO (ZBTB33), ZBTB4 and ZBTB38, which bind to methylated DNA via zinc-finger motifs. The third family includes two ubiquitin-like proteins with PHD and RING finger domains, UHRF1 and UHRF2, which recognize 5-mC via RING finger-associated (SRA) domains. On the other hand, methylation of DNA can also be a barrier for certain transcription factors to bind to promoter sites such as *AP-2*, *c-Myc*, *CREB/ATF*, *E2F*, and *NF-κB*.¹³

As for methyl-group binding proteins, many studies have investigated their roles in various cancers, but the mechanism underlying these alterations remains unclear. MBD proteins cooperate with other proteins to regulate gene transcription.^{57,58} However, the role of MBD1 and MBD2 has not been identified in human lung or colon cancer, with only limited mutations being detected.⁵⁹ Furthermore, loss of MBD1 did not show any carcinogenic effect in *MBD-/-* mice.⁶⁰ Compared with MBD1, MBD2 shows more effect on tumorigenesis. Deficiency of MBD2 strongly suppresses intestinal tumorigenesis in *APC^{Min}*-background mice.⁶¹ A possible reason is that many important signaling pathways are downregulated in colorectal cancer, and loss of MBD2 leads to reexpression of these genes.⁶² Meanwhile, inhibition of MBD2 shows promising effects on suppression of the tumorigenesis of human lung cancer and colon cancer.⁶³ Although MBD3 does not directly bind to methylated DNA, it regulates the methylation process via interactions with other

proteins, such as MBD2 and HDAC. For example, application of an HDAC inhibitor in lung cancer cells upregulated p21 (also known as CDKN1A) and downregulated ErbB2, leading to inhibition of cancer cell growth. Silencing of MBD3 blocked the effects of an HDAC inhibitor.⁶⁴ MBD3 and MBD2 form a complex, nucleosome remodeling and deacetylase (NuRD), which interacts with histone-demethylating enzymes to regulate gene expression in cancer.⁶⁵ Mutation of MBD4 has been found in colorectal cancer, endometrial carcinoma and pancreatic cancer.⁶⁶ Furthermore, this mutation unexpectedly affects the stability of the whole genome, not only CpG sites.⁶⁷ Knockout of MBD4 indeed increased tumorigenesis in *APC^{Min}*-background mice, which makes MBD4 a tumor suppressor.⁶⁸ MBD4 is important in DNA damage repair, given the interaction between MBD4 and MMR.⁶⁹ In contrast, the expression of MeCP2 and the UHRF family tends to promote tumor growth.⁷⁰⁻⁷⁴ In the KAISO family, KAISO directly binds to p120^{ctn}, a protein with an alternative location in some cancer cells, and they together regulate cell adhesion and motility.^{75,76} However, deficiency of ZBTB4 contributes to tumorigenesis⁷⁷ (Table 1).

DNA-demethylating enzymes

DNA methylation is a stable and highly conserved epigenetic modification of DNA in many organisms.⁷⁸ However, loss of 5-mC and DNA demethylation have been identified in different biologic processes. For example, DNA demethylation is important for primordial germ cells (PGCs) to gain pluripotent ability.^{79,80} DNA demethylation is actively regulated by the TET protein family (ten-eleven translocation enzymes, TET1-3) via the removal of a methyl group from 5-mC. These three proteins differ from each other in terms of expression depending on the developmental stage and cell type.¹⁸ TETs oxidize 5-mC in an iterative manner and catalyze the conversion of 5-mC to 5-hydroxymethylcytosine (5-hmC), which is a key intermediate in the demethylation process.⁸¹ 5-hmC, as a relatively stable intermediate substrate, is less prone to further oxidation by TET proteins than 5-mC.⁸² However, overexpression of only TET1 and TET2 can cause a global decrease of 5-mC.¹⁸ Stepwise oxidation of 5-hmC by TET proteins can yield two products: 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC).⁸³ These two molecules can be excised by thymine-DNA glycosylase (TDG) and eventually be repaired to unmodified C.⁸⁴ DNA demethylation or restoration of the unmodified cytosine can also occur passively through replication-dependent dilution of 5-mC.

Disruption of normal DNA demethylation is thought to be associated with oncogenesis. TET proteins were initially associated with leukemia. Researchers have found that in a small number of AML patients, TET1 is fused to MLL via the chromosome translocation t(10;11)(q22;q23).⁸⁵ Further studies found that TET2 was more widely expressed in different tissues than TET1 and TET3. Analyses revealed that mutation or deficiency of TET2 occurred in ~15% of patients with myeloid cancers, including myelodysplastic syndrome (MDS), myeloproliferative disorders, and AML.⁸⁶ In patients with CML, mutation of TET2 has been detected in ~50% of patients.⁸⁷ Although TET2 mutations have been found in several myeloid malignancies, their prognostic effect remains controversial. Based on the phenomenon that mutation of TET2 was elevated in patients whose disease transformed from chronic myeloid malignancy to AML, researchers considered that TET2 loss was important for cells to regain the ability to self-renew.⁸⁸ The role of TET proteins has also been investigated in several solid tumors. Compared with surrounding normal tissues, 5-hmC is significantly reduced in human breast, liver, lung, pancreatic, and prostate cancers with reduced expression of TET family proteins.⁸⁹ Deficiency of TET1 in prostate and breast cancer is associated with tumor cell invasion and breast xenograft tumor formation via the inhibition of the methylation of metalloproteinase (TIMP) family proteins 2 and

3.⁹⁰ Loss of 5-hmC is an epigenetic hallmark of melanoma, and thus, introducing TET2 into melanoma cells results in suppression of tumor growth and increased survival in an animal model⁹¹ (Table 1).

HISTONE MODIFICATION

Histone modification can occur to the flexible tails as well as the core domain of histones, including those sites that are buried by DNA. In particular, the flexible histone tails are enriched with basic Lys/Arg and hydroxyl group-containing Ser/Thr/Tyr residues, thereby being hotspots for hallmark histone modifications. The tails extend from the surface of the nucleosome and are readily modulated by covalent posttranslational modification (PTM). PTMs modify histones by adding or removing chemical groups and regulate many biological processes via the activation or inactivation of genes. These processes mainly include acetylation and methylation of lysines (K) and arginines (R), phosphorylation of serines (S) and threonines (T), ubiquitylation, and sumoylation of lysines. In addition to those mentioned and discussed above, histone modifications also include citrullination, ADP-ribosylation, deamination, formylation, O-GlcNAcylation, propionylation, butyrylation, crotonylation, and proline isomerization at over 60 amino acid residues.^{157,158} In addition to conventional PTMs, novel PTM sites are also found outside of the N-terminal tails.

Histone modifications at certain sites, such as promoters and enhancers, are thought to be largely invariant, whereas a small number of these sites remain dynamic. H3K4me1 and H3K27ac, two dynamic modifications, were identified to activate enhancers and regulate gene expression.¹⁵⁹ H3K9ac and H3K9me3 are two common modifications at promoters.^{160,161} Appropriate histone modifications are important in gene expression and human biology; otherwise, alterations in PTMs may be associated with tumorigenesis. Analysis of cancer cells reveals that they exhibit aberrant histone modifications at individual genes or globally at the single-nuclei level.^{6,162} Understanding histone modification patterns in cancer cells can help us to predict and treat cancers. Thus far, most studies have focused on aberrant modifications within an individual site, such as H4K20me3 or H4K16ac, rather than enzymatic activity-associated abnormalities. Generally, alterations in histone modifications occur at an early stage and accumulate during tumorigenesis.¹⁶³

Histone acetylation (lysine)

Histone acetylation occurs at multiple lysine residues at the N-terminus via the catalysis of histone acetyltransferases (HATs), also named lysine acetyltransferases (KATs). Histone acetylation regulates the compaction state of chromatin via multiple mechanisms, such as neutralizing the basic charge at unmodified lysine residues, and is associated with active transcription, especially at gene promoters and enhancers and the gene body; it also facilitates the recruitment of coregulators and RNA polymerase complexes to the locus.^{157,164} To date, HATs and histone deacetylases (HDACs) are the two of the best characterized groups of enzymes involved in histone PTMs. HATs transfer the acetyl groups from acetyl-CoA cofactors to lysine residues at histones, whereas the role of HDACs is the opposite, which makes histone acetylation a highly reversible process.

Histone acetyltransferases. HATs are predominantly located in the nucleus, but multiple lines of evidence have shown lysine acetylation in the cytoplasm, and their acetylation is associated with key cellular events.¹⁶⁵ In addition, lysine acetylation found outside histones reminds us of the role of HATs in nonhistone PTMs.¹⁶⁶ The first HAT was identified in yeast, and was named HAT1,¹⁶⁷ and was then isolated from tetrahymena as HAT A by Allis and coworkers.¹⁶⁸ In humans, HATs can be roughly divided into three groups: general control nondepressible 5 (GCN5)-

related N-acetyl transferase (GNAT) (based on the protein Gcn5 found in yeast; including GCN5 and PCAF), MYST (based on the protein MOZ; including MOZ, MOF, TIP60, and HBO1), and p300/cAMP-responsive element-binding protein (CBP).¹⁶⁹ Other HATs, including nuclear receptors and transcription factors, such as SRC1, MGEA5, ATF-2, and CLOCK, also harbor the ability to acetylate histones. Notably, a number of acetyltransferases also perform protein acetylation outside histones, such as TFIIIB, MCM3AP, ESCO, and ARD1.¹⁷⁰ Knockout of CBP/p300 is lethal for early embryonic mouse models.^{171,172} The acetyl group transfer strategies for each HAT subfamily are different. For the GCN5 and PCAF family, the protein crystal structure shows a conserved glutamate in the active site. Blockade of this amino leads to a significantly decreased acetylation function.^{173,174} Similarly, there is also a conserved glutamate plus a cysteine residue located at active sites of MYST family proteins.¹⁷⁵ Unlike the other two families, the p300/CBP HAT subfamily has two other potential conserved residues, a tyrosine and a tryptophan.¹⁷⁶ Generally, their catalytic mechanisms of acetyl group transfer can be divided into two groups. The GNAT family depends on a sequential ordered mechanism, whereas the members of the MYST family use a so-called ping-pong (i.e., double displacement) catalytic mechanism, which means that the acetyl groups are first transferred to a cysteine residue and then transferred to a lysine residue.¹⁷⁷ In addition to differences in the acetyl transfer mechanism, HAT subfamilies, even different proteins in the same family, also have remarkable diversity in targeting sites.

Appropriate acetylation within cells is important since upregulation or downregulation of HATs is associated with tumorigenesis or poor prognosis.^{162,178} Compared with solid tumors, the association between histone modifications and cancer has been widely investigated in hematological malignancies. Germline mutation of CBP results in Rubinstein-Taybi syndrome along with an increased predisposition to childhood malignancies. Meanwhile, loss of another family member, p300, has also been associated with hematological malignancies.^{179,180} Therefore, both CBP and p300 seem to function as tumor suppressors. During cancer development, the expression of HAT genes can be disrupted by chromosomal translocations, although these are rare events. Generation of the fused protein CBP-MOZ is the result of the t(8;16)(p11;p13) translocation in AML.¹⁸¹ Translocation of t(10;16)(q22;p13) leads to the CBP-MORF chimera.¹⁸² Similarly, p300-MOZ, MLL-CBP, and MLL-p300 (MLL, mixed lineage leukemia) have also been identified in hematological malignancies.¹⁸³⁻¹⁸⁵ Generally, chromosomal rearrangements involving CBP are more common than those involving p300. Researchers have also investigated solid tumors, which are less mutated. The expression of translocated P300 in laryngeal squamous cell carcinoma (LSCC) tissue is much higher than that in adjacent normal tissue and is associated with advanced stage and poor prognosis.¹⁷⁸ Missense point mutations in p300 are found in colorectal adenocarcinoma, gastric adenocarcinoma and breast cancer with quite low incidences.^{186,187} Rare inactivating mutations in CBP and PCAF have only been identified in cancer cell lines but not primary tumors.¹⁸⁸ Based on these findings, we hypothesize that the differences between cell lines and primary tumors cannot be ignored. Amplified in breast cancer 1 (AIB1), also frequently called NCOA3 (nuclear receptor coactivator 3) or SRC3 (steroid receptor coactivator 3), is overexpressed in ~60% of human breast cancers, and increased levels of AIB1 are associated with tamoxifen resistance and decreased overall survival.¹⁸⁹ Steroid receptor coactivator 1 (SRC1) is also associated with the chromosomal translocation t(2;2)(q35;p23), which results in PAX3-NCOA1 gene fusion in rhabdomyosarcoma without a consistent genetic abnormality during embryonic development¹⁹⁰ (Table 2).

Acetyl-lysine recognition proteins. The bromodomain (BRD) motif is an ~110-amino-acid conserved protein module and is regarded

Table 2. Important enzymes or proteins that regulate histone acetylation in cancer.

Enzyme	Synonym	Role in cancer	Cancer type	Associated biological process (involved mechanism and molecules)
<i>Histone acetylases: the writers</i>				
HAT1				
HAT1	/	Promoter	Pancreatic cancer, nasopharyngeal cancer, hepatocellular carcinoma, esophageal carcinoma ²²⁷⁻²³⁰	Promote cell apoptosis, proliferation, differentiation and cisplatin resistance, associated with poor prognosis and upregulates PD-L1
		Suppressor	Lung cancer, osteosarcoma ^{231,232}	Restores Fas expression and induces cancer cell apoptosis (Ras-ERK1/2 signaling)
<i>GANT</i>				
GCN5L2	GCN5	Promoter	Prostate cancer, breast cancer, non-small-cell lung cancer, colorectal cancer ²³³⁻²³⁵	Promotes cell proliferation, apoptosis, EMT, poor prognosis of patients, promotion of E2F1, cyclin D1, and cyclin E1 expression (PI3K/PTEN/Akt signaling, TGF- β /Smad signaling pathway)
PCAF	/	Suppressor	Colorectal cancer, gastric cancer, prostate cancer, breast cancer ²³⁶⁻²³⁸	Decreased PCAF is associated with 5-FU resistance, poor clinical outcome (PCAF-p16-CDK4 axis, p53, miR-17)
<i>MYST</i>				
HTATIP	TIP60	Promoter	Liver cancer, prostate cancer ^{239,240}	Promotes cancer cell EMT, metastasis, radioresistance
		Suppressor	Breast cancer, lung cancer, bladder cancer, colorectal cancer ²⁴¹⁻²⁴³	Is associated with cell viability and invasion, and low Tip60 expression is correlated with poor overall survival and relapse-free survival
MYST1	MOF	Promoter	Prostate cancer ²⁴⁴	MYST1 increases the resistance to therapeutic regimens and promotes aggressive tumor growth (androgen receptor and NF- κ B)
MYST2	HBO1	Promoter	Ovarian cancer, bladder cancer, breast cancer, pancreatic cancer, leukemia ²⁴⁵⁻²⁴⁷	Promotes cell proliferation, enrichment of cancer stem-like cells, gemcitabine resistance (Wnt/ β -catenin signaling)
MYST3	MOZ	Promoter	Colorectal cancer, breast cancer, leukemia ²⁴⁸⁻²⁵⁰	Promotes cell proliferation, activates ER α expression (multiple fusion proteins: MOZ-TIF2, MOZ-NCOA2 and MOZ-CBP)
MYST4	MORF	Promoter	Leukemia ²⁵¹	MORF-CREBBP fusion
p300/CBP				
P300	EP300, KAT3B	Promoter	Laryngeal squamous cell carcinoma, leukemia, nasopharyngeal carcinoma, hepatocellular carcinoma, cutaneous squamous cell carcinoma, head and neck squamous cell carcinoma, colorectal cancer, breast cancer, lung cancer, gastric cancer, prostate cancer, cervical cancer, pancreatic cancer ²⁵²⁻²⁵⁷	Promotes cell proliferation, migration, invasion, EMT, and malignant transformation, is associated with advanced clinical stage, poor recurrence-free survival and overall survival, enhances ER α expression and contributes to tamoxifen resistance, castration resistance, and gemcitabine sensitivity, p21, p27, β -catenin, MLL-p300, MOZ-p300 fusion, Smad2 and Smad3 in the TGF- β signaling pathway, p300/Y11/miR-500a-5p/HDAC2 signaling axis)
		Suppressor	Bladder cancer, colorectal cancer ^{258,259}	Downregulation of P300 is associated with chemosensitivity to 5-FU treatment and doxorubicin resistance
CBP	CREBBP, KAT3A	Promoter	Lung cancer, leukemia, gastric cancer, ovarian cancer, prostate cancer, hepatocellular carcinoma ²⁶⁰⁻²⁶²	Is associated with drug resistance, a highly tumorigenic, cancer stem-like phenotype and enhances the activity of estrogen receptor-beta (ER- β) (CXCL8, PI3K/Akt/ β -catenin/CBP axis); KAT6A-CREBBP, MOZ-CBP, MORF-CREBBP, MLL-CBP fusions in leukemia
		Suppressor	Lung cancer, prostate cancer ^{263,264}	Loss of CBP reduces transcription of cellular adhesion genes while driving tumorigenesis
<i>SRG/pi160</i>				
NCOA1	SRC1	Promoter	Prostate cancer, colon cancer, breast cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma ²⁶⁵⁻²⁶⁷	Promotes cell invasion, proliferation, metastasis, is associated with shorter overall survival and progression-free survival (M-CSF1, miR-4443, miR-105-1)
NCOA2	TIF2	Promoter	Prostate cancer, leukemia ^{268,269}	Is associated with resistance to AR antagonism and bicalutamide; MOZ-TIF2 fusion in leukemia
NCOA3	AIB1, ACTR	Suppressor	Colorectal cancer, liver cancer ^{270,271}	TIF2 is able to impair protumorigenic phenotypes
		Promoter	Ovarian cancer, breast cancer, bladder cancer, gastric cancer, lung cancer, prostate cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, colorectal cancer, pancreatic cancer ²⁷²⁻²⁷⁵	Promotes cell proliferation, EMT, metastasis, invasiveness and is correlated to higher estrogen receptor expression, poor PFS and OS and predicts resistance to chemoradiotherapy (Akt, E2F1, SNAI1, cyclin E, cdk2, p53, matrix metalloproteinase 2 (MMP2) and MMP9 expression); however, high AIB1 expression has been correlated to both a good response to adjuvant tamoxifen and tamoxifen resistance.

Table 2 continued

Enzyme	Synonym	Role in cancer	Cancer type	Associated biological process (involved mechanism and molecules)
Others				
ATF-2	CREB2, CREBP1	Promoter	Pancreatic cancer, lung cancer, renal cell carcinoma, leukemia ^{276–278}	Promotes cell proliferation, EMT, gemcitabine sensitivity (JNK1/c-Jun and p38 MAPK/ATF-2 pathways, miR-451); however, the level of ATF-2 is a key determinant of the sensitivity to tamoxifen
TFIIIC	/	Promoter	Ovarian cancer ²⁷⁹	TFIIIC is overexpressed in cancer tissues
TAF1	TAFII250	/	/	/
CLOCK	KIAA0334	Promoter	Ovarian cancer, breast cancer ^{280,281}	Promotes cell proliferation, migration, and invasion, is associated with drug resistance (cisplatin)
CIITA	MHC2TA	Suppressor	Lung cancer ²⁸²	Is associated with cancer progression and metastasis
MGEA5	NCOAT	Suppressor	Breast cancer, colorectal cancer, gastric cancer, head and neck cancer, hepatocellular carcinoma ^{283–285}	Regulates the expression of MHC II and HLA-DR induction
		promoter	Laryngeal cancer ²⁸⁶	Is associated with larger tumor size, nodal metastases, higher grade and tumor behavior (TGFB3-MGEA5 fusion)
		Suppressor	Breast cancer ²⁸⁷	MGEA5 transcript levels were significantly lower in grade II and III than in grade I tumors; associated with lymph node metastasis
CDY	/	/	/	/
<i>Acetyl-lysine binding protein: the readers</i>				
BRD and extraterminal domain (BET) proteins family				
BRD2-4,	/	Promoter	Breast cancer, prostate cancer, gastric tumors, lung cancer, ovarian carcinoma, pancreatic cancer, hematologic malignancy, Ewing sarcoma, glioblastoma, melanoma ^{288–291}	Is associated with cell proliferation, self-renewal, metabolism, metastasis, and expression of immune checkpoint molecules (oncogenic AR and MYC signaling, AMIGO2-PTK7 axis, Jagged1/Notch1 signaling, IKK activity)
<i>Histone deacetylases (HDACs): the erasers</i>				
HDAC Class I				
HDAC1	/	Promoter	Thyroid cancer, lung cancer, ovarian cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, gallbladder cancer, prostate cancer, gastric cancer ^{292–295}	Promotes cell invasion, viability, apoptosis, EMT; is associated with chemotherapy response. (CXCL8, P53, p38 MAPK, miRNA-34a)
HDAC2	/	Promoter	Pancreatic cancer, colorectal cancer, lung cancer, squamous cell carcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, renal carcinoma, ovarian cancer, gastric cancer ^{296–300}	Promotes cell proliferation, metastasis, invasion, clonal expansion and EMT (E-cadherin, p63, mTORC1, AKT, PELP1/HDAC2/miR-200, p300/YY1/miR-500a-5p/HDAC2 axis, Sp1/HDAC2/p27 axis)
HDAC3	/	Promoter	Colorectal cancer, pancreatic cancer, breast cancer, colorectal cancer, prostate cancer, esophageal cancer, lung cancer ^{301–304}	Promotes cell proliferation and invasion, migration, chemosensitivity; increases PD-L1 expression (NF-κB signaling)
HDAC8	/	Promoter	Cervical cancer, breast cancer, colon cancer ^{305–307}	Promotes cell migration, affects cell morphology and promotes the cell cycle (p53, HDAC8/YY1 axis)
		Suppressor	Breast cancer ³⁰⁸	HDAC8 suppresses EMT (HDAC8/FOXA1 signaling)
HDAC Class II				
HDAC4	/	Promoter	Head and neck cancer, breast cancer, colorectal cancer, gastric cancer, ovarian cancer, prostate cancer ^{309–311}	Promotes cell viability, drug resensitization (tamoxifen, platinum) (STAT1, p21, miR-10b)
HDAC5	/	Promoter	Breast cancer, colorectal cancer, lung cancer, prostate cancer ^{312,313}	Promotes cell proliferation, invasion, migration and EMT; is associated with hormone therapy resistance (HDAC5-LSD1 axis, Survivin and miR-125a-5p, miR-589-5p)
HDAC6	/	Promoter	Cervical cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, prostate cancer, liver cancer, ovarian cancer ^{314–317}	Promotes pluripotency of CSCs, cancer cell proliferation and migration (α-tubulin, heat shock protein (HSP) 90, the NF-κB/MMP2 pathway, JNK/c-Jun pathway, miR-22, miR-221)
HDAC7	/	Promoter	Breast cancer, colorectal cancer, prostate cancer, ovarian cancer ^{318–320}	Is associated with cancer stem cell-specific functions, tumor growth and invasion, and therapy resistance (miR-489, miR-34a)
HDAC9	/	Promoter	Breast cancer ³²¹	Enhances invasive and angiogenic potential (miR-206)
		Suppressor	Lung cancer ³²²	HDAC9 is downregulated in adenocarcinomas; is associated with tumor growth ability

Table 2 continued

Enzyme	Synonym	Role in cancer	Cancer type	Associated biological process (involved mechanism and molecules)
HDAC10	/	Promoter	Ovarian cancer, lung cancer ^{323,324}	Promotes cells proliferation, reduced DNA repair capacity and sensitization to platinum therapy (AKT phosphorylation)
HDAC Class III: sir2-like proteins (sirtuins)				
Sirt1	/	Promoter	Breast cancer, colorectal cancer, prostate cancer, liver cancer, lung cancer, pancreatic cancer, cervical cancer, gastric cancer, ovarian cancer ³²⁵⁻³²⁷	Promotes cell proliferation, migration, metastasis, EMT, metabolic flexibility and self-renewal of cancer stem cells, chemoresistance (miR-30a, miR-15b-5p)
Sirt2	/	promoter	Colorectal cancer lung cancer, renal cell carcinoma, gastric cancer, cervical cancer ³²⁸⁻³³⁰	Highly expressed in stem-like cells and promotes migration, invasion and metastasis (p53, RAS/ERK/JNK/MMP-9 pathway)
		Suppressor	Breast cancer, prostate cancer lung cancer ³³¹⁻³³³	Sensitizes cancer cells to intracellular DNA damage and the cell death induced by oxidative stress, and low Sirt2 levels were associated with poor patient survival (p27)
Sirt3	/	Promoter	Cervical cancer, lung cancer ^{334,335}	Is associated with PD-L1-induced lymph node metastasis (p53)
		Suppressor	Pancreatic cancer, breast cancer, prostate cancer, gastric cancer, ovarian cancer ³³⁶⁻³³⁸	Loss of SIRT3 leads to reactive oxygen species (ROS) generation that amplifies HIF- α stabilization; metastasis (c-MYC, CagA, PI3K/Akt pathway, Wnt/ β -catenin pathway, AMP-activated protein kinase (AMPK))
Sirt4	/	Suppressor	Pancreatic cancer, thyroid cancer, gastric cancer, colorectal cancer ^{339,340}	Promotes cell proliferation, aerobic glycolysis, migration and invasion, and in inhibition of glutamine metabolism (E-cadherin)
Sirt5	/	Promoter	Colorectal cancer, lung cancer, breast cancer ³⁴¹⁻³⁴³	Promotes autophagy, cell proliferation, and drug resistance, and is associated with poor clinical outcomes
		Suppressor	Liver cancer, gastric cancer ^{344,345}	Inhibits peroxisome-induced oxidative stress (CDK2)
Sirt6	/	Promoter	Pancreatic cancer, lung cancer, prostate cancer ³⁴⁶⁻³⁴⁸	Enhances cytokine production, and promotes EMT, cell migration and tumor metastasis, and predicts poor prognosis (ERK1/2/MMP9 pathway, SIRT6/Smad1/ KLF4 axis)
		Suppressor	Pancreatic cancer, breast cancer, liver cancer ^{349,350}	Promotes increased glycolysis, cancer cell proliferation and tumor growth, and is associated with paclitaxel, epirubicin, and trastuzumab sensitivity (survivin, NF- κ B pathway)
Sirt7	/	Promoter	Colorectal cancer, gastric cancer, bladder cancer ^{351,352}	Accelerates cell growth, proliferation, motility and apoptosis (MAPK pathway)
		Suppressor	Pancreatic cancer, breast cancer, lung cancer, colorectal cancer ³⁵³⁻³⁵⁵	Sensitizes to gemcitabine and radiotherapy, and low levels of SIRT7 are associated with an aggressive tumor phenotype and poor outcome (TGF- β signaling, p38 MAPK)
HDAC Class IV				
HDAC11	/	Promoter	Liver cancer, Hodgkin lymphoma, neuroblastoma, colorectal cancer, prostate cancer, breast cancer, ovarian cancer ³⁵⁶⁻³⁵⁹	Promotes the mitotic cell cycle, cell apoptosis; is associated with cancer progression and survival (OX40 ligand, p53)
<i>EMT</i> epithelial-mesenchymal transition, <i>PI3K</i> phosphatidylinositol 3-kinase, <i>TGF-β</i> transforming growth factor β , <i>ER</i> estrogen receptor, <i>AR</i> androgen receptor, <i>MMP</i> matrix metalloproteinase				

as the first and sole histone-binding module that contains a hydrophobic pocket to identify acetyl-lysine.¹⁹¹ The specificity of different BRDs depends on the sequences within the loops that form the hydrophobic pocket. Therefore, each BRD has a preference for different histones.^{192,193} In addition to their recognition of acetyl-lysine, BRDs are also capable of interacting with other chromatin molecules, such as plant homeodomain (PHD) finger motifs or another BRD. To date, 42 proteins containing bromodomains and 61 unique bromodomains have been discovered.^{194,195} Based on the sequence length and sequence identity of BRDs, the human BRD family can be divided into nine groups and one additional set of outliers, which has been well illustrated in published papers.^{169,194} Different BRD-containing proteins contain one to six BRDs. Intriguing, the most notable and well-studied bromodomain proteins are also HATs, such as PCAF, GCN5, and p300/CBP. Yaf9, ENL, AF9, Taf14, Sas5 (YEATS), and double PHD finger (DPF) have also been discovered to be acyl-lysine reader domains.^{191,196} Human MOZ and DPF2 are two proteins containing the DPF domain. Mutations in the YEATS and DPF domains are associated with cancer. For example, mutation of AF9 has been found in hematological malignancies, and ENL dysregulation leads to kidney cancer.^{197,198}

Another important family is the BRD and extraterminal domain (BET) protein family, including BRD2, BRD3, BRD4, and BRDt, and this family shares two conserved N-terminal bromodomains and a more divergent C-terminal recruitment domain.^{199,200} These bromodomain proteins are critical as mediators of gene transcriptional activity.²⁰¹ Of note, bromodomains have also been found in some histone lysine methyltransferases, such as ASH1L and MLL. BRDs are promiscuous domains and have been discussed in other well-constructed papers.^{169,194} In this review, we focus on the role of BRDs in tumorigenesis.

As histone acetylation “readers”, bromodomain proteins play important roles in tumorigenesis. BRD4 recruits the positive transcription elongation factor complex (P-TEFb), a validated target in chronic lymphocytic leukemia associated with *c-Myc* activity.^{202–204} Chromosomal translocation of BRD4, via the t(15;19) translocation, results in the generation of the fusion protein BRD4-NUT (nuclear protein in testis), which is found in NUT midline carcinoma (NMC). Importantly, inhibition of BRD4-NUT induces differentiation of NMC cells.²⁰⁵ Moreover, BRD4 is required for the maintenance of AML with sustained expression of *Myc*²⁰⁶ (Table 2).

Histone deacetylases. Histone deacetylases (HDACs) have recently attracted increasing attention. In humans, the genome encodes 18 HDACs. In contrast to the function of HATs, HDACs usually act as gene silencing mediators and repress transcription. Similarly, HDACs are expressed not only in the nucleus but also in the cytoplasm, and their substrates are also not limited to histones. Based on sequence similarity, HDACs can be divided into four classes: class I HDACs, yeast Rpd3-like proteins, are transcriptional corepressors and have a single deacetylase domain at the N-terminus and diversified C-terminal regions (HDAC1, HDAC2, HDAC3, and HDAC8); class II HDACs, yeast Hda1-like proteins, have a deacetylase domain at a C-terminal position (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10); class III HDACs are yeast silent information regulator 2 (Sir2)-like proteins (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7); and class IV involves one protein (HDAC11). The class IV protein shares sequence similarity with both class I and class II proteins.^{207,208} Classes I, II, and IV are included in the histone deacetylase family, whereas class III HDACs belong to the Sir2 regulator family.²⁰⁹ The catalytic mechanisms for these two families are different; classes I, II, and IV are Zn²⁺-dependent HDACs, whereas sir2-like proteins (sirtuins) are nicotinamide adenine dinucleotide (NAD⁺)-dependent HDACs and are also capable of mono-ADP-ribosyltransferase activity, another pattern of histone modification.²¹⁰ Intriguingly, SIRT4 is

thought to have more mono-ADP-ribosyltransferase activity than HDAC activity. SIRT2 and SIRT6 seem to have equal levels of both mono-ADP-ribosyltransferase and HDAC activities.^{211,212} Moreover, after revealing the crystal structure of SIRT5, researchers found that SIRT5 is also a lysine desuccinylase and demalonylase.²¹³ Therefore, the diversity of the sirtuin family makes them a group of multifunctional enzymes.

So far, the major known recognition sites of each HDAC are different, and these largely remain to be uncovered. For example, HDAC3 is thought to deacetylate H4K8 and H4K12,²¹⁴ but in an HDAC3-knockout HeLa cell line, the acetylation levels of H4K8 and H4K12, even the overall acetylation levels of H3 and H4, were comparable with those in wild-type cells.²¹⁵ Nevertheless, HDAC1 or HDAC3 siRNA can indeed increase the acetylation levels of H3K9 and H3K18.²¹⁵ Therefore, partially because of the functional complementation and diversity within HDAC families, especially in class I, II, and IV, it is difficult to identify the specific substrates of certain HDACs. However, the substrates of the sirtuin family are quite clear. It is notable that because SIRT4 and SIRT5 are only located in mitochondria, they have no effect on histones. However, nonhistone lysine acetylation is also prevalent, since more than 3600 acetylation sites on 1750 proteins have been identified.¹⁶⁶ The tumor suppressor p53 and the cytoskeletal protein α -tubulin are two representative substrates of HDACs.^{216–218} Notably, HDACs are also capable of regulating gene transcription by deacetylating other proteins that are responsible for epigenetic events, such as DNMTs, HATs, and HDACs.^{166,219} Another phenomenon is that some HDACs have to form a complex along with other components to function as transcriptional corepressors, which provides ideas and methods to design novel HDAC inhibitors. The Sin3, NuRD, and CoREST complexes are three complexes containing HDAC1 and HDAC2. Studies have found that purified HDAC1 or HDAC2 without associated components shows fairly weak deacetylation activity *in vitro*.²²⁰ HDAC3 interacts with the corepressors SMRT/NCOR to form the functional complexes, which significantly increases HDAC3 activity. NCoR also interacts with HDAC1, HDAC2 and the class II deacetylases HDAC4, HDAC5, and HDAC7, but usually not in the form of a complex.^{221,222} Deleted in breast cancer 1 (DBC1) and active regulator of SIRT1 (AROS) are two proteins that are able to bind to SIRT1, whereas their interactions present opposite functions. The DBC1/SIRT1 complex inhibits the deacetylation activity of SIRT1, whereas the combination of AROS and SIRT1 stimulates the activity of SIRT1.^{223,224}

HDACs not only are able to deacetylate histones and nonhistone proteins but also interact with other epigenetic-associated enzymes, which gives them a vital role in tumorigenesis.^{162,178} Alterations in HDACs in cancers usually result in aberrant deacetylation and inactivation of tumor suppressor genes. For example, hypoacetylation of the promoter of p21, a tumor suppressor encoded by *CDKN1A*, can be reversed by HDAC inhibitors, resulting in an antitumor effect.²²⁵ A screen of the mutations in several HATs and HDACs, such as CBP, PCAF, HDAC1, HDAC2, HDAC5, HDAC7, and SIRT1, in more than 180 cancer samples including primary tumors and cancer cells indicated that the expression profiles of HDAC1, HDAC5, HDAC7, and SIRT1 are distinctive for colorectal cancers and normal colorectal mucosa, and the expression profiles of HDAC4 and CBP are capable of distinguishing breast cancer tissue from normal tissues²²⁶ (Table 2).

Histone methylation (lysine and arginine)

Similar to the process of histone acetylation, histone methylation also consists of three important components: “writers”, histone methyltransferases (HMTs), “readers”, histone methylation-recognizing proteins, and “erasers”, histone demethylases (HDMs). Methylation of histones occurs at arginine and lysine residues. Arginine and lysine both can be monomethylated or

dimethylated, whereas lysine is also capable of being trimethylated. Histone methylation can either promote or inhibit gene expression, which depends on the specific situation. For example, lysine methylation at H3K9, H3K27, and H4K20 is generally associated with suppression of gene expression, whereas methylation of H3K4, H3K36, and H3K79 induces gene expression.³⁶⁰ Mutation of H3K27M (lysine 27 to methionine) and H3K36M are two important oncogenic events, and H3K27M and H3K36M serve as drivers of pediatric gliomas and sarcomas. H3K27M has been identified in more than 70% of diffuse intrinsic pontine gliomas (DIPGs) and 20% of pediatric glioblastomas, which results in a global reduction in the trimethylation of H3K27 (H3K27me3).^{361–363} However, the H3K36M mutation impairs the differentiation of mesenchymal progenitor cells and generates undifferentiated sarcoma, leading to increased levels of H3K27me3 and global loss of H3K36 (me2 and me).^{364,365} Meanwhile, depletion of H3K36 methyltransferases results in similar phenotypes to those seen with H3K36M mutation.³⁶⁴ To date, KMTs (lysine methyltransferases) have been better studied than arginine methyltransferases (PRMTs) due to their sequence of discovery, different prevalence and impact. Their targets are not limited to only histones, they also modify other key proteins, such as the tumor suppressor p53, TAF10, and Piwi proteins.^{366–368}

Histone methyltransferases. All KMTs contain a 130-amino-acid conserved domain, the SET (suppressor of variegation, enhancer of Zeste, trithorax) domain, except for DOT1L. The SET domain is responsible for the enzymatic activity of SET-containing KMTs. Instead of methylating lysine residues in histone tails, DOT1L methylates lysine in the globular core of the histone, and its catalytic domain is more similar to that of PRMTs.^{369,370} The enzymatic activity of KMTs results in the transfer of a methyl group from S-adenosylmethionine (SAM) to a the ϵ -amino group of a lysine residue. The first identified KMT was SUV39H1, which targets H3K9.³⁷¹ Sequentially, more than 50 SET-containing proteins have been identified with proven or predicted lysine methylation potential. Of note, KMTs are highly specific enzymes, meaning that they are highly selective for lysine residues they can methylate and the specific methylation degree they can achieve. For example, SUV39H1 and SUV39H2 specifically methylate histone 3 at lysine 9 (H3K9), and DOT1L only methylates H3K79.³⁷¹ Based on their structure and sequence around the SET domain, generally, KMTs can be divided into six groups, SUV39, SET1, SET2, EZH, SMYD, and RIZ (PRDM) (reviewed by Volkkel and Angrand³⁷²). The Pre-SET domain of the SUV39 family contains nine conserved cysteines that coordinate with three zinc ions to function. The SET1 family members share a similar Post-SET motif that contains three conserved cysteine residues. The SET2 family possesses an AWS motif that contains 7–9 cysteines. Their SET domain is located between the AWS motif and a Post-SET motif. The members of the enhancer of zeste homolog (EZH) family are the catalytic components of polycomb repressive complexes (PRCs), which are responsible for gene silencing. EZH proteins have no Post-SET motif but have 15 cysteines in front of the SET domain and show no methylated activity as isolated proteins.³⁷³ PRC2 shows lysine methylation activity through its catalytic components, EZH2 or its homolog EZH1.³⁷⁴ EZH2 can methylate not only histone H3 but also histone H1 at lysine 26.³⁷⁵ The SMYD family members, which are SET and MYND domain-containing proteins, possesses a MYND (myeloid-nervy-DEAF1) domain, a zinc-finger motif responsible for protein–protein interaction.³⁷⁶ The RIZ (PRDM) family is a large family containing a homolog of the SET domain, the PR domain. The PR and SET domains share 20–30% sequence identity and are both capable of inducing histone H3 methylation.³⁷⁷ However, most members of the RIZ family responsible for histone methylation are still unknown. So far, two of them have been proven to induce the methylation of histones: PRDM2 (RIZ1) is associated with H3K9

methylation; and Meisetz, the mouse homolog of PRDM9, trimethylates H3K4.³⁷⁸ Meanwhile, PRDM1 has been identified to interact with EHMT2, a member of the SUV39 family. PRDM6 acts as a transcription suppressor by interacting with class I HDACs and EHMT2 to induce cell proliferation and inhibit cell differentiation.³⁷⁹ Meanwhile, the recruitment of EHMT2 is based on the formation of a complex with PRDM1.³⁸⁰ Due to the lack of a characteristic sequence or structure flanking the SET domain, other SET-containing KMTs, such as SET7/9, SET8, SUV4-20H1, and SUV4-20H2, cannot be classified into these families. Notably, some KMTs contain more than one domain, which allows them to interact with other proteins, especially other epigenetic modifying proteins. SUV39H1 possesses a chromodomain that directly binds to nucleic acids and forms heterochromatin.³⁸¹ MLL1 recognizes unmethylated DNA through its CpG-interacting CXXC domain. SETDB1 contains an MBD that interacts with methylated DNA.³⁸² The Tudor domain in SETDB1 may potentially recognize the methylation of lysine residues.³⁸³ ASH1 is able to interact with CBP, a HAT, via a bromodomain within ADH1.³⁸⁴

Protein arginine methyltransferases (PRMTs) can be divided into two groups. Among the nine PRMTs, only PRMT5, PRMT7, and PRMT9 are type II PRMTs, and the other five PRMTs, except for PRMT2, are type I PRMTs. PRMT2 was identified by sequence homology³⁸⁵ but has not shown any catalytic activity during investigations, although PRMT2 acts as a strong coactivator for androgen receptor (AR), which is thought to be associated with arginine methylation.³⁸⁶ Both types of PRMTs first catalyze the formation of monomethylarginine as an intermediate. However, sequentially, type I PRMTs can form asymmetric dimethylarginine (ADMA, Rme2a), but type II PRMTs form symmetric dimethylarginine (SDMA, Rme2s). Rme2a means two methyl groups on one ω -amino group, whereas an Rme2s has one methyl group on each ω -amino group. PRMT1-PRMT8 were investigated by Herrmann and Fackelmayer,³⁸⁷ and FBXO11 was identified as PRMT9, which symmetrically dimethylates arginine residues.³⁸⁸

Most enzymes for histone methylation are substrate-specific proteins; therefore, alterations in the aberrant expression of enzymes are usually associated with specific histone residue mutations. One of the best-known examples of alterations in tumorigenesis is H3K4me3, which is associated with biphenotypic (mixed lineage) leukemia (MLL). The location of the MLL gene is where chromosomal translocations in AML and ALL usually occur.³⁸⁹ When the MLL gene is translocated, the catalytic SET domain is lost, which results in MLL translocation-generated fusion proteins, which recruit DOT1L.³⁹⁰ Maintenance of MLL-associated ALL depends on the methylation of H3K79 catalyzed by DOT1L.³⁹¹ Therefore, DOT1L is usually associated with hematological malignancies rather than solid tumors. Alteration of the EZH2-induced methylation of H3K27 has been observed in multiple cancers, including various solid tumors (prostate, breast, kidney, bladder, and lung cancers) and hematological malignancies.³⁹² Meanwhile, overexpression of EZH2 has been found in multiple cancers and is associated with poor prognosis.³⁹³ Different mechanisms have been proposed to describe the role of EZH2 in tumorigenesis (Table 3).

Methyl-histone recognition proteins. “Readers” of histone methylation contain several specific domains recognizing lysine or arginine methylation, such as a chromodomain,³⁹⁴ the WD40 repeat, the MBT (malignant brain tumor) domain, the Tudor domain³⁹⁵ and the PHD (plant homeodomain) finger motif.³⁹⁶ Representative chromodomain-containing proteins in humans are HP1 and Chd1, which can recognize H3K9me and H3K27me, respectively.^{394,397} WDR5 is a protein containing WD40 repeats. In addition to H3K4me, WDR5 prefers to bind to H3K4me2 via a histone-methylating complex and is required for maintaining H3K4me3.³⁹⁵ Later, WDR5 was shown to directly read H3R2, a “WIN” motif of MLL1, as well as symmetrical H3R2 dimethylation

Table 3. Important enzymes or proteins that regulate histone methylation in cancer.

Enzymes	Synonyms	Role in cancer	Cancer type	Mechanism
<i>Histone methyltransferases (lysine): the writers for lysine</i>				
SUV39				
KMT1A	SUV39H1, MG44, SUV39H	Promoter	Gastric cancer, prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer ⁴²¹⁻⁴²⁶	Promotes cell migration and cancer stem cell self-renewal (KMT1A-GATA3-STAT3 axis)
KMT1B	FLJ23414, SUV39H2	Suppressor	Breast cancer, cervical cancer ^{427,428}	SUV39H1-low tumors are correlated with poor clinical outcomes
KMT1C	EHMT2, G9A, BAT8, NG36	Promoter	Colorectal cancer, lung cancer, gastric cancer ⁴²⁹⁻⁴³¹	Promotes cell proliferation, migration and invasion and tumor metastasis
KMT1E	SETDB1, ESET, KGIT	Promoter	Breast cancer, pancreatic cancer, bladder cancer, ovarian cancer, liver cancer, colon cancer, lung cancer ⁴³²⁻⁴³⁵	Promotes cell proliferation, metastasis, and apoptosis, and is associated with poor prognosis (p27, PMAIP1-USP9X-MCL1 axis, Wnt signaling pathway)
SET1		Suppressor	Breast cancer, colorectal cancer, hepatocellular carcinoma, liver cancer ⁴³⁶⁻⁴³⁹	SETDB1 promotes cell proliferation, migration, invasion, and EMT (p53)
KMT2A	MLL1, HRX, TRX1, ALL-1	Promoter	Lung cancer ⁴⁴⁰	SETDB1 acts as a metastasis suppressor, and inhibits cell migration and invasive behavior.
KMT2B	ALR, MLL2	Promoter	Head and neck cancer, pancreatic cancer, prostate cancer ^{441,442}	Promotes PD-L1 transcription and is associated with the self-renewal of cancer cells (Wnt/ β -catenin pathway)
KMT2C	MLL3, HALR	Suppressor	Bladder cancer, lung cancer, breast cancer ⁴⁴³⁻⁴⁴⁵	Is associated with the self-renewal of CSCs and expansion (Wnt/ β -catenin pathway)
KMT2D	MLL4, HRX2	Promoter	Colorectal cancer, esophageal squamous cell carcinoma ⁴⁴⁶	Inhibits tumor growth and metastasis
KMT2E	MLL5	Promoter	Breast cancer ⁴⁴⁷	Promotes cell proliferation and invasiveness
KMT2F	SET1A	Promoter	Glioblastoma ⁴⁴⁸	Is associated with cancer cell self-renewal
EZH			Liver cancer ⁴⁴⁹	Promotes liver cancer growth and hepatocyte-like stem cell malignant transformation
EZH1	KIAA0388	Promoter	Breast cancer, prostate cancer, bladder cancer, colorectal cancer, liver cancer, gastric cancer, melanoma, lymphoma, myeloma, Ewing's sarcoma, glioblastoma, thyroid carcinoma, esophageal squamous cell carcinoma, lung cancer, ovarian cancer, renal cancer ^{392,450-452}	Promotes cell proliferation, colony formation, migration and tumor metastasis; is associated with cancer stem cell maintenance; predicts chemotherapeutic efficacy and response to tamoxifen therapy (E-cadherin, RUXN3, MEK-ERK1/2-Elk-1 pathway)
EZH2	KMT6, ENX-1, MGC9169			
SET2				
KMT3A	SETD2, SET2, HIF-1,	Suppressor	Renal cancer, lung cancer ^{453,454}	Maintains genome integrity and attenuates cisplatin resistance (ERK signaling pathway)
WHSC1	NSD2, WHS, TRX5	Promoter	Prostate cancer, gastric cancer ^{455,456}	Promotes cell invasive properties, EMT and cancer metastasis
WHSC1L1	NSD3, MGC126766	Promoter	Breast cancer, head and neck cancer ⁴⁵⁷	Is associated with ER α overexpression and enhances the oncogenic activity of EGFR
RIZ (PRDM)				
PRDM1	BLIMP1	Promoter	Pancreatic cancer, breast cancer ^{458,459}	Promotes cell invasiveness and cancer metastasis
PRDM2	RIZ	Suppressor	Lung cancer, colon cancer ^{460,461}	Inhibits cell invasion and metastasis (p21)
PRDM3	EV11, MDS1-EV11	Promoter	Colorectal cancer, breast cancer ^{462,463}	Is associated with poor clinicopathological variables and mediates the proliferative effect of estrogen
PRDM4	PFM1	Promoter	Ovarian cancer, nasopharyngeal carcinoma ^{464,465}	Promotes cell proliferation, migration, EMT, cancer stem cells and chemoresistance/radioresistance
PRDM5	PFM2	Suppressor	Breast cancer ⁴⁶⁶	Is associated with cancer cell stemness, tumorigenicity, and tumor metastasis
PRDM9	PFM6	Promoter	Colorectal cancer, gastric cancer, cervical cancer ⁴⁶⁷	Among the PRDM family genes tested, PRDM5 was the most frequently silenced in colorectal and gastric cancer
PRDM14	PFM11	Promoter	N/A ⁴⁶⁸	Impairs genomic instability and drives tumorigenesis
PRDM16	MEL1, PFM13	Promoter	Testicular cancer, pancreatic cancer ^{469,470}	Is associated with early germ cell specification and promotes cancer stem-like properties and liver metastasis

Table 3 continued

Enzymes	Synonyms	Role in cancer	Cancer type	Mechanism
SMYD				
KMT3C	SMYD2	Promoter	Pancreatic cancer, gastric cancer, breast cancer, lung cancer ^{472,473}	Promotes cancer cell proliferation and survival (STAT3, EML4-ALK, p65)
KMT3E	SMYD3, ZMYND1, ZNFN3A1, FLJ21080	Promoter	Liver and colon cancer, prostate cancer, breast cancer ⁴⁷⁴⁻⁴⁷⁶	Promotes cell proliferation, invasion, EMT and cancer stem cell maintenance (Myc, MMP-9, Ctnnb1, JAK/Stat3 pathway, Wnt pathway, androgen receptor transcription)
SMYD4	ZMYND21	Suppressor	Breast cancer ⁴⁷⁷	SMYD4 acts as a suppressor in tumorigenesis
Others				
DOT1L	KMT4	promoter	MLL-rearranged leukemia, colorectal cancer, breast cancer, ovarian cancer ^{478,479}	Increases EMT, cancer stemness and tumorigenic potential and is required for MLL rearrangement
SET8	KMT5A, SETD8, PR-set7	promoter	Breast cancer, prostate cancer, ovarian cancer, lung cancer ^{480,481}	Promotes cell proliferation, migration, invasion, and EMT (MIR-502)
SUV4-20H2	KMT5C, MGC2705	Suppressor	Breast cancer ⁴⁸²	SUV4-20H2 is downregulated in breast cancer
SetD6	/	Promoter	Colorectal cancer, bladder cancer, breast cancer ^{483,484}	Promotes cell survival and colony formation and contributes to increased susceptibility to cancer
SET7/9	SETD7, KMT7	Suppressor	Breast cancer, gastric cancer, AML, lung cancer ⁴⁸⁵⁻⁴⁸⁷	Promotes cell proliferation, EMT and the generation of cancer stem cells; a low level of SET7/9 is correlated with clinical aggressiveness and worse prognosis (β -catenin stability)
<i>Histone methyltransferases (arginine): the writers for arginine</i>				
PRMT1	ANM1, HCP1, IR1B4	Promoter	Breast cancer, colon cancer, gastric cancer, lung cancer ⁴⁸⁸⁻⁴⁹⁰	Promotes EMT, cancer cell migration, and invasion and is associated with chemosensitivity and poor clinical and histological parameters
PRMT2	/	Suppressor	Pancreatic cancer ⁴⁹¹	Inhibits cell proliferation and invasion in pancreatic cancer
PRMT4	CARM1	Suppressor	Breast cancer ⁴⁹²	Induces cell cycle arrest and apoptosis in breast cancer
		Promoter	Ovarian cancer, breast cancer, liver cancer, colorectal cancer, prostate cancer ^{493,494,494}	Promotes cell proliferation and blocks cell differentiation (Wnt/ β -catenin signaling)
		Suppressor	Pancreatic cancer ⁴⁹⁵	Inhibits glutamine metabolism and suppresses cancer progression
PRMT5	JBP1, SKB1, IBP72	Promoter	Breast cancer, prostate cancer, colorectal cancer, lung cancer ⁴⁹⁶⁻⁴⁹⁸	Promotes cell survival, proliferation, invasiveness and sensitivity to 5-Fluorouracil (5-FU) (SHARPIN-PRMT5-H3R2me1 axis)
PRMT6	HRMT1L6	Suppressor	Breast cancer ⁴⁹⁹	High PRMT5 expression favors a better prognosis in BC patients
		Promoter	Prostate cancer, gastric cancer ^{500,501}	Is associated with cell apoptosis, invasiveness and viability (PI3K/AKT/mTOR pathway, H3R2me2as)
		Suppressor	Hepatocellular carcinoma ⁵⁰²	Negatively correlates with aggressive cancer features
PRMT7	FLJ10640, KIAA1933	Promoter	Lung cancer, breast cancer ^{503,504}	Promotes cancer cell EMT and tumor metastasis
PRMT8	HRMT1L3, HRMT1L4	Promoter	Breast, ovarian and gastric cancer ⁵⁰⁵	Overexpression of PRMT8 is correlated with decreased patient survival
PRMT9	FBXO11	Promoter	Breast cancer ⁵⁰⁶	Fuels tumor formation via restraint of the p53/p21 pathway
<i>Methyl-histone recognition proteins: the readers</i>				
Chromodomain				
HP1	/	Promoter	Breast cancer ⁵⁰⁷	Overexpression of HP1 is associated with breast cancer progression
Chd1	/	Promoter	Prostate cancer ⁵⁰⁸	Is associated with cell invasiveness, double-strand break repair and response to DNA-damaging therapy
		Suppressor	Prostate cancer ⁵⁰⁹	Loss of MAP3K7 and CHD1 promotes an aggressive phenotype in prostate cancer
WD40 repeat domain				
WDR5	/	/	/	
MBT domain				
BPTF	/	Promoter	Lung cancer, hepatocellular carcinoma ^{510,511}	Promotes cell proliferation, migration, stem cell-like traits and invasion (miR-3666)
L3MBTL1	/	Suppressor	Breast cancer ⁵¹²	Expression of L3MBTL1 is associated with a low risk of disease recurrence and breast cancer-related death
ING2		Promoter	Colon cancer ⁵¹³	Increases invasion by enhancing MMP13 expression
		Suppressor	Lung cancer ⁵¹⁴	Suppresses tumor progression via regulation of p53

Table 3 continued

Enzymes	Synonyms	Role in cancer	Cancer type	Mechanism
BHC80		Promoter	Prostate cancer ⁵¹⁵	Stimulates cell proliferation and tumor progression via the MyD88-p38-TTP pathway
<i>Tudor domains</i>				
JMJD2A		Promoter	Breast cancer, liver cancer, colon cancer ^{516,517}	Promotes cells apoptosis and proliferation and contributes to tumor progression (ARH1, miR372)
		Suppressor	Bladder cancer ⁵¹⁸	Low JMJD2A correlates with poor prognostic features and predicts significantly decreased overall survival
<i>KDMs: the erasers</i>				
KDM1				
KDM1A	LSD1	Promoter	Breast cancer, lung cancer, prostate cancer, liver cancer, pancreatic cancer, gastric cancer ^{519–521}	Contributes to cell proliferation and stem cell maintenance and self-renewal (p21, AR, HIF1 α -dependent glycolytic process)
KDM1B	LSD2	Suppressor	Breast cancer ⁵²²	Inhibits invasion and metastatic potential
KDM2/JHDM1		Promoter	Breast cancer ⁵²³	Contributes to cancer progression and cancer stem cell enrichment
KDM2A	JHDM1A, CXXC8	Promoter	Breast cancer, gastric cancer, lung cancer, cervical cancer ^{524–526}	Promotes cancer cell proliferation, metastasis, and invasiveness (HDAC3, TET2)
KDM2B	JHDM1B, FBXL10,	Promoter	Prostate cancer, breast cancer, gastric cancer ^{527,528}	Promotes cell migration, angiogenesis, and the self-renewal of cancer stem cells
KDM3/JHDM2/JMJD1				
KDM3A	JHDM2A, JMJD1A	Promoter	Colorectal cancer, ovarian cancer, breast cancer, prostate cancer, bladder cancer ^{529–531}	Promotes cancer cell growth, metastasis, stemness and chemoresistance (<i>c-Myc</i> , Wnt/ β -catenin signaling, glycolysis, HIF1 α)
KDM3C	JHDM2C, JMJD1C	Promoter	Esophageal cancer, colorectal cancer ^{532,533}	Promotes cancer cell proliferation and metastasis (YAP1 signaling, ATF-2)
KDM4/JHDM3/JMJD2				
KDM4A	JHDM3A, JMJD2A	Promoter	Breast cancer, liver cancer ^{516,534}	Promotes cancer progression through repression of the tumor suppressor ARH1 (miR372)
		Suppressor	Bladder cancer ⁵¹⁸	Downregulated in cancer tissues and significantly decreases as cancer progresses
KDM4B	JMJD2B	Promoter	Breast cancer, gastric cancer, ovarian cancer, colorectal cancer, prostate cancer ^{535–537}	Promotes EMT and metastasis, and regulates the seeding and growth of peritoneal tumors; is involved in resistance to PI3K inhibition (β -ERK, β -catenin)
KDM4C	JMJD2C, GASC1	Promoter	Breast cancer, pancreatic cancer ^{538,539}	Promotes cancer progression (HIF-1 α , miR-335-5p)
KMD4D	JMJD2D	Promoter	Colorectal cancer ⁵⁴⁰	Promotes cell proliferation and tumor growth (β -catenin)
KDM5/JARID				
KDM5A	JARID1A, RBP2	Promoter	Breast cancer, colorectal cancer, cervical cancer ^{541,542}	Promotes proliferative activity and invasion, and inhibition of KDM5A causes growth arrest at the G1 phase (<i>c-Myc</i>)
KDM5B	JARID1B, RBP2-like	Promoter	Colorectal cancer, lung cancer, gastric cancer ⁵⁴³	Promotes cell proliferation, metastasis, and expression of CSCs, and inhibition of KDM5B results in cell cycle arrest, apoptosis, and senescence (E2F/RB pathway)
KDM5C	JARID1C, SMCX	Promoter	Prostate cancer, lung cancer ⁵⁴⁴	Overexpression of KDM5C predicts therapy failure and is associated with cancer cell growth, migration and invasion
		Suppressor	Colon cancer ⁵⁴⁵	Inhibits the multidrug resistance of colon cancer cell lines by downregulating ABCG1
KDM5D	JARID1D, SMCY	Promoter	Gastric cancer ⁵⁴⁶	Promotes cell proliferation and EMT
		Suppressor	Prostate cancer ⁵⁴⁷	Loss of KDM5D expression induces resistance to docetaxel
JARID2	JUMONJI	Promoter	Bladder cancer, lung and colon cancers ^{548,549}	Regulates cancer cell EMT and stem cell maintenance and is associated with poor survival
		Suppressor	Prostate cancer ⁵⁵⁰	Inhibits cell proliferation, migration, and tumor development via inhibition of Ax1
KDM6/UT				
KDM6A	UTX	Promoter	Breast cancer ⁴⁴⁷	Promotes cell proliferation and invasiveness
		Suppressor	Bladder cancer, pancreatic cancer ^{551,552}	KDM6A loss induces squamous-like, metastatic pancreatic cancer
KDM6B	JMJD3	Promoter	Ovarian cancer, breast cancer, gastric cancer ^{553,554}	High expression of KDM6B is correlated with poor prognosis
KDM6C	UTY	Suppressor	Bladder cancer ⁵⁵⁵	UTY-knockout cells have increased cell proliferation compared to wild-type cells

Table 3 continued

Enzymes	Synonyms	Role in cancer	Cancer type	Mechanism
KDM7/PHF				
KDM7A	JHDM1D	Promoter	Prostate cancer ⁵⁵⁶	Promotes cell proliferation and upregulated androgen receptor activity
KDM7C	PHF2, JHDM1E	Suppressor	N/A ⁴²⁰	Is a suppressor and promotes p53-driven gene expression
KDM7B	PHF8, JHDM1F	Promoter	Prostate cancer, gastric cancer, lung cancer, leukemia, colorectal cancer ⁵⁵⁷⁻⁵⁵⁹	Promotes cell proliferation, migration and invasion, and high PHF8 expression predicts poor survival (miR-488)
Others				
JMJD5	KDM8	Promoter	Breast cancer ^{560,561}	Promotes metastasis and indicates a poor prognosis; is required for cell cycle progression via because of its actions in the cyclin A1 coding region.
RSBN1	KDM9	Promoter	Breast cancer ⁵⁶²	Is a new potential HIF target
JMJD6	PSR, PTDSR	Promoter	Breast cancer, oral cancer, lung cancer ⁵⁶³⁻⁵⁶⁵	Promotes cancer cell proliferation, EMT and motility, and maintains cancer cell stemness properties (autophagy pathway, WNT/ β -catenin pathway)
PAD4	/	Promoter	Breast cancer, esophageal cancer ⁵⁶⁶	Promotes cancer progression and is correlated with pathological classification (c-Fos)

EMT epithelial-mesenchymal transition, CSC cancer stem cell, EGFR epidermal growth factor receptor, MMP matrix metalloproteinase, PI3K phosphatidylinositol 3-kinase

through the WD40 domain.³⁹⁸ L3MBTLs are a group of proteins containing three MBT repeat domains. L3MBTL1 represses gene expression via monomethylation or dimethylation of H4K20 or H1BK26.³⁹⁹ BPTF, RAG2, PYGO, and the tumor suppressor ING2 are representative proteins containing PHD finger motifs. They are all able to recognize and bind to H3K4me3.⁴⁰⁰ Intriguingly, DNMT3L and BHC80 also possess a PHD finger motif, but they selectively bind to unmethylated H3K4.^{401,402} There are a number of proteins containing Tudor domains, with a representative protein being JMJD2A. JMJD2A is a histone demethylase that equally binds to H3K4me3 and H4K20me3⁴⁰³ (Table 3).

Histone demethylases. The identification of histone demethylases (HDMs or KDMs) has lagged behind that of HMTs. Thus far, KDMs can be classified into two groups. The amine-oxidase type lysine-specific demethylases (LSDs) and the highly conserved JumonjiC (JMJC) domain-containing histone demethylases. LSD1 and LSD2, also known as KDM1A and B, are flavin adenine dinucleotide (FAD)-dependent amine oxidases that can only demethylate monomethylated and dimethylated lysine residues. LSD1 has been identified to specifically activate androgen receptor (AR) target genes along with AR by demethylating H3K9.⁴⁰⁴ The human genome codes more than 30 JMJC-containing KDMs that are able to remove methyl groups from all three methyl-lysine states. JHDM1A was the first characterized JMJC domain-containing HDM and specifically demethylates H3K36me2 and H3K36me1.⁴⁰⁵ Not all JMJC domain-containing proteins are able to demethylate histone proteins, such as HIF1AN and the transmembrane phosphatidylserine receptor PTDSR. JMJC-containing HDMs can be divided into six families:³⁶⁰ the JHDM1, JHDM2 (JMJD1), JHDM3 (JMJD2), JARID, PHF, and UT families. Notably, not all of these families possess the ability of histone demethylation. However, some JMJC-containing proteins, including those that are not included in these six families, contain one or more methylated-histone-binding domains. Their potential to demethylate methyl-lysine or methyl-arginine must be investigated. In addition to demethylases for lysine residues, JMJD6 is the first described arginine demethylase and lysine hydroxylase. It can remove methyl groups from H3R2 and H4R3.⁴⁰⁶ Another kind of protein is peptidylarginine deiminases (PADs or PADIs) or protein-arginine deiminases, which are able to convert arginine and monomethylated arginine to citrulline.⁴⁰⁷

LSD1 (KDM1A) is one of the best-studied KDMs and has been found to be increased in multiple cancers. Inhibition of LSD1 leads to global H3K4 methylation and promotes differentiation of neuroblastoma cells.⁴⁰⁸ Unlike KDM1A, KDM1B is mostly involved in growing oocytes with a restricted expression pattern.⁴⁰⁹ Similar to the dual roles of LSD1, members of the KDM2 family can either promote tumor formation or inhibit tumorigenesis.⁴¹⁰ Through dimethylating H3K36 in DUSP3 (dual specific phosphatase 3), KDM2A activates ERK1/2 expression in lung cancer cells.⁴¹¹ Knockout of KDM2B in breast cancer downregulates the tumor stem cell markers ALDH and CD44 via the repression of polycomb complexes. KDM2B is also overexpressed in pancreatic ductal adenocarcinoma (PDAC) and cooperates with KrasG12D to promote PDAC formation in mouse models.⁴¹² The LSD1 and KDM2 family possesses context-dependent tumor-promoting and -inhibiting functions, which might depend on the different features of various cancers and the specific substrates of the enzymes. Therefore, further studies should take the dual roles of these enzymes into consideration. KDM3A, induced by hypoxia and nutrient starvation within the tumor microenvironment, shows carcinogenic effects via the promotion of tumor cell migration and invasion. Inhibition of KDM3A downregulates tumor-associated angiogenesis and macrophage infiltration.^{413,414} KDM3C is required for MLL-AF9 leukemia maintenance and is mutated in patients with intracranial germline tumors.^{415,416} KDM4A, KDM4B, and KDM4C have shown increased expression

in prostate cancer with decreased levels of H3K9me2/3 and increased levels of H3K9me1.⁴¹⁷ H3K9me3 is thought to be a hallmark of heterochromatic areas of the genome. In addition, KDM4 family members were the first identified demethylases targeting trimethylated lysines. Aberrant expression of KDM4 family members might lead to instability of the genome and become involved in tumorigenesis.⁴¹⁰ Members of the KDM6 family usually act as tumor suppressors and are thought to cause cell growth arrest.⁴¹⁸ For example, the tumor suppressor proteins p16INK4A and p14ARF, encoded by the INK4A-ARF locus, are repressed by H3K27me3. When stimulated by oncogenic factors, KDM6B is recruited to the INK4A-ARF locus and activates the transcription of these two tumor suppressors.⁴¹⁹ In colorectal cancer, KDM7C is required for the efficacy of oxaliplatin and doxorubicin and for the activation of p53⁴²⁰ (Table 3).

NONCODING RNA

Epigenetic related noncoding RNAs (ncRNAs) include microRNAs (miRNAs), small interfering RNA (siRNAs), Piwi-interacting RNA (piRNAs), and long noncoding RNAs (lncRNAs). MiRNAs, one of the most studied ncRNAs, are small RNAs between 19 and 22 nucleotides in length that play important roles in the regulation of gene expression by controlling mRNA translation. Intriguingly, the regions that miRNAs usually target are frequently associated with carcinogenesis.⁵⁶⁷ Generally, they can be divided into tumor-promoting and tumor-suppressing miRNAs. During tumorigenesis, oncogenic miRNAs such as miR-155, miR-21 and miR-17-92 are usually overexpressed, and tumor-suppressive miRNAs such as miR-15-16 are downregulated.⁵⁶⁸ There is another type of miRNA, cellular context-dependent miRNAs, functioning in tumorigenesis. For example, miR-146 has been shown to be overexpressed in multiple cancers, whereas a recent study has proven that miR-146 can reduce the expression of BRCA1.^{568,569} Meanwhile, the expression of proteins and enzymes is also regulated by certain miRNAs. MiR-101 directly represses EZH2, and abnormal down-regulation of miR-101 has been observed in cancers.^{570,571} The expression of the miR-29 family is inversely correlated with that of DNMT3A and -3B in lung cancer tissues. Forced expression of miR-29 inhibits tumorigenesis by inducing reexpression of methylation-silenced tumor suppressor genes.⁵⁷² lncRNAs are another large group of noncoding RNAs that play a vital role in tumorigenesis. Some lncRNAs are cancer type-specific, such as PCGEM1 in prostate cancer and HEIH in hepatocellular carcinoma.^{573,574} Many aberrant lncRNAs have been discovered in various cancers. Dysregulation of HOTAIR has been found in lung, pancreatic, and colorectal cancer.⁵⁷⁵⁻⁵⁷⁷

Therefore, ncRNAs can either be directly involved in tumorigenesis or indirectly affect tumor development by participating in other epigenetic events.

INHIBITORS AND CLINICAL TRIALS

Unlike genetic mutations, epigenetic alterations are reversible. Given the importance of epigenetic marks in tumorigenesis, the availability of corresponding inhibitors has attracted extensive attention. Meanwhile, epigenetic regulation of a gene usually requires more than one epigenetic event. Currently, there are six epigenetic drugs approved for clinical use by the FDA (Table 4).

Targeting DNA methylation

Blockade of DNMTs is the most effective way to prevent aberrant DNA hypermethylation. However, until now, targeting of the methyltransferase enzymes still lacks specificity and even causes hypomethylation of the global genome.⁵⁷⁸ Complete deletion of DNMT1 in mice results in embryonic lethality.⁵⁷⁹ Knockout of DNMT1 in fibroblast cells causes aberrant expression of 10% of genes and p53-dependent death.⁵⁸⁰ Administration of DNA

methylation inhibitors results in tumorigenesis in male Fischer rats.⁵⁸¹ Regulation of DNA methylation is vital in cell survival and function, and in addition to the specificity needed and the side effect associated, it is hard to identify proper drugs.

DNA methylation inhibitors can be divided into two groups: nucleoside analogs and nonnucleoside analogs. Nucleoside analogs have a modified cytosine ring and can be turned into nucleotides and incorporated into newly synthesized DNA or RNA. DNA methyltransferases are bound by covalent complexes with the analogs, which inhibits DNA methylation. 5-Azacytidine (5-Aza-CR) and 5-aza-2'-deoxycytidine (5-Aza-CdR) are currently the two most studied and promising demethylation agents.⁵⁸² 5-Aza-CR and zebularine are ribonucleoside analogs that can be phosphorylated to be able to incorporate into RNA. However, they can also be incorporated into DNA via the ribonucleotide reductase pathway. 5-Azacytidine, an analog of cytidine, is an injectable suspension for the treatment of myelodysplastic syndromes (MDSs). It promotes cell differentiation, demethylation, and reexpression of inactivated genes.⁵⁸³ The 5-azacytidine side effects include fetal abnormalities⁵⁸⁴ and decreased male fertility, especially at high doses, but its analog, 6-azacytidine, does not show such effects.⁵⁸⁵ Notably, after treating the noninvasive breast cancer cell lines MCF-7 and ZR-75-1 with azacytidine, the cells gained invasive abilities due to the hypomethylation of several prometastasis genes.⁵⁸⁶ Decitabine (5-Aza-CdR) and 5-fluoro-2'-deoxycytidine (5-F-CdR) are deoxyribonucleoside analogs that are capable of incorporating into DNA following phosphorylation. Decitabine (5-aza-2'-deoxycytidine) inhibits DNA methylation in a dosage-dependent manner. It can reactivate silenced genes at low doses but gains cytotoxicity at high doses, while myelosuppression is the major side effect at all doses.⁵⁸⁷ Dihydro-5-azacytidine (DHAC) is a biologically active and chemically stable analog of 5-azacytidine with decreased toxicity.^{588,589} Because of its hydrolytic stability, it may be administered via prolonged i.v. infusion, potentially eliminating the acute toxicities caused by administration of 5-azacytidine.⁵⁹⁰ Zebularine is a potential oral DNA-demethylating drug with stability in acidic environments and in aqueous solutions.⁵⁹¹ However, the near millimolar dose requirements and the limited bioavailability in rodents (<7%) and primates (<1%) leave zebularine far from clinical translation.⁵⁹²

Among the drugs discussed, 5-Aza-CR⁵⁹³ and 5-Aza-CdR⁵⁹⁴ have already been approved by the US Food and Drug Administration (FDA) for the treatment of certain subtypes of MDS and chronic myelomonocytic leukemia. Because of their intrinsic preference for newly synthetic DNA, they tend to affect dividing cells, i.e., cancer cells.⁵⁹⁵ Ongoing preclinical experiments and clinical trials are exploring their efficacy in solid tumors. The common side effects of these nucleoside-like analogs are mutagenic risk and genomic instability. Nonnucleoside analogs are capable of avoiding these side effects.

Currently, many nonnucleoside analogs have been developed to prevent DNA from aberrant hypermethylation. These drugs are usually small molecular inhibitors and directly target catalytic sites rather than incorporating into DNA. Based on a three-dimensional model of DNMT1, RG108 was designed to block the activity of this enzyme and cause demethylation.⁵⁹⁶ Psammoplins are a group of natural extracts from the sponge *Pseudoceratina purpurea* and is capable of inhibiting both DNA methyltransferases and histone deacetylases with mild cytotoxicity.⁵⁹⁷ Similarly, EGCG ((-)-epigallocatechin-3-gallate) is the major polyphenol from green tea and reversibly demethylates methyl-DNA, resulting in the reactivation of multiple key genes, including hMLH1, P16, and RA, in colon, esophageal, and prostate cancer cell lines.⁵⁹⁸ Both hydralazine and procainamide, two drugs associated with lupus-like autoimmune diseases, can inhibit DNA methylation and induce self-reactivity in cloned T-cell lines.⁵⁹⁹ They have promising tumor suppressor-reactivating and antitumor actions in breast cancer.^{600,601} Another

Table 4. Epigenetic drugs approved by the FDA.

Compound	Synonym	Clinical name	Condition	Approved year	Company
Azacitidine	5-Azacitidine, 5-Aza-CR	Vidaza	MDS	U.S. FDA (2004)	Pharmion Corporation
5-Aza-2'-deoxycytidine	5-Aza-CdR, decitabine	Dacogen	MDS	U.S. FDA (2006)	Janssen Pharmaceuticals
Suberoylanilide hydroxamic acid (SAHA)	Vorinostat	Zolinza	CTCL	U.S. FDA (2006)	Merck
Romidepsin	Depsipeptide, FK-229, FR901228	Istodax	CTCL	U.S. FDA (2009)	Celgene
Belinostat	PXD101	Beleodaq	PTCL	U.S. FDA (2014)	TopoTarget
Panobinostat	LBH589	Farydak	Multiple myeloma	U.S. FDA (2015)	Novartis
Chidamide	Tucidinostat, HBI-8000	Epidaza	PTCL	China FDA (2015)	Chipscreen Biosciences

FDA Food and Drug Administration, MDS myelodysplastic syndrome, CTCL cutaneous T-cell lymphoma, PTCL peripheral T-cell lymphoma

strategy is developing antisense oligonucleotides to inhibit DNMT transcription. MG98 is a second-generation phosphorothioate antisense oligodeoxynucleotide that prevents DNMT1 mRNA translation effects but has no obvious antitumor effect.⁶⁰² It has been under investigation in preclinical experiments and phase I/II clinical trials, especially in solid tumors.^{603,604} Of note, in a systemic analysis comparing nonnucleoside inhibitors with 5-Aza-CdR, the latter showed better efficacy in DNA demethylation inhibition.⁶⁰⁵

To date, hundreds of clinical trials have investigated the effects of anti-DNA methylation therapy for various cancers (Table 5).

Inhibitors of histone modifications

Compared with DNA methylation, histone modifications have been investigated in broader areas of diseases, including solid tumors, hematological malignancies, and even many inflammatory diseases (such as viral infection, diabetes and inflammatory lung diseases). During the process of gene silencing, lysine deacetylation and demethylation of H3K4 rather than demethylation of H3K9 or cytosine methylation might be the primary causative event.⁶⁰⁶ Therefore, histone modification plays an essential role in the regulation of gene expression, which also makes it a promising target for disease treatment. Clinical trials targeting histone acetylation and histone methylation are listed in Table 6 and Table 7, respectively.

Inhibitors for HATs and BETs. Generally, there are two strategies for preventing aberrant histone acetylation, including altering interactions within the active sites within HATs or using mimetic products of enzymatic substrates. To date, many inhibitors targeting BRD proteins have been investigated in clinical trials, whereas there are no clinical trials investigating inhibitors for HATs.

Bisubstrate inhibitors are selective inhibitors for PCAF, p300, and TIP60. They mimic two substrates of HATs: the cofactor acetyl coenzyme A (Ac-CoA) and a peptide resembling the lysine substrate.^{607,608} However, due to their peptidic nature and size, they are not membrane-permeable and require the assistance of a delivery system. Based on inhibitory strategies for HATs, nonpeptide small molecular inhibitors have been developing as potential therapeutic agents. Several small molecule inhibitors are natural products, including garcinol, curcumin, and anacardic acid.^{609–611} These natural HAT inhibitors lack selectivity between HATs and often have other targets. Therefore, structurally modified and synthetic compounds have been reported. A-Methylene-g-butyrolactones are small molecular inhibitors of HATs with selectivity for either GCN5L2 or PCAF.⁶¹² Isothiazolone is another HAT inhibitor targeting p300 and PCAF.⁶¹³ However, high reactivity towards thiolates limits the application of HAT inhibitors in

biological systems. Other inhibitors of HATs, such as thiazide sulfonamide and C646, have been gradually identified and show promising effects in multiple cancers. Another strategy to inhibit HAT activity is to target protein–protein interactions between HATs and their interaction partners. This method is dependent on the function of the interactions rather than the acetylation activity of HATs. ICG-001 and PRI-724 are representatives of this kind of inhibitor. Appropriately applying HAT agonists is also important to correct aberrant acetylation during diseases. CTPB is derived from anacardic acid and selectively activates p300, resulting in gene transcription.⁶⁰⁹ TTK21 and SPV106 are two other agonists based on anacardic acid.

Binding to BRDs and blocking acetylated lysine recognition is another mechanism that inhibits acetylation. JQ1 and I-BET762 are two representative inhibitors of the BET family. JQ1 is a cell-permeable small molecule and can competitively bind to BRD4 fusion oncoproteins, such as BRD4-NUT, resulting in cancer cell differentiation and apoptosis.⁶¹⁴ Similarly, I-BET762 is also a synthetic mimic of and competes with BRD4.⁶¹⁵ Other compounds, such as MS417, OTX-015, RVX-208, OXFBD, I-BET151, PFI-1, MS436, and XD14, are also BET inhibitors and have been well illustrated in other published papers.⁶¹⁶ We will focus on the associations between these compounds and cancers. However, a number of non-BET proteins containing BRDs have attracted considerable attention. Many non-BET bromodomain inhibitors are based on a structure called the “WPF shelf” and a “gatekeeper” residue located at the start of the C helix.⁶¹⁷ Several HATs have a BRD, such as Gcn5, PCFA, p300, and CBP. Inhibitors for CBP include MS2126, MS7972, ischemin, SGC-CBP30 and I-CBP112; optimized 1-(1H-indol-1-yl) ethanone derivatives have also shown promising results in inhibiting CBP and p300.⁶¹⁸ BAZ2A/B bromodomain inhibitors include BAZ2-ICR and GSK2801. The quinolone-fused lactam LP99 was the first synthetic selective inhibitor for BRD7/9. I-BRD9 was identified by GlaxoSmithKline (GSK) and is a selective inhibitor of BRD9, which has more than 200-fold selectivity for BRD9 over BRD7 and 700-fold selectivity for BRD9 over BET family members.⁶¹⁹ PFI-3 is a potential inhibitor of SMARCA4 and PB1 with a stronger affinity for the bromodomain of SMARCA4. However, Vangamudi et al. identified that the ATPase domain within SMARCA4 bypassed the anticancer effects related to the bromodomain since PFI-3 did not inhibit cell proliferation.⁶²⁰ The BRPF1 (bromodomain and PHD finger-containing 1) protein is part of the BRPF family, which is a component of MYST family complexes. The inhibitors of BRPF1 include PFI-4, OF-1, and NI-57. 1,3-Dimethyl benzimidazolones were the first selective inhibitors of BRPF1. PFI-4 and OF-1 are two close analogs of 1,3-dimethyl benzimidazolone that have been identified by the Structural Genomics Consortium (SGC). Another BRPF1 inhibitor, NI-57, was discovered by the SGC based on a new quinolinone scaffold. Both NI-57 and OF-1 are thought to interact

Table 5. Important ongoing clinical trials with DNA methylation-targeted therapies.

Condition	Design	Sample size	Phase	Current status	NCT
<i>Azacitidine (5-azacitidine)-based trials</i>					
High-risk MDS	Azacitidine	44	IV	Completed	NCT01201811
Low-risk MDS	Azacitidine	216	III	Active, not recruiting	NCT01566695
High-risk MDS	Azacitidine	358	III	Completed	NCT00071799
CML	Azacitidine	11	II	Completed	NCT01350947
AML, MDS	Azacitidine	187	III	Completed	NCT00887068
Relapsed or refractory T-cell lymphoma	Azacitidine	20	III	Recruiting	NCT03703375
AML with complete remission	Azacitidine	472	III	Active, not recruiting	NCT01757535
Recurrent IDH1/2-mutated glioma recruiting	Azacitidine NCT03666559	63	II	Not yet	
Prostate cancer	Azacytidine	36	II	Completed	NCT00384839
Head and neck squamous cell carcinoma	Azacitidine	25	II	Recruiting	NCT02178072
Locally advanced or metastatic nasopharyngeal carcinoma	Azacitidine	36	II	Completed	NCT02269943
Pancreatic cancer	Azacitidine	80	II	Recruiting	NCT01845805
Solid tumors and hematological disorders	Azacitidine	125	II	Recruiting	NCT02494258
AML	Azacitidine + venetoclax	42	II	Recruiting	NCT03466294
AML	Azacitidine + venetoclax	30	II	Recruiting	NCT03573024
AML	Azacitidine + venetoclax	400	III	Recruiting	NCT02993523
AML, MDS	Azacitidine + eltrombopag	25	II	Completed	NCT01488565
MDS	Azacitidine + eltrombopag	356	III	Terminated	NCT02158936
MDS	Azacitidine + APR-246	156	III	Recruiting	NCT03745716
AML, MDS	Azacitidine + DLI	30	II	Completed	NCT01541280
AML/MDS	Azacitidine + lenalidomide	72	II	N/A	NCT01556477
High-risk MDS with 5q deletion	Azacytidine + lenalidomide	50	II	Completed	NCT01088373
AML	Azacitidine + lenalidomide	88	II	Completed	NCT01358734
Elderly patients with AML	Azacitidine + lenalidomide	120	II	Completed	NCT01301820
Refractory AML	Azacitidine + lenalidomide	37	II	Completed	NCT01743859
MDS, CMML and AML relapsing after allo-HSCT	Azacitidine + lenalidomide + DLI	50	II	Active, not recruiting	NCT02472691
MDS with excess blasts 2	Azacitidine + vosaroxin	168	II	Recruiting	NCT03338348
AML	Azacitidine vs conventional care regimen	488	III	Completed	NCT01074047
AML, MDS with FLT3-ITD mutation	Azacitidine + sorafenib	17	II	Completed	NCT02196857
Advanced solid tumors	Azacitidine + durvalumab	60	II	Recruiting	NCT02811497
High-risk MDS, AML	Azacitidine + durvalumab	213	II	Active, not recruiting	NCT02775903
MDS patients with excess blasts, progressing	Azacitidine + rigosertib	67	III	Active, not recruiting	NCT01928537
AML, MDS, CML recruiting	Azacitidine + HAG regimen NCT03873311	120	III	Not yet	
Refractory or relapsed AML	Azacitidine + lirilumab	37	II	Completed	NCT02399917
AML	Azacitidine + induction therapy	336	II	N/A	NCT01180322
AML with NPM1 mutation	Azacitidine + pembrolizumab	28	II	Not yet recruiting	NCT03769532
Pancreatic cancer	Azacitidine + pembrolizumab	31	II	Recruiting	NCT03264404
Metastatic melanoma	Azacitidine + pembrolizumab	71	II	Recruiting	NCT02816021
MDS	Azacitidine + pembrolizumab	40	II	Recruiting	NCT03094637
Chemorefractory metastatic colorectal cancer	Azacitidine + pembrolizumab	31	II	Active, not recruiting	NCT02260440
Advanced or metastatic non-small-cell lung cancer	Azacitidine + pembrolizumab	100	II	Active, not recruiting	NCT02546986
Platinum-resistant ovarian cancer	Azacitidine + pembrolizumab	20	II	Recruiting	NCT02900560
MDS	Azacitidine + lintuzumab	7	II	Terminated	NCT00997243
Prostate cancer	Azacitidine + ATRA	20	II	Recruiting	NCT03572387
Recurrent or refractory disease with IDH2 mutation	Azacitidine + enasidenib	50	II	Recruiting	NCT03683433
High-risk MDS with IDH2 mutation	Azacitidine + enasidenib	105	II	Recruiting	NCT03383575
Elderly patients with AML	Azacitidine + standard therapy	214	II	Completed	NCT00915252

Table 5 continued

Condition	Design	Sample size	Phase	Current status	NCT
Refractory or relapsed AML	Azacitidine + avelumab	52	I/II	Recruiting	NCT02953561
AML, MDS, CML	Azacitidine + pevonedistat	450	III	Recruiting	NCT03268954
Relapsed or refractory AML	Azacitidine + pevonedistat	72	II	Not yet recruiting	NCT03745352
High-risk MDS, AML, CML	Azacitidine + pevonedistat	120	II	Active, not recruiting	NCT02610777
AML without remission after allogeneic stem cell transplantation	Azacitidine + pevonedistat	30	II	Recruiting	NCT03709576
MDS	Azacitidine + pevonedistat	71	II	Recruiting	NCT03238248
Elderly patients with AML	Azacitidine + gemtuzumab ozogamicin	133	II	Active, not recruiting	NCT00658814
Recurrent and resectable osteosarcoma	Azacitidine + nivolumab	51	I/II	Not yet recruiting	NCT03628209
Childhood relapsed/refractory AML	Azacitidine + nivolumab	26	I/II	Not yet recruiting	NCT03825367
Elderly patients with AML or high-risk MDS	Azacitidine/decitabine + nivolumab or midostaurin	1670	II/III	Suspended	NCT03092674
Refractory/relapsed AML	Azacitidine + ipilimumab + nivolumab	182	II	Recruiting	NCT02397720
MDS	Azacitidine + nivolumab + ipilimumab	120	II	Recruiting	NCT02530463
MDS	Azacitidine + lirilumab + nivolumab	12	II	Completed	NCT02599649
High-risk MDS, AML	Azacitidine + sirolimus	74	II	Recruiting	NCT01869114
AML with IDH1 mutation	Azacitidine + AG-120	392	III	Recruiting	NCT03173248
Relapsed/refractory diffuse large B-cell lymphoma	Azacitidine + rituximab	27	II	Not yet recruiting	NCT03719989
Leukemia	Azacitidine + PKC412	54	I/II	Completed	NCT01202877
MDS	Azacitidine + sonidegib	78	I	Active, not recruiting	NCT02129101
MDS, AML and CMML	Azacitidine + PF-04449913	102	II	Recruiting	NCT02367456
MDS	Azacitidine + etanercept	32	I/II	Completed	NCT00118287
MDS, myeloproliferative neoplasm	Azacitidine + ruxolitinib Phosphate	123	II	Completed	NCT01787487
Relapsed or refractory AML, MDS	Azacitidine + quizartinib	72	I/II	Recruiting	NCT01892371
AML	Azacitidine vs fludarabine + cytarabine	289	III	Active, not recruiting	NCT02319135
AML, high-risk MDS	Azacitidine + cytarabine + tosedostat	96	I/II	Active, not recruiting	NCT01636609
Peripheral T-cell lymphoma	Azacitidine + CHOP	20	II	Recruiting	NCT03542266
AML	Azacitidine + intensive chemotherapy	720	III	Recruiting	NCT03416179
Advanced non-small-cell lung cancer	Azacitidine + paclitaxel	240	II	Active, not recruiting	NCT02250326
<i>Decitabine (5-aza-2'deoxyctidine)-based trials</i>					
Refractory CML	Decitabine	40	II	Completed	NCT00042003
Metastatic papillary thyroid cancer or follicular thyroid cancer	Decitabine	12	II	Completed	NCT00085293
AML with TP53 mutation	Decitabine	60	II	Recruiting	NCT03063203
AML	Decitabine	546	II	Completed	NCT00416598
MDS	Decitabine	128	II	Completed	NCT00067808
Elderly patients with AML	Decitabine	238	II	Completed	NCT00866073
Advanced-stage MDS	Decitabine	160	III	Completed	NCT00043381
Relapse and refractory diffuse large B-cell lymphoma	Decitabine	60	IV	Recruiting	NCT03579082
Relapsed or refractory T lymphoblastic lymphoma	Decitabine	40	IV	Recruiting	NCT03558412
CML	Decitabine + imatinib mesylate	80	II	Completed	NCT00054431
High-risk MDS, AML	Decitabine + tosedostat	34	II	Completed	NCT01567059
Metastatic castration-resistant prostate cancer	Decitabine + enzalutamide	21	I/II	Not yet recruiting	NCT03709550
Peripheral T-cell lymphoma	Decitabine + CHOP	100	III	Not yet recruiting	NCT03553537
Relapsed FLT3-ITD-mutated AML, MDS	Decitabine + quizartinib	52	I/II	Recruiting	NCT03661307
AML	Decitabine + clofarabine	727	II	Active, not recruiting	NCT02085408
AML	Decitabine + ruxolitinib Phosphate	42	I/II	Recruiting	NCT02257138
AML	Decitabine + bortezomib	165	II	Active, not recruiting	NCT01420926
AML	Decitabine + cytarabine + daunorubicin hydrochloride	180	II	Active, not recruiting	NCT01627041

Table 5 continued

Condition	Design	Sample size	Phase	Current status	NCT
<i>Guadecitabine (SGI-110)-based trials</i>					
AML	Guadecitabine	815	III	Completed	NCT02348489
Philadelphia-negative MDS	Guadecitabine	50	II	Recruiting	NCT03075826
High-risk MDS	Guadecitabine	103	II	Recruiting	NCT02131597
Advanced hepatocellular carcinoma (HCC)	Guadecitabine	51	II	Completed	NCT01752933
AML, MDS	Guadecitabine	401	I/II	Completed	NCT01261312
MDS, CMML	Guadecitabine	408	III	Recruiting	NCT02907359
AML, MDS	Guadecitabine + DLI	40	II	Not yet recruiting	NCT03454984
MDS relapsing post AlloSCT	Guadecitabine + DLI	90	II	Recruiting	NCT02684162
Refractory metastatic colorectal cancer	Guadecitabine + nivolumab	45	I/II	Not yet recruiting	NCT03576963
Recurrent ovarian, primary peritoneal, or fallopian tube cancer	Guadecitabine + Pembrolizumab	38	II	Recruiting	NCT02901899
Metastatic colorectal cancer	Guadecitabine + irinotecan	108	II	Active, not recruiting	NCT01896856
Advanced kidney cancer	Guadecitabine + durvalumab	58	I/II	Recruiting	NCT03308396
Refractory or resistant urothelial carcinoma	Guadecitabine + atezolizumab (anti-PD-L1 antibody)	53	II	Recruiting	NCT03179943
Advanced MDS CMML	Guadecitabine + atezolizumab	72	I/II	Recruiting	NCT02935361
Recurrent ovarian, fallopian tube, or primary peritoneal cancer	Guadecitabine + CDX-1401 Vaccine + atezolizumab	75	I/II	Recruiting	NCT03206047
Ovarian cancer	Guadecitabine + carboplatin	120	II	Completed	NCT01696032
<i>5-F-CdR-based trials</i>					
Advanced cancer	5-Fluoro-2-deoxycytidine (FdCyd)	58	I	Completed	NCT00359606
<i>Hydralazine-based trials</i>					
Ovarian cancer	Hydralazine + valproate	211	III	N/A	NCT00533299
Cervical cancer	Hydralazine + valproate	143	III	N/A	NCT00532818
Recurrent-persistent cervical cancer	Hydralazine + valproate	230	III	N/A	NCT02446652
Cervical cancer	Hydralazine + valproate + cisplatin	18	II	Completed	NCT00404326
Refractory solid tumors	Hydralazine + magnesium valproate	15	II	Completed	NCT00404508
Venetoclax, Bcl-2-selective inhibitor; Eltrombopag, c-mpl (TpoR) receptor agonist; APR-246, p53 agonist; DLI, donor leukocyte infusion; lenalidomide, derivative of thalidomide; sorafenib, multiple tyrosine kinase inhibitor; durvalumab, anti-PD-L1 monoclonal antibody; rigosertib, Ras mimetic; HAG regimen, homoharringtonine + cytarabine + G-CSF; lirilumab, anti-KIR monoclonal antibody; pembrolizumab, anti-PD-1 monoclonal antibody; lintuzumab, anti-CD33 monoclonal antibody; enasidenib, IDH2 inhibitor; avelumab, anti-PD-L1 monoclonal antibody; pevonedistat, NEDD8 inhibitor; nivolumab, anti-PD-1 monoclonal antibody; sirolimus, mTOR inhibitors; AG-120, IDH1 inhibitor; rituximab, anti-CD20 monoclonal antibody; PKC412, multitargeted protein kinase inhibitor; birinapant, SMAC mimetic antagonist; sonidegib, Hedgehog signaling pathway inhibitor; PF-04449913 (glasdegib), hedgehog signaling pathway inhibitor; etanercept, TNF inhibitor; ruxolitinib phosphate, JAK inhibitor; quizartinib, tyrosine kinase inhibitor; tosedostat, inhibitor of the M1 family of aminopeptidases; atezolizumab, anti-PD-L1 monoclonal antibody					

with BRPF1-3 as pan-BRPF bromodomain inhibitors. Based on the bromodomain contained within both TRIM24 (tripartite motif containing protein 24) and BRPF1, a dual inhibitor, IACS-9571, has been identified.⁶²¹ Bromosporine is a panbromodomain inhibitor with good cellular activity, whereas in a recent study, researchers noticed that bromodomain inhibitors only targeted the BET family rather than other BRDs.⁶²²

Inhibition of HDACs. Given that multiple methods can regulate HDAC activity, the designation of HDAC inhibitors has its own advantages. In the 1970s, butyrate was found to induce the accumulation of acetylated histones in cancer cells, which is thought to be associated with the inhibition of deacetylation.⁶²³ Later, a natural extract, trichostatin A (TSA), was identified to inhibit the activity of partially purified HDACs and induce cancer cell differentiation and apoptosis.⁶²⁴ Gradually, more natural and synthetic compounds have been identified to inhibit histone deacetylation. A study reported that administration of HDAC inhibitors only regulates a small number of genes (1–2%) but induces an obvious and rapid decrease in *c-Myc* gene expression, which indicated that a restricted set of cellular genes was uniquely sensitive to regulation of histone acetylation.⁶²⁵ The combination

of two HDAC inhibitors, SAHA and TSA, induced melanoma cell growth arrest by upregulating p21, p27 and NF-κB, and MG132 can enhance the effect of TSA.⁶²⁶ The inhibition of HDACs has been investigated in various cancers, with promising antitumor effects.^{627,628} Based on the characteristics of their chemical structures, HDAC inhibitors can be divided into five groups: short-chain fatty acids, hydroxamic acids, benzamides, cyclic peptides, and hybrid molecules. In addition to those included in the five groups, some new synthetic compounds also act as inhibitors of HDACs.

The short-chain fatty acid group contains sodium butyrate, valproic acid (VPA), sodium phenylbutyrate, and AN-9 (pivaloyloxymethyl butyrate). The effective concentration of butyrate is usually at the micromolar level. The group of hydroxamic acids includes more than ten members and is the best-studied class. Structural analyses of TSA and suberoylanilide hydroxamic acid (SAHA) show that they are noncompetitive inhibitors of HDACs since they share significant homology with class I and class II HDACs, which makes them mimics of the lysine substrates.⁶²⁹ In addition, they chelate the active zinc ion in a bidentate manner, which is crucial for enzymatic activity.⁶²⁴ Hexamethylene bisacetamide (HMBA) is a representative of the hybrid polar compounds

Table 6. Important ongoing clinical trials with histone acetylation-targeted therapies.

Condition	Design	Sample size	Phase	Current status	NCT
Anti-HDAC					
<i>Valproic acid-based trials</i>					
Advanced thyroid cancers	Valproic acid	13	II	Completed	NCT01182285
Uveal melanoma	Valproic acid	150	II	Recruiting	NCT02068586
Pancreatic cancer	Valproic acid	20	II	N/A	NCT01333631
Non-Hodgkin lymphoma, Hodgkin lymphoma, CLL	Valproic acid	52	II	N/A	NCT01016990
Locally advanced head and neck squamous cell carcinoma	Valproic acid + platinum-based chemoradiation	14	II	Completed	NCT01695122
Non-small-cell lung cancer	Valproic acid + chemoradiotherapy	20	I/II	N/A	NCT01203735
Recurrent high-grade glioma	Valproic acid + sildenafil citrate + sorafenib tosylate	66	II	Recruiting	NCT01817751
Glioma	Valproic acid + levetiracetam	120	IV	Recruiting	NCT03048084
Virus-associated cancer	Valproic acid + avelumab	39	II	Recruiting	NCT03357757
Colorectal cancer	Valproic acid + radiation therapy	152	I/II	N/A	NCT01898104
Refractory or relapsing small-cell lung cancer	Valproic acid + doxorubicin, cyclophosphamide and vindesine	64	II	Completed	NCT00759824
High-grade gliomas, brain tumors	Valproic acid + temozolomide + radiation therapy	43	II	Completed	NCT00302159
High-grade gliomas or diffuse intrinsic pontine glioma	Valproic acid + radiation	38	II	Active, not recruiting	NCT00879437
Advanced malignant neoplasm	Valproic acid + bevacizumab + temsirolimus	216	I	Recruiting	NCT01552434
Malignant mesothelioma	Valproic acid + doxorubicin	45	II	Completed	NCT00634205
Diffuse large B-cell lymphoma	Valproic acid + rituximab + CHOP	50	I/II	Completed	NCT01622439
<i>Sodium phenylbutyrate-based trials</i>					
Progressive or recurrent brain tumors	Phenylbutyrate	120	II	Completed	NCT00006450
Relapsed or refractory Epstein-Barr virus-positive cancer	Phenylbutyrate + valganciclovir	14	II	N/A	NCT00387530
Refractory or relapsed AML	Phenylbutyrate + dexamethasone + sargramostim	N/A	II	Completed	NCT00006240
<i>AN-9 (pivaloyloxymethyl butyrate)-based trials</i>					
Advanced non-small-cell lung cancer	Pivanex + docetaxel	225	II	Completed	NCT00073385
<i>Phenylacetate-based trials</i>					
Children with recurrent or progressive brain tumors	Phenylacetate	N/A	II		NCT00003241
<i>Vorinostat (SAHA)-based trials</i>					
Advanced cancer	Vorinostat	143	I	Active, not recruiting	NCT01266057
BRAFV600-mutated advanced melanoma	Vorinostat	22	I/II	Recruiting	NCT02836548
Breast cancer	Vorinostat	49	I/II	N/A	NCT00416130
Advanced, metastatic soft tissue sarcoma	Vorinostat	40	II	Completed	NCT00918489
AML	Vorinostat	37	II	Completed	NCT00305773
Advanced non-small-cell lung cancer	Vorinostat	16	II	Completed	NCT00138203
Recurrent or persistent ovarian epithelial or primary peritoneal cavity cancer	Vorinostat	60	II	Completed	NCT00132067
advanced adenoid cystic carcinoma advanced thyroid cancer	Vorinostat	30	II	Completed	NCT01175980
Advanced thyroid cancer	Vorinostat	19	II	Completed	NCT00134043
Kidney cancer	Vorinostat	14	II	Completed	NCT00278395
Metastatic or unresectable melanoma	Vorinostat	32	II	Completed	NCT00121225
Low-grade non-Hodgkin lymphoma	Vorinostat	37	II	Completed	NCT00253630
Progressive glioblastoma multiforme	Vorinostat	103	II	Completed	NCT00238303
Progressive metastatic prostate cancer	Vorinostat	29	II	Completed	NCT00330161
Advanced cutaneous T-cell lymphoma	Vorinostat	74	II	Completed	NCT00091559
Advanced malignant pleural mesothelioma	Vorinostat	662	III	Completed	NCT00128102
Metastatic or recurrent gastric cancer	Vorinostat + capecitabine + cisplatin	45	I/II	Completed	NCT01045538
Breast cancer	Vorinostat + tamoxifen	43	II	Completed	NCT00365599
T-cell non-Hodgkin lymphoma	Vorinostat + CHOP	14	I/II	Completed	NCT00787527
Advanced non-small-cell lung cancer	Vorinostat + bortezomib	18	II	Completed	NCT00798720
Relapsed or refractory multiple myeloma	Vorinostat + bortezomib	143	II	Completed	NCT00773838
Recurrent glioblastoma multiforme	Vorinostat + bortezomib	44	II	Completed	NCT00641706
Advanced soft tissue sarcoma	Vorinostat + bortezomib	16	II	Completed	NCT00937495

Table 6 continued

Condition	Design	Sample size	Phase	Current status	NCT
Multiple myeloma	Vorinostat + bortezomib	637	III	Completed	NCT00773747
Unresectable or metastatic kidney cancer	Vorinostat + bevacizumab	37	I/II	Completed	NCT00324870
Glioblastoma multiforme	Vorinostat + temozolomide + radiation therapy	125	I/II	Active, not recruiting	NCT00731731
Diffuse intrinsic pontine glioma	Vorinostat + radiation therapy	80	I/II	Active, not recruiting	NCT01189266
Recurrent ovarian cancer	vorinostat + paclitaxel + carboplatin vorinostat + pembrolizumab	70	II	N/A	NCT00772798
Stage IV non-small-cell lung cancer (NSCLC)	Vorinostat + pembrolizumab	100	I/II	Recruiting	NCT02638090
CLL, small lymphocytic lymphoma	Vorinostat + fludarabine phosphate + cyclophosphamide + rituximab	40	I/II	Active, not recruiting	NCT00918723
Relapse/refractory AML	Vorinostat + temozolomide	23	II	Completed	NCT01550224
Stage II, III, or IV diffuse large B-cell lymphoma	Vorinostat + rituximab	83	I/II	Active, not recruiting	NCT00972478
Metastatic breast cancer	Vorinostat + paclitaxel + bevacizumab	54	I/II	Completed	NCT00368875
High-grade glioma	Vorinostat + radiation therapy	101	II/III	Completed	NCT01236560
High-risk MDS, AML	Vorinostat + idarubicin + cytarabine	106	II	Completed	NCT00656617
Colorectal cancer	Vorinostat + hydroxychloroquine	76	II	Recruiting	NCT02316340
Advanced non-small-cell lung cancer	Vorinostat + carboplatin + paclitaxel	94	II	Completed	NCT00481078
Metastatic colorectal cancer	Vorinostat + fluorouracil + leucovorin calcium	58	II	Completed	NCT00942266
Recurrent glioblastoma multiforme (GBM)	Vorinostat + isotretinoin + temozolomide	135	I/II	Active, not recruiting	NCT00555399
Breast cancer	Vorinostat + carboplatin + nab-paclitaxel	68	II	Completed	NCT00616967
Diffuse large B-cell non-Hodgkin lymphoma	Vorinostat + chemotherapy + rituximab	107	I/II	Active, not recruiting	NCT01193842
Advanced sarcoma	Vorinostat + gemcitabine + docetaxel	67	I/II	Recruiting	NCT01879085
AML	Vorinostat + cytarabine + daunorubicin Hydrochloride/idarubicin	754	III	Completed	NCT01802333
Neuroblastoma	Vorinostat + 131I-MIBG	105	II	Recruiting	NCT02035137
Multiple myeloma	Vorinostat + lenalidomide	4420	III	Active, not recruiting	NCT01554852
Relapsed/refractory cutaneous T-cell lymphoma (CTCL)	Vorinostat vs KW-0761	372	III	Active, not recruiting	NCT01728805
<i>TSA (Trichostatin A)-based trials</i>					
Relapsed or refractory hematologic malignancies	Trichostatin A	42	I	Recruiting	NCT03838926
<i>Belinostat (PAHA, PXD101)-based trials</i>					
Advanced solid tumors or lymphoma	Belinostat	121	I	Completed	NCT00413075
Relapsed or refractory peripheral T-cell lymphoma	Belinostat	129	II	Completed	NCT00865969
Liver cancer	Belinostat	54	I/II	Completed	NCT00321594
MDS	Belinostat	21	II	Completed	NCT00357162
Relapsed or refractory aggressive B-cell non-Hodgkin lymphoma	Belinostat	22	II	Completed	NCT00303953
Advanced multiple myeloma	Belinostat	25	II	Completed	NCT00131261
Solid tumors or hematological malignancies	Belinostat + warfarin	27	I	Completed	NCT01317927
Soft tissue sarcomas	Belinostat + doxorubicin	41	I/II	Completed	NCT00878800
Relapsed/refractory NHL	Belinostat + carfilzomib	19	I	Completed	NCT02142530
Relapsed or refractory AML, MDS	Belinostat + pevonedistat	45	I	Not yet recruiting	NCT03772925
Adult T-cell leukemia-lymphoma	Belinostat + zidovudine	20	II	Recruiting	NCT02737046
Recurrent ovarian epithelial cancer	Belinostat + carboplatin	29	II	Completed	NCT00993616
Stage IV non-small-cell lung cancer (NSCLC)	Belinostat + carboplatin + paclitaxel	23	I/II	Completed	NCT01310244
Ovarian cancer	Belinostat + carboplatin + paclitaxel	80	I/II	Completed	NCT00421889
Cancer of unknown primary site	Belinostat + carboplatin + paclitaxel	89	II	Completed	NCT00873119
<i>Entinostat (MS-275)-based trials</i>					
Relapsed or refractory Hodgkin lymphoma	Entinostat	49	II	Completed	NCT00866333
MDS, AML, ALL	Entinostat	24	II	Completed	NCT00462605
Metastatic melanoma	Entinostat	28	II	Completed	NCT00185302
Advanced breast cancer	Entinostat	512	III	Recruiting	NCT03538171
Metastatic kidney cancer	Entinostat + aldesleukin	45	I/II	Active, not recruiting	NCT01038778
TN breast cancer	Entinostat + atezolizumab	88	I/II	Active, not recruiting	NCT02708680
Advanced epithelial ovarian cancer	Entinostat + avelumab	140	I/II	Active, not recruiting	NCT02915523
Metastatic colorectal cancer	Entinostat + regorafenib + hydroxychloroquine	44	I/II	Recruiting	NCT03215264
Advanced renal cell carcinoma	Entinostat + bevacizumab + atezolizumab	62	I/II	Recruiting	NCT03024437
Endometrioid endometrial cancer	Entinostat + medroxyprogesterone acetate	50	II	Active, not recruiting	NCT03018249

Table 6 continued

Condition	Design	Sample size	Phase	Current status	NCT
Renal cell carcinoma	Entinostat + IL-2	46	II	Recruiting	NCT03501381
NSCLC, melanoma, and colorectal cancer	Entinostat + pembrolizumab	202	I/II	Active, not recruiting	NCT02437136
Relapsed and refractory lymphomas	Entinostat + pembrolizumab	78	II	Recruiting	NCT03179930
Stage III/IV melanoma	Entinostat + pembrolizumab	14	II	Recruiting	NCT03765229
High-risk refractory malignancies	Entinostat + nivolumab	128	I/II	Not yet recruiting	NCT03838042
Metastatic cholangiocarcinoma and pancreatic adenocarcinoma	Entinostat + nivolumab	54	II	Recruiting	NCT03250273
Renal cell carcinoma	Entinostat + nivolumab + ipilimumab	53	II	Recruiting	NCT03552380
Advanced breast cancer	Entinostat + exemestane	130	II	Completed	NCT00676663
Breast cancer	Entinostat + exemestane	600	III	Active, not recruiting	NCT02115282
Advanced NSCLC	Entinostat + erlotinib	132	I/II	Completed	NCT00602030
Non-small-cell lung carcinoma	Entinostat + erlotinib	70	II	Completed	NCT00750698
<i>Panobinostat (LBH589)-based trials</i>					
High-risk MDS, AML	Panobinostat	62	I/II	Active, not recruiting	NCT01451268
Advanced hematological malignancies	Panobinostat	175	I/II	Completed	NCT00621244
Metastatic thyroid cancer	Panobinostat	13	II	Completed	NCT01013597
Advanced soft tissue sarcoma	Panobinostat	53	II	Completed	NCT01136499
Refractory prostate cancer	Panobinostat	35	II	Completed	NCT00667862
Refractory clear cell renal carcinoma	Panobinostat	20	II	Completed	NCT00550277
Relapsed/refractory classical Hodgkin lymphoma	Panobinostat	129	II	Completed	NCT00742027
Refractory colorectal cancer	Panobinostat	29	II	Completed	NCT00690677
HER2-negative locally recurrent or metastatic breast cancer	Panobinostat	54	II	Completed	NCT00777049
Relapsed and bortezomib-refractory multiple myeloma	Panobinostat	55	II	Completed	NCT01083602
Relapsed or refractory non-Hodgkin lymphoma	Panobinostat	41	II	Active, not recruiting	NCT01261247
Refractory CML	Panobinostat	27	II/III	Completed	NCT00449761
Refractory/resistant cutaneous T-cell lymphoma	Panobinostat	9	II/III	Completed	NCT00490776
Refractory CML	Panobinostat	29	II/III	Completed	NCT00451035
Refractory cutaneous T-cell lymphoma	Panobinostat	139	II/III	Completed	NCT00425555
Hodgkin lymphoma (HL)	Panobinostat	41	III	Completed	NCT01034163
Relapsed/refractory multiple myeloma	Panobinostat + carfilzomib	80	I/II	Active, not recruiting	NCT01496118
Recurrent high-grade glioma	Panobinostat + bevacizumab	51	I/II	Completed	NCT00859222
Recurrent prostate cancer after castration	Panobinostat + bicalutamide	52	I/II	Completed	NCT00878436
AML	Panobinostat + idarubicin + cytarabine	46	I/II	Completed	NCT00840346
Diffuse large B-cell lymphoma (DLBCL)	Panobinostat + rituximab	42	II	N/A	NCT01238692
Relapsed and refractory lymphoma	Panobinostat + everolimus	31	I/II	Completed	NCT00967044
Gliomas	Panobinostat + everolimus	32	II	Recruiting	NCT03632317
Recurrent multiple myeloma, Non-Hodgkin lymphoma, or Hodgkin lymphoma	Panobinostat + everolimus	124	I/II	Active, not recruiting	NCT00918333
Relapsed/refractory peripheral T-cell lymphoma or NK/T-cell lymphoma	Panobinostat + bortezomib	25	II	Completed	NCT00901147
Relapsed or relapsed- and-refractory multiple myeloma	Panobinostat + bortezomib + dexamethasone	240	II	Recruiting	NCT02654990
Relapsed multiple myeloma	Panobinostat + bortezomib + dexamethasone	768	III	Completed	NCT01023308
Relapsed or refractory Hodgkin lymphoma	Panobinostat + lenalidomide	24	II	Completed	NCT01460940
<i>Mocetinostat (MGCD0103)-based trials</i>					
Advanced solid tumors or non-Hodgkin lymphoma	Mocetinostat	42	I	Completed	NCT00323934
Refractory chronic lymphocytic leukemia	Mocetinostat	21	II	Completed	NCT00431873
Relapsed and refractory lymphoma	Mocetinostat	74	II	Completed	NCT00359086
Tumors	Mocetinostat + gemcitabine	47	I/II	Completed	NCT00372437
Relapsed or refractory Hodgkin lymphoma	Mocetinostat + brentuximab vedotin	7	I/II	Active, not recruiting	NCT02429375
Advanced solid tumors and NSCLC	Mocetinostat + durvalumab	119	I/II	Active, not recruiting	NCT02805660
Metastatic leiomyosarcoma	Mocetinostat + gemcitabine	20	II	Completed	NCT02303262
Non-small-cell lung cancer	Mocetinostat + glesatinib + sitravatinib + nivolumab	209	II	Recruiting	NCT02954991

Table 6 continued

Condition	Design	Sample size	Phase	Current status	NCT
<i>CI-994-based trials</i>					
Advanced myeloma	CI-994	6	II	Completed	NCT00005624
Advanced pancreatic cancer	CI-994 + gemcitabine	N/A	II	Completed	NCT00004861
Advanced non-small-cell lung cancer	CI-994 + gemcitabine	N/A	III	Completed	NCT00005093
<i>Romidepsin (Depsipeptide, FR901228, FK228)-based trials</i>					
Recurrent high-grade gliomas	Romidepsin	50	I/II	Completed	NCT00085540
Progressive or relapsed peripheral T-cell lymphoma	Romidepsin	131	II	Active, not recruiting	NCT00426764
Soft tissue sarcoma	Romidepsin	40	II	Completed	NCT00112463
Squamous cell carcinoma of the head and neck	Romidepsin	14	II	Completed	NCT00084682
Metastatic breast cancer	Romidepsin	37	II	Completed	NCT00098397
Relapsed small-cell lung cancer	Romidepsin	36	II	Completed	NCT00086827
Cutaneous T-cell lymphoma and peripheral T-cell lymphoma	Romidepsin	131	II	Completed	NCT00007345
Relapsed or refractory AML	Romidepsin	47	II	Completed	NCT00062075
Relapsed or refractory multiple myeloma	Romidepsin	50	II	Completed	NCT00066638
Relapsed or refractory non-Hodgkin lymphoma	Romidepsin	35	II	Completed	NCT00077194
Triple-negative breast cancer (TNBC)	Romidepsin + nivolumab + cisplatin	54	I/II	Recruiting	NCT02393794
Relapsed/refractory T-cell lymphoma	Romidepsin + tenalisib	42	I/II	Recruiting	NCT03770000
Lymphoid hematopoietic malignancy	Romidepsin + pembrolizumab	39	I/II	Recruiting	NCT03278782
Peripheral T-cell lymphoma (PTCL)	Romidepsin + ixazomib	48	I/II	Recruiting	NCT03547700
Relapsed/refractory lymphoid malignancies	Romidepsin + pralatrexate	93	I/II	Recruiting	NCT01947140
Peripheral T-cell lymphoma	Romidepsin + CHOP	421	III	Active, not recruiting	NCT01796002
Relapsed/refractory peripheral T-cell lymphoma	Romidepsin + gemcitabine	20	II	Completed	NCT01822886
Relapsed or refractory lymphomas and myeloma	Romidepsin + lenalidomide	62	I/II	Active, not recruiting	NCT01755975
Relapsed or refractory B- and T-cell lymphomas	Romidepsin + lenalidomide + carfilzomib	31	I/II	Active, not recruiting	NCT02341014
Peripheral T-cell lymphoma	Romidepsin + lenalidomide	35	II	Recruiting	NCT02232516
<i>Nicotinamide-based trials</i>					
Skin cancer prevention	Nicotinamide	120	II	Recruiting	NCT03769285
Lung cancer	Nicotinamide	110	II/III	Active, not recruiting	NCT02416739
Bladder cancer	Niacinamide + radiation + carbogen	330	III	Completed	NCT00033436
Inhibitors of sirtuins					
<i>Suramin-based trials</i>					
Recurrent primary brain tumors	Suramin	N/A	II	Completed	NCT00002639
Hormone-refractory prostate cancer	Suramin	390	III	Completed	NCT00002723
Metastatic renal cell (kidney) cancer	Suramin + fluorouracil	36	I/II	Completed	NCT00083109
Advanced non-small-cell lung cancer	Suramin + docetaxel	80	II	N/A	NCT01671332
Stage IIIB-IV breast cancer	Suramin + paclitaxel	31	I/II	Completed	NCT00054028
Stage IIIB or IV non-small-cell lung cancer	Suramin + paclitaxel + carboplatin	82	II	Completed	NCT00006929
Poor-prognosis prostate carcinoma	Suramin + flutamide + leuprolide	70	II	Completed	NCT00001266
Prostate cancer	Suramin + flutamide + hydrocortisone	N/A	III	Completed	NCT00002881
Inhibitors for HATs					
<i>CBP-targeted therapy</i>					
Advanced myeloid malignancies	PRI-724	49	I/II	Completed	NCT01606579
Advanced pancreatic adenocarcinoma	PRI-724 + gemcitabine	20	I	Completed	NCT01764477
BRD (BET) inhibitors					
<i>GSK525762 (I-BET762, molibresib)-based trials</i>					
Relapsed, refractory hematologic malignancies	GSK525762	180	I	Recruiting	NCT01943851
NUT midline carcinoma (NMC) and other cancers	GSK525762	195	I	Active, not recruiting	NCT01587703
Castration-resistant prostate cancer	GSK525762 + androgen deprivation therapy	37	I	Active, not recruiting	NCT03150056
Advanced or metastatic breast cancer	GSK525762 + fulvestrant	294	II	Recruiting	NCT02964507
<i>CPI-0610-based trials</i>					
Multiple myeloma	CPI-0610	30	I	Completed	NCT02157636
Progressive lymphoma	CPI-0610	64	I	Active, not recruiting	NCT01949883
<i>RO6870810 (TEN-010, RG6146, JQ2)-based trials</i>					
AML, MDS	RO6870810	26	I	Completed	NCT02308761
Advanced solid tumors	RO6870810	52	I	Completed	NCT01987362

Table 6 continued

Condition	Design	Sample size	Phase	Current status	NCT
Advanced multiple myeloma	RO6870810	86	I	Recruiting	NCT03068351
Advanced ovarian cancer or triple-negative breast cancer	RO6870810 + atezolizumab	116	I	Suspended	NCT03292172
High-grade B-cell lymphoma	RO6870810 + venetoclax + rituximab	94	I	Recruiting	NCT03255096
<i>BAY1238097-based trials</i>					
Neoplasms	BAY1238097	8	I	Terminated	NCT02369029
<i>MK8628 (OTX-015, birabresib)-based trials</i>					
Advanced solid tumors	MK-8628	47	I	Completed	NCT02259114
Hematologic malignancies	MK-8628	9	I	Active, not recruiting	NCT02698189
Hematologic malignancies	MK-8628	141	I	Completed	NCT01713582
<i>FT-1101-based trials</i>					
Relapsed or refractory hematologic malignancies	FT-1101	160	I	Recruiting	NCT02543879
<i>INCB057643-based trials</i>					
Advanced malignancies	INCB057643	136	I/II	Active, not recruiting	NCT02711137
Lenalidomide, derivative of thalidomide; durvalumab, anti-PD-L1 monoclonal antibody; avelumab, anti-PD-L1 monoclonal antibody; bevacizumab, VEGF inhibitor; temsirolimus, mTOR inhibitor; rituximab, anti-CD20 monoclonal antibody; regorafenib, multikinase inhibitor; nivolumab, anti-PD-1 monoclonal antibody; sitravatinib, multiple tyrosine kinase inhibitor; tenalisib, inhibitor of PI3K; pembrolizumab, anti-PD-1 monoclonal antibody; atezolizumab, anti-PD-L1 monoclonal antibody					

(HPCs), whereas second-generation HPCs, such as oxamflatin, SAHA, suberic bishydroxamic acid (SBHA), and m-carboxycinnamic acid bishydroxamide (CBHA), have shown better inhibition of HDACs and anticancer effects than first-generation agents.⁶³⁰ Oxamflatin, scriptaid, and amide are analogs of TSA and show anticancer effects.^{631–633} Benzamide inhibitors (MS-275, MGCD0103, and CI-994) are well-studied and show promising effects in the treatment of diseases, especially cancers. They inhibit histone deacetylation via binding to catalytic zinc ions within HDACs through carbonyl and amino groups. Inhibition of HDACs by benzamide inhibitors is thought to be reversible, but the bond may become tight and pseudoirreversible in a time-dependent manner.^{634,635} However, benzamide inhibitors have less activity than members of the hydroxamate or cyclic peptide families, with an effective concentration around the micromolar range.⁶³⁶ Cyclic peptides can be further divided into two groups: cyclic tetrapeptide containing a 2-amino-8-oxo-9, 10-epoxydecanoyl (AOE) moiety (HC-toxin, trapoxin) and cyclic peptides without the AOE moiety (apicidin and romidepsin). The epoxyketone group is essential for the inhibitors to bind to active zinc ions, but the epoxyketone-based bond is irreversible. Trapoxin is a fungal cyclic peptide and can irreversibly inhibit the activity of HDACs.⁶³⁷ Romidepsin, also known as FK228, most likely relies on one of the thiol groups to coordinate to the active site zinc ion.⁶³⁸ Garlic-associated derivatives, such as diallylsulfide and allylmercaptan, are capable of generating a thiol group that makes them potential inhibitors of HDACs.⁶³⁹ K-trap, an analog of trapoxin, and other derivatives, including 9-acyloxyapicidins and 9-hydroxy, have been under investigation. Depudecin is a natural epoxide derivative isolated from the fungus *Alternaria brassicicola*. Psammaplins is isolated from a marine sponge *Pseudoceratina purpurea*. These two natural extracts can inhibit the activity of HDACs.

Early HDAC inhibitors were nonselective because of the high homology of the structure and catalytic mechanism of HDACs within each group. The first selective HDAC inhibitor was tubacin, which targets HDAC6 with increased tubulin acetylation but not histone acetylation.⁶⁴⁰ PCI-34051, a specific inhibitor of HDAC8, can induce caspase-dependent apoptosis in T-cell lymphoma but does not increase histone acetylation.⁶⁴¹ Another benzamide inhibitor, SHI-1:2, shows HDAC1/HDAC2-specific inhibitory activity that is >100-fold more selective than that of other HDACs.⁶⁴² New

synthetic chemicals, such as SK7041 and splitomicin, selectively target class I HDACs and sir2-like family members, respectively. The same efforts have been made to develop inhibitors for sirtuins, the class III HDACs. Nicotinamide, a byproduct of the sirtuin enzyme reaction, is a widely used inhibitor of all sirtuins. Other compounds, such as cambinol, salermide, tenovin, EX-527, suramin, and AGK2, have also been reported as sirtuin inhibitors. Sirtuin inhibitors (such as nicotinamide) function via interactions with the NAD⁺ within the active site of sirtuins or through binding to acetyl-lysine.

Of note, second-generation HDACs, including hydroxamic acids (vorinostat (SAHA), belinostat (PXD101), LAQ824, and panobinostat (LBH589)) and benzamides (entinostat (MS-275), tacedinaline (CI-994), and mocetinostat (MGCD0103)), are currently in clinical trials, and some of them have already been approved for disease treatment. The success of romidepsin in phase I clinical trials in cutaneous and peripheral T-cell lymphoma accelerated the development of HDAC inhibitors as anticancer drugs. In 2006, SAHA (vorinostat) was first approved by the US Food and Drug Administration (FDA) for the treatment of cancer, restricted to patients with cutaneous T-cell lymphoma (CTCL), as an HDAC inhibitor.⁶⁴³ Romidepsin (Istodax) was the second approved HDAC inhibitor, which was approved in 2009. Three members of the benzamide family have also shown clinical significance in anticancer drug development. Belinostat (Beleodaq, previously known as PXD101) was approved in 2014 by the US FDA and European Medicines Agency to treat peripheral T-cell lymphoma. Another HDAC inhibitor, panobinostat, is a nonselective HDAC (pan-HDAC). It has shown promising effects in anticancer treatments; therefore, the FDA accelerated its approval for the treatment of patients with multiple myeloma. Intriguing, as we mentioned before, truncating mutations in HDAC2 have been found in sporadic carcinomas and colorectal cancer and result in resistance to traditional HDAC inhibitors.⁶⁴⁴ Mutations in other HDACs also exist; therefore, screening of these mutations in cancer can improve the efficacy of HDAC inhibitors.

Inhibitor of HMTs and HDMTs. EPZ004777 was the first identified selective inhibitor of DOT1L and selectively kills MLL-translocated cells over those without MLL translocation.⁶⁴⁵ However, due to its poor pharmacokinetic properties, a second generation of EPZ004777, EPZ-5767, was developed with a cyclobutyl ring

Table 7. Important ongoing clinical trials with histone methylation-targeted therapies.

Condition	Design	Sample size	Phase	Current status	NCT
HMT inhibitor					
DOT1L-targeted therapy					
<i>Pinometostat (EPZ-5676)-based trials</i>					
Relapsed/refractory leukemias	Pinometostat	51	I	Completed	NCT01684150
Acute myeloid leukemia with MLL gene rearrangement	Pinometostat + standard chemotherapy	37	I/II	Recruiting	NCT03724084
<i>Tazemetostat (EPZ-6438)-based trials</i>					
Diffuse large B-cell lymphoma	Tazemetostat	133	I/II	Suspended	NCT02889523
Advanced tumors/lymphomas	Tazemetostat	420	I/II	Recruiting	NCT01897571
Relapsed or refractory B-cell lymphoma with EZH2 gene mutation	Tazemetostat	21	II	Active, not recruiting	NCT03456726
Recurrent ovarian, primary peritoneal, or endometrial cancer	Tazemetostat	43	II	Recruiting	NCT03348631
Lymphoma, advanced solid tumors	Tazemetostat	300	II	Recruiting	NCT02875548
Malignant mesothelioma	Tazemetostat	67	II	Active, not recruiting	NCT02860286
IN11-negative tumors or relapsed/ refractory synovial sarcoma	Tazemetostat	250	II	Recruiting	NCT02601950
Relapsed/refractory lymphoma	Tazemetostat + atezolizumab	92	I	Active, not recruiting	NCT02220842
Advanced urothelial carcinoma	Tazemetostat + pembrolizumab	30	I/II	Not yet recruiting	NCT03854474
<i>GSK2816126-based trials</i>					
Relapsed/refractory lymphomas, solid tumors and multiple myeloma	GSK2816126	41	I	Terminated	NCT02082977
<i>CPI-1205-based trials</i>					
B-cell lymphomas	CPI-1205	41	I	Active, not recruiting	NCT02395601
Advanced solid tumors	CPI-1205	24	I/II	Active, not recruiting	NCT03525795
Castration-resistant prostate cancer	CPI-1205	242	I/II	Recruiting	NCT03480646
Histone demethylase inhibitors					
LSD1-targeted therapy					
<i>TCP-based trials</i>					
AML and MDS	TCP	17	I	Active, not recruiting	NCT02273102
Relapsed or refractory AML	TCP	16	I/II	N/A	NCT02261779
<i>ORY-2001-based trials</i>					
Mild to moderate Alzheimer's disease	ORY-2001	33	II	Not yet recruiting	NCT03867253
<i>GSK2879552-based trials</i>					
High-risk MDS	GSK2879552 + azacitidine	74	II	Recruiting	NCT02929498
<i>4SC-202-based trials</i>					
Advanced hematologic malignancy	4SC-202	36	I	Completed	NCT01344707
Malignant melanoma	4SC-202 + pembrolizumab	40	I/II	Recruiting	NCT03278665
Atezolizumab, anti-PD-L1 monoclonal antibody; pembrolizumab, anti-PD-1 monoclonal antibody					

replacing the ribose moiety.⁶⁴⁶ EPZ-5676 also shows synergistic effects with cytarabine, daunorubicin, and the DNMT inhibitor azacitidine in treatments for ALL with MLL translocation. EPZ-5676, though still showing low oral bioavailability, has been investigated in clinical trials for the treatment of leukemia with MLL rearrangement.⁶⁴⁷ There are several inhibitors of EZH2. 3-Deazaneplanocin A (DZNep), a derivative of the antibiotic neplanocin-A, is one of the most studied compounds. In fact, DZNep is a SAH-hydrolase inhibitor and decreases EZH2 expression via upregulation of SAH, which leads to degradation of PRC2 in a feedback inhibition mechanism.^{648,649} Another kind of inhibitor is SAM competitive inhibitors. SAM is responsible for the methyl moiety of KMTs. EI1, a small molecular inhibitor of EZH2, inhibits EZH2 activity by directly binding to EZH2 and competing with SAM.⁶⁵⁰ GSK343 and GSK126 are two other SAM competitive inhibitors that have been investigated in clinical

trials.^{651,652} EPZ005687, a potent inhibitor of EZH2, significantly reduces H3K27 methylation in lymphoma cells with point mutations at the Tyr641 and Ala677 residues of EZH2 without obvious effects on the proliferation of wild-type cells.⁶⁵³ EPZ-6438, which shows similar effects and superior oral bioavailability, was developed next.⁶⁵⁴ CPI-1205 is a novel inhibitor of EZH2 that belongs to the pyridone family.

Tranylcypromine (TCP) is an approved drug for depression due to its ability to inhibit monoamine oxidase (MAO) activity. The structures of LSD enzymes and MAOs share many similarities. Therefore, the side effects of TCP as an HDMT inhibitor, including orthostatic hypotension, dizziness, and drowsiness,⁶⁵⁵ are mostly caused by targeting of MAO. Administration of TCP in MLL-AF9 leukemia promotes tumor cell differentiation and apoptosis.⁶⁵⁶ TCP is also capable of resensitizing non-acute promyelocytic leukemia (APL) AML cells to all-trans retinoic acid (ATRA)

Table 8. Important ongoing clinical trials with combination therapies including DNA methylation and histone modification.

Condition	Design	Sample size	Phase	Current status	NCT
<i>Histone acetylation inhibitor + DNA methylation inhibitor</i>					
Solid tumors, hematologic malignancies	Azacitidine + pracinostat	85	I	Completed	NCT00741234
MDS	Azacitidine + pracinostat	102	II	Completed	NCT01873703
High-risk MDS	Azacitidine + pracinostat	60	II	Active, not recruiting	NCT03151304
AML	Azacitidine + pracinostat	500	III	Recruiting	NCT03151408
MDS	Azacitidine + mocetinostat	18	I/II	Completed	NCT02018926
High-risk MDS, AML	Azacitidine + mocetinostat	66	I/II	Completed	NCT00324220
Advanced cancers	Azacitidine + valproic acid	69	I	Completed	NCT00496444
AML, MDS	Azacitidine + valproic acid	50	II	Recruiting	NCT02124174
Intermediate II and high-risk MDS	Azacitidine + valproic acid	62	II	Completed	NCT00439673
AML, MDS	Azacitidine + valproic acid + ATRA	34	II	Completed	NCT00326170
High-risk MDS	Azacitidine + valproic acid/lenalidomide/idarubicin	320	II	Active, not recruiting	NCT01342692
Higher-risk MDS, CML	Azacitidine + vorinostat	282	II	Active, not recruiting	NCT01522976
AML, high-risk MDS	Azacitidine + vorinostat	260	II	Active, not recruiting	NCT01617226
AML, MDS	Azacitidine + vorinostat	135	I/II	Active, not recruiting	NCT00392353
Relapsed/refractory lymphoma	Azacitidine + vorinostat	17	I/II	Completed	NCT01120834
Relapsed/refractory lymphoid malignancies	Azacitidine + romidepsin	60	I/II	Recruiting	NCT01998035
Relapsed or refractory AITL	Azacitidine + romidepsin + bendamustine + gemcitabine	86	III	Recruiting	NCT03593018
Lymphoma	Azacitidine + romidepsin + durvalumab + pralatrexate	148	I/II	Recruiting	NCT03161223
Advanced non-small-cell lung cancer	Azacitidine + entinostat	162	II	Completed	NCT00387465
AML	Azacitidine + entinostat	108	II	Recruiting	NCT01305499
Advanced breast cancer	Azacitidine + entinostat	58	II	Active, not recruiting	NCT01349959
AML, MDS, CML	Azacitidine + entinostat	197	II	Completed	NCT00313586
Metastatic colorectal cancer	Azacitidine + entinostat	47	II	Completed	NCT01105377
Non-small-cell lung cancer	Azacitidine + entinostat + nivolumab	120	II	Recruiting	NCT01928576
Leukemia, lung cancer, lymphoma, multiple myeloma, prostate cancer	Azacitidine + phenylbutyrate	N/A	II	Completed	NCT00006019
AML with 11q23 rearrangement	Azacitidine + pinometostat	36	I/II	Not yet recruiting	NCT03701295
High-risk MDS	Azacitidine + GSK2879552	74	II	Recruiting	NCT02929498
AML, MDS	Decitabine + valproic acid	153	II	Completed	NCT00414310
Relapsed/refractory MDS, leukemia	Decitabine + valproic acid	54	I/II	Completed	NCT00075010
AML	Decitabine + valproic acid	204	II	Completed	NCT00867672
AML, MDS	Decitabine + vorinostat	71	I	Completed	NCT00479232
AML, MDS	Decitabine + panobinostat	52	I/II	Completed	NCT00691938
Relapsed or refractory leukemia and MDS	Decitabine + romidepsin	36	I	Completed	NCT00114257
Advanced lung cancer	Guadecitabine + mocetinostat + pembrolizumab	40	I	Recruiting	NCT03220477
Lung cancer	Hydralazine + valproic acid	29	I	Completed	NCT00996060
Metastatic cervical cancer	Hydralazine + valproate	143	III	N/A	NCT00532818
Ovarian cancer	Hydralazine + valproate	211	III	N/A	NCT00533299
Cervical cancer	Hydralazine + valproate + cisplatin chemoradiation	18	II	Completed	NCT00404326
Refractory solid tumors	Hydralazine + magnesium valproate	15	II	Completed	NCT00404508
<i>BET inhibitor + DNA methylation inhibitor</i>					
Relapsed or refractory hematologic malignancies	FT-1101 + azacitidine	160	I	Recruiting	NCT02543879
AML, MDS	GSK3326595 (selective inhibitor of protein arginine methyltransferase 5 (PRMT5)) vs azacitidine	302	I/II	Recruiting	NCT03614728
Pembrolizumab, anti-PD-1 monoclonal antibody; lenalidomide, derivative of thalidomide; durvalumab, anti-PD-L1 monoclonal antibody; nivolumab, anti-PD-1 monoclonal antibody					

treatment via increasing H3K4me2 and the expression of myeloid-differentiation-associated genes.⁶⁵⁷ Several derivatives of TCP have been developed to achieve better bioavailability and selectivity, including OG-002, RN-1, SP2509, and GSK690.^{658–660} Another LSD1 selective inhibitor, ORY-1001, can also promote the differentiation of leukemia cell lines, especially cells with translocations in MLL, and has good oral bioavailability.⁶⁶¹ To date, three LSD1 inhibitors, including TCP, ORY-1001, and GSK2879552, have been under investigation in clinical trials for the treatment of cancer patients. Daminozide (N-(dimethylamino)

succinamic acid, 160 Da), a plant growth regulator, selectively inhibits KDM2/7 by chelating the active site metal.⁶⁶² Daminozide and siRNA can similarly downregulate KDM7 expression and then regulate tumor-repopulating cells via demethylation of H3K9.⁶⁶³ GSK-J1 was the first identified KDM6 inhibitor with restricted cellular permeability, which resulted from its highly polar structure. Its ethyl ester, GSK-J4, possesses an improved ability to enter cells.⁶⁶⁴ However, scientists have found that GSK-J1 shows compatible selectivity for the KDM6 and KDM5 families and that GSK-J4 is also a potential inhibitor for KDM5B and KDM4C.⁶⁶⁵ EPT-

103182, a selective inhibitor of KDM5B, has shown promising results in terms of antiproliferative effects in hematological and solid cancer cells. KDM8 and JMJD6 share homology and can be inhibited by a broad spectrum inhibitor, NOG.⁶⁶¹

Specific inhibitors usually have similar selectivity to closely related homologs within a group, and even across different groups, which needs to be taken into consideration when using compounds that are not highly selective.

Combined therapy

Epigenetic regulation during tumorigenesis is complicated and involves multiple steps. Therefore, the combination of two or more therapies targeting various epigenetic events seems helpful. This combination synergistically inhibits the expression of tumor-growth-promoting genes and promotes the reexpression of tumor suppressor genes. 4SC-202 is a small molecular drug with dual effects that can inhibit HDAC1/2/3 and LSD1 with similar low micromolar potency. This drug is under clinical investigation. Other studies have administered two or more kinds of epigenetic drugs for anticancer therapy. Relevant clinical trials are listed in Table 8.

CONCLUSION

Although more specific mechanisms need to be investigated, it is well accepted that epigenetic events are important in normal biological processes as well as in tumorigenesis and that the epigenetic status is usually widely altered during cancer initiation. This makes epigenome-targeted therapy a promising strategy for the treatment of cancer. Based on the complexity of cancer, epigenetic alterations have influenced multiple aspects in cancer, such as the expression of oncogenes and tumor suppressor genes and signal transduction, resulting in enhanced cancer growth, invasion and metastasis. Although epigenetic therapy has a rational and profound basis in theory, some problems remain to be discussed and solved. The first and most important is the problem of selectivity. Epigenetic events are ubiquitously distributed across normal and cancer cells. In fact, some cancers depend on certain epigenetic alterations and can be sensitive to this regulation, whereas under usual regulation, normal cells have the ability to compensate for these epigenetic changes. Therefore, the priority is to determine the most important epigenetic alterations for different cancers. The second problem extends from the first problem. Thus far, epigenetic therapy has obtained impressive results in hematological malignancies but not in solid tumors. The properties of hematological malignant cells and solid tumor cells are different. However, researchers have still investigated the appropriate strategies for solid tumors. Since epigenetic alterations have effects on the sensitivity of small molecule targeted therapy and chemotherapy or radiotherapy, epigenetic-targeted therapy seems to be an important adjunctive therapy. The combination of epigenetic therapy and immunotherapy has also been investigated in preclinical and clinical trials.

Based on the achievements obtained, epigenetic-targeted therapy is a promising strategy for anticancer treatment. Epigenomes in cancer are related to many aspects during cancer initiation. A better understanding of the specific mechanisms underlying those alterations in different cancers is necessary. Meanwhile, optimized treatment options, including a variety of combinations, still remain to be discovered.

ACKNOWLEDGEMENTS

This work is supported by the Excellent Youth Foundation of Sichuan Scientific Committee Grant in China (No. 2019JJDJQ0008), the National Major Scientific and Technological Special Project for "Significant New Drugs Development" of China (No. 2018ZX09733001), and the National Key Research and Development Program of China (No. 2016YFA0201402). This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

ADDITIONAL INFORMATION

Conflict of interest: The authors declare that they have no conflict of interest.

REFERENCES

1. Waddington, C. H. The epigenotype. *Int J. Epidemiol.* **41**, 10–13 (2012).
2. Holliday, R. The inheritance of epigenetic defects. *Science* **238**, 163–170 (1987).
3. Bird, A. Perceptions of epigenetics. *Nature* **447**, 396–398 (2007).
4. Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. *Cell* **153**, 38–55 (2013).
5. Holliday, R. A new theory of carcinogenesis. *Br. J. Cancer* **40**, 513–522 (1979).
6. Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. *Nature* **435**, 1262–1266 (2005).
7. Fahrner, J. A., Eguchi, S., Herman, J. G. & Baylin, S. B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. *Cancer Res.* **62**, 7213–7218 (2002).
8. Ben-Porath, I. & Cedar, H. Epigenetic crosstalk. *Mol. Cell.* **8**, 933–935 (2001).
9. Richards, E. J. & Elgin, S. C. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. *Cell* **108**, 489–500 (2002).
10. Cedar, H. & Bergman, Y. Programming of DNA methylation patterns. *Annu. Rev. Biochem.* **81**, 97–117 (2012).
11. Sun, D. et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. *Cell. Stem Cell.* **14**, 673–688 (2014).
12. Valentini, E. et al. Analysis of the machinery and intermediates of the 5hmC-mediated DNA demethylation pathway in aging on samples from the MARK-AGE Study. *Aging* **8**, 1896–1922 (2016).
13. Kulis, M. & Esteller, M. DNA methylation and cancer. *Adv. Genet.* **70**, 27–56 (2010).
14. Karatzas, P. S., Mantzaris, G. J., Safioleas, M. & Gazouli, M. DNA methylation profile of genes involved in inflammation and autoimmunity in inflammatory bowel disease. *Medicine* **93**, e309 (2014).
15. Easwaran, H., Tsai, H. C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. *Mol. Cell.* **54**, 716–727 (2014).
16. Klutstein, M., Nejman, D., Greenfield, R. & Cedar, H. DNA methylation in cancer and aging. *Cancer Res.* **76**, 3446–3450 (2016).
17. Keshet, I. et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. *Nat. Genet.* **38**, 149–153 (2006).
18. Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature* **466**, 1129–1133 (2010).
19. Keshet, I., Lieman-Hurwitz, J. & Cedar, H. DNA methylation affects the formation of active chromatin. *Cell* **44**, 535–543 (1986).
20. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome—biological and translational implications. *Nat. Rev. Cancer* **11**, 726–734 (2011).
21. Merlo, A. et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat. Med.* **1**, 686–692 (1995).
22. Rideout, W. M., Coetzee, G. A., Olumi, A. F. & Jones, P. A. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. *Science* **249**, 1288–1290 (1990).
23. Kleihues, P. et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. *Am. J. Pathol.* **150**, 1–13 (1997).
24. Caputo, S. et al. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. *Nucleic Acids Res.* **40**, D992–D1002 (2012).
25. Christensen, B. C. et al. Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. *PLoS Genet.* **6**, e1001043 (2010).
26. Mayor, R. et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. *Br. J. Cancer* **100**, 1534–1539 (2009).
27. Devaney, J. et al. Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. *Cancer Epidemiol. Biomark. Prev.* **20**, 148–159 (2011).
28. Bell, A., Bell, D., Weber, R. S. & El-Naggar, A. K. CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. *Cancer* **117**, 2898–2909 (2011).
29. He, S. et al. Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. *PLoS ONE* **6**, e27684 (2011).
30. Ibrahim, A. E. et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. *Gut* **60**, 499–508 (2011).
31. Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. *Nat. Rev. Cancer* **6**, 107–116 (2006).

32. Markl, I. D. et al. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. *Cancer Res.* **61**, 5875–5884 (2001).
33. Wolf, S. F. et al. Methylation of the hypoxanthine phosphoribosyltransferase locus on the human X chromosome: implications for X-chromosome inactivation. *Proc. Natl Acad. Sci. USA* **81**, 2806–2810 (1984).
34. Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat. Rev. Genet.* **13**, 484–492 (2012).
35. Lee, W. H. et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. *Proc. Natl Acad. Sci. USA* **91**, 11733–11737 (1994).
36. Wilting, R. H. & Dannenberg, J. H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. *Drug Resist Updat.* **15**, 21–38 (2012).
37. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *N. Engl. J. Med.* **343**, 1350–1354 (2000).
38. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N. Engl. J. Med.* **352**, 997–1003 (2005).
39. Esteller, M. et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. *J. Natl Cancer Inst.* **94**, 26–32 (2002).
40. Ramsahoye, B. H. et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. *Proc. Natl Acad. Sci. USA* **97**, 5237–5242 (2000).
41. Saxnov, S., Berg, P. & Brutlag, D. L. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. *Proc. Natl Acad. Sci. USA* **103**, 1412–1417 (2006).
42. Smith, Z. D. & Meissner, A. DNA methylation: roles in mammalian development. *Nat. Rev. Genet.* **14**, 204–220 (2013).
43. Mitchell, A. R. et al. Epigenetic control of mammalian centromere protein binding: does DNA methylation have a role. *J. Cell Sci.* **109**(Pt 9), 2199–2206 (1996).
44. Schübeler, D. Function and information content of DNA methylation. *Nature* **517**, 321–326 (2015).
45. Goyal, R., Reinhardt, R. & Jeltsch, A. Accuracy of DNA methylation pattern preservation by the Dnmt1 methyltransferase. *Nucleic Acids Res.* **34**, 1182–1188 (2006).
46. Li, Y. et al. Stella safeguards the oocyte methylome by preventing de novo methylation mediated by DNMT1. *Nature* **564**, 136–140 (2018).
47. Wu, H. & Zhang, Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. *Cell* **156**, 45–68 (2014).
48. Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* **99**, 247–257 (1999).
49. Chedin, F., Lieber, M. R. & Hsieh, C. L. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. *Proc. Natl Acad. Sci. USA* **99**, 16916–16921 (2002).
50. Robertson, K. D. et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. *Nucleic Acids Res.* **27**, 2291–2298 (1999).
51. Piyathilake, C. J. et al. A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. *Int J. Women's Health* **9**, 413–420 (2017).
52. Mizuno, S. et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. *Blood* **97**, 1172–1179 (2001).
53. Mirza, S. et al. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. *J. Breast Cancer* **16**, 23–31 (2013).
54. Klose, R. J. & Bird, A. P. Genomic DNA methylation: the mark and its mediators. *Trends Biochem Sci.* **31**, 89–97 (2006).
55. Feng, Q. & Zhang, Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. *Genes Dev.* **15**, 827–832 (2001).
56. Yildirim, O. et al. Mbd3/NuRD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. *Cell* **147**, 1498–1510 (2011).
57. Villa, R. et al. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. *Proc. Natl Acad. Sci. USA* **103**, 1400–1405 (2006).
58. Watanabe, S. et al. Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link transcriptional repression and DNA repair in chromatin. *Proc. Natl Acad. Sci. USA* **100**, 12859–12864 (2003).
59. Bader, S. et al. MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. *Oncogene* **22**, 3506–3510 (2003).
60. Zhao, X. et al. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. *Proc. Natl Acad. Sci. USA* **100**, 6777–6782 (2003).
61. Sansom, O. J. et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. *Nat. Genet.* **34**, 145–147 (2003).
62. Suzuki, H. et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. *Nat. Genet.* **36**, 417–422 (2004).
63. Campbell, P. M., Bovenzi, V. & Szyf, M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumorigenesis of human cancer cell lines in vitro and in vivo. *Carcinogenesis* **25**, 499–507 (2004).
64. Noh, E. J. et al. Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells. *Cancer Res.* **65**, 11400–11410 (2005).
65. Biswas, M. et al. MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia. *FASEB J.* **33**, 5268–5286 (2019).
66. Riccio, A. et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. *Nat. Genet.* **23**, 266–268 (1999).
67. Bader, S. A., Walker, M. & Harrison, D. J. A human cancer-associated truncation of MBD4 causes dominant negative impairment of DNA repair in colon cancer cells. *Br. J. Cancer* **96**, 660–666 (2007).
68. Millar, C. B. et al. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. *Science* **297**, 403–405 (2002).
69. Sansom, O. J., Bishop, S. M., Bird, A. & Clarke, A. R. MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR. *Oncogene* **23**, 5693–5696 (2004).
70. Bernard, D. et al. The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth. *Oncogene* **25**, 1358–1366 (2006).
71. Müller, H. M. et al. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. *Br. J. Cancer* **89**, 1934–1939 (2003).
72. Mudbhary, R. et al. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. *Cancer Cell.* **25**, 196–209 (2014).
73. Unoki, M. et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. *Br. J. Cancer* **101**, 98–105 (2009).
74. Unoki, M. et al. UHRF1 is a novel diagnostic marker of lung cancer. *Br. J. Cancer* **103**, 217–222 (2010).
75. Prokhortchouk, A. et al. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. *Genes Dev.* **15**, 1613–1618 (2001).
76. van Roy, F. M. & McCrea, P. D. A role for Kaiso-p120ctn complexes in cancer. *Nat. Rev. Cancer* **5**, 956–964 (2005).
77. Kim, K. et al. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. *Oncogene* **31**, 1034–1044 (2012).
78. Law, J. A. & Jacobsen, S. E. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. *Nat. Rev. Genet.* **11**, 204–220 (2010).
79. Feng, S., Jacobsen, S. E. & Reik, W. Epigenetic reprogramming in plant and animal development. *Science* **330**, 622–627 (2010).
80. Hajkova, P. et al. Epigenetic reprogramming in mouse primordial germ cells. *Mech. Dev.* **117**, 15–23 (2002).
81. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* **324**, 930–935 (2009).
82. Hu, L. et al. Structural insight into substrate preference for TET-mediated oxidation. *Nature* **527**, 118–122 (2015).
83. Ito, S. et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. *Science* **333**, 1300–1303 (2011).
84. He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. *Science* **333**, 1303–1307 (2011).
85. Lorschach, R. B. et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22; q23). *Leukemia* **17**, 637–641 (2003).
86. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. *N. Engl. J. Med.* **360**, 2289–2301 (2009).
87. Kosmider, O. et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. *Haematologica* **94**, 1676–1681 (2009).
88. Abdel-Wahab, O. et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. *Cancer Res.* **70**, 447–452 (2010).
89. Yang, H. et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. *Oncogene* **32**, 663–669 (2013).
90. Hsu, C. H. et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. *Cell Rep.* **2**, 568–579 (2012).
91. Lian, C. G. et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. *Cell* **150**, 1135–1146 (2012).
92. Cao, Y. L. et al. Fucosylated DNMT1 mediates cisplatin resistance in ovarian cancer. *Cell Biochem Funct.* **35**, 296–303 (2017).

93. Rajendran, G. et al. Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. *J. Neurooncol.* **104**, 483–494 (2011).
94. Xing, J. et al. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. *Br. J. Cancer* **98**, 1716–1722 (2008).
95. Hong, L. et al. The interaction between miR-148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer. *Oncol. Rep.* **40**, 2916–2925 (2018).
96. Nagai, M., Nakamura, A., Makino, R. & Mitamura, K. Expression of DNA (5-cytosine)-methyltransferases (DNMTs) in hepatocellular carcinomas. *Hepatol. Res.* **26**, 186–191 (2003).
97. Wang, Y., Hu, Y., Guo, J. & Wang, L. miR-148a-3p suppresses the proliferation and invasion of esophageal cancer by targeting DNMT1. *Genet. Test. Mol. Biomark.* **23**, 98–104 (2019).
98. Hu, Y. et al. LncRNA-SNHG1 contributes to gastric cancer cell proliferation by regulating DNMT1. *Biochem Biophys. Res Commun.* **491**, 926–931 (2017).
99. Chen, F. et al. MiR-137 suppresses triple-negative breast cancer stemness and tumorigenesis by perturbing BCL11A-DNMT1 interaction. *Cell Physiol. Biochem.* **47**, 2147–2158 (2018).
100. Gao, X. et al. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF- κ B/DNMT1 signaling pathway. *Prostate* **78**, 682–690 (2018).
101. Zhang, Y. et al. Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells. *J. Exp. Clin. Cancer Res.* **30**, 98 (2011).
102. Lee, E. et al. DNMT1 regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. *Neoplasia* **18**, 553–566 (2016).
103. Chen, B. F. et al. microRNA-199a-3p, DNMT3A, and aberrant DNA methylation in testicular cancer. *Epigenetics* **9**, 119–128 (2014).
104. Sun, J. et al. miR-182 induces cervical cancer cell apoptosis through inhibiting the expression of DNMT3a. *Int. J. Clin. Exp. Pathol.* **8**, 4755–4763 (2015).
105. Pang, Y. et al. MYC and DNMT3A-mediated DNA methylation represses microRNA-200b in triple negative breast cancer. *J. Cell Mol. Med.* **22**, 6262–6274 (2018).
106. Zhou, Y. et al. Ginsenoside 20(S)-Rg3 inhibits the warburg effect via modulating DNMT3A/ MiR-532-3p/HK2 pathway in ovarian cancer cells. *Cell Physiol. Biochem.* **45**, 2548–2559 (2018).
107. Zhang, Q., Feng, Y., Liu, P. & Yang, J. MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer. *Tumour Biol.* **39**, 1010428317711312 (2017).
108. Gao, Q. et al. Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. *Proc. Natl Acad. Sci. USA* **108**, 18061–18066 (2011).
109. Garzon, R. et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. *Blood* **113**, 6411–6418 (2009).
110. Deivendran, S. et al. Metastasis-associated protein 1 is an upstream regulator of DNMT3a and stimulator of insulin-growth factor binding protein-3 in breast cancer. *Sci. Rep.* **7**, 44225 (2017).
111. Tang, X. et al. Autocrine TGF- β 1/miR-200s/miR-221/DNMT3B regulatory loop maintains CAF status to fuel breast cancer cell proliferation. *Cancer Lett.* **452**, 79–89 (2019).
112. Chen, Z. et al. miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. *Oncotarget* **6**, 38139–38150 (2015).
113. Qiu, W. et al. Kaempferol modulates DNA methylation and downregulates DNMT3B in bladder cancer. *Cell Physiol. Biochem.* **41**, 1325–1335 (2017).
114. Peres, R. et al. Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation. *Oncotarget* **7**, 43109–43123 (2016).
115. Song, N. et al. Lentivirus-mediated knockdown of MeCP2 inhibits the growth of colorectal cancer cells in vitro. *Mol. Med Rep.* **13**, 860–866 (2016).
116. Ray, B. K. et al. Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family. *Cancer Res.* **73**, 736–744 (2013).
117. Xu, M. et al. MeCP2 suppresses LIN28A expression via binding to its methylated-CpG islands in pancreatic cancer cells. *Oncotarget* **7**, 14476–14485 (2016).
118. Yaqinuddin, A. et al. Silencing of MBD1 and MeCP2 in prostate-cancer-derived PC3 cells produces differential gene expression profiles and cellular phenotypes. *Biosci. Rep.* **28**, 319–326 (2008).
119. Zhang, B. et al. MBD1 is an epigenetic regulator of KEAP1 in pancreatic cancer. *Curr. Mol. Med.* **16**, 404–411 (2016).
120. Pulkuri, S. M. & Rao, J. S. CpG island promoter methylation and silencing of 14-3- σ gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. *Oncogene* **25**, 4559–4572 (2006).
121. Martin, V. et al. MBD2-mediated transcriptional repression of the p14ARF tumor suppressor gene in human colon cancer cells. *Pathobiology* **75**, 281–287 (2008).
122. Pontes, T. B. et al. Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis. *Tumour Biol.* **35**, 3447–3453 (2014).
123. Zhang, Y. et al. Epigenetic silencing of RNF144A expression in breast cancer cells through promoter hypermethylation and MBD4. *Cancer Med.* **7**, 1317–1325 (2018).
124. Abdel-Rahman, W. M. et al. Truncation of MBD4 predisposes to reciprocal chromosomal translocations and alters the response to therapeutic agents in colon cancer cells. *DNA Repair* **7**, 321–328 (2008).
125. Pierre, C. C., Hercules, S. M., Yates, C. & Daniel, J. M. Dancing from bottoms up—roles of the POZ-ZF transcription factor Kaiso in cancer. *Biochim Biophys. Acta Rev. Cancer* **1871**, 64–74 (2019).
126. Wang, H. et al. Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression. *Oncotarget* **7**, 5677–5689 (2016).
127. Dai, S. D. et al. Kaiso is expressed in lung cancer: its expression and localization is affected by p120ctn. *Lung Cancer* **67**, 205–215 (2010).
128. Basse-archibong, B. I. et al. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. *Cell Death Dis.* **8**, e2689 (2017).
129. Roussel-Gervais, A. et al. Loss of the methyl-CpG-binding protein ZBTB4 alters mitotic checkpoint, increases aneuploidy, and promotes tumorigenesis. *Cancer Res.* **77**, 62–73 (2017).
130. Yu, Y. et al. Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. *Biomed. Pharmacother.* **100**, 108–115 (2018).
131. Kim, K. et al. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. *Mol. Cancer Ther.* **11**, 1852–1862 (2012).
132. Jing, J. et al. The role of ZBTB38 in promoting migration and invasive growth of bladder cancer cells. *Oncol. Rep.* **41**, 1980–1990 (2019).
133. Saidi, S., Popov, Z., Janevska, V. & Panov, S. Overexpression of UHRF1 gene correlates with the major clinicopathological parameters in urinary bladder cancer. *Int. Braz. J. Urol.* **43**, 224–229 (2017).
134. Jiao, D. et al. UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP. *Oncogene* **38**, 5686–5699 (2019).
135. Kong, X. et al. Defining UHRF1 domains that support maintenance of human colon cancer DNA methylation and oncogenic properties. *Cancer Cell.* **35**, 633–648.e7 (2019).
136. Hu, Q. et al. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. *Cancer Lett.* **452**, 226–236 (2019).
137. Wei, C. et al. Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation. *Oncol. Rep.* **39**, 2553–2562 (2018).
138. Gao, S. P. et al. UHRF1 promotes breast cancer progression by suppressing KLF17 expression by hypermethylating its promoter. *Am. J. Cancer Res.* **7**, 1554–1565 (2017).
139. Lu, S. et al. Ubiquitin-like with PHD and ring finger domains 2 is a predictor of survival and a potential therapeutic target in colon cancer. *Oncol. Rep.* **31**, 1802–1810 (2014).
140. Zhang, T. et al. UHRF2 decreases H3K9ac expression by interacting with it through the PHD and SRA/YDG domain in HepG2 hepatocellular carcinoma cells. *Int. J. Mol. Med.* **39**, 126–134 (2017).
141. Iguchi, T. et al. Identification of UHRF2 as a negative regulator of epithelial-mesenchymal transition and its clinical significance in esophageal squamous cell carcinoma. *Oncology* **95**, 179–187 (2018).
142. Jin, C. et al. Loss of UHRF2 is associated with non-small cell lung carcinoma progression. *J. Cancer* **9**, 2994–3005 (2018).
143. Si, Y. et al. Fisetin decreases TET1 activity and CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell. *J. Cell Mol. Med.* **23**, 1095–1105 (2019).
144. Huang, H. et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. *Proc. Natl Acad. Sci. USA* **110**, 11994–11999 (2013).
145. Jiang, X. et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. *Nat. Commun.* **8**, 2099 (2017).
146. Chen, L. Y. et al. TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2 α as a therapeutic target. *J. Pathol.* **248**, 363–376 (2019).
147. Filipczak, P. T. et al. p53-Suppressed oncogene TET1 prevents cellular aging in lung cancer. *Cancer Res.* **79**, 1758–1768 (2019).
148. Liu, C. et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. *PLoS ONE* **8**, e62828 (2013).
149. Guo, H. et al. TET1 suppresses colon cancer proliferation by impairing β -catenin signal pathway. *J. Cell Biochem.* **120**, 12559–12565 (2019).
150. Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. *Cell* **170**, 1079–1095.e20 (2017).

151. Langemeijer, S. M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. *Nat. Genet.* **41**, 838–842 (2009).
152. Zhu, X. & Li, S. TET2 inhibits tumorigenesis of breast cancer cells by regulating caspase-4. *Sci. Rep.* **8**, 16167 (2018).
153. Huang, Y. et al. Loss of nuclear localization of TET2 in colorectal cancer. *Clin. Epigenetics.* **8**, 9 (2016).
154. Chen, D. et al. TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. *Urology* **102**, 265.e1–265.e7 (2017).
155. Yang, L. et al. Reduced expression of TET1, TET2, TET3 and TDG mRNAs are associated with poor prognosis of patients with early breast cancer. *PLoS ONE* **10**, e0133896 (2015).
156. Ye, Z. et al. TET3 inhibits TGF- β 1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells. *J. Exp. Clin. Cancer Res.* **35**, 72 (2016).
157. Kouzarides, T. Chromatin modifications and their function. *Cell* **128**, 693–705 (2007).
158. Audia, J. E. & Campbell, R. M. Histone modifications and cancer. *Cold Spring Harb. Perspect. Biol.* **8**, a019521 (2016).
159. Hawkins, R. D. et al. Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotency. *Cell Res.* **21**, 1393–1409 (2011).
160. Hon, G. C., Hawkins, R. D. & Ren, B. Predictive chromatin signatures in the mammalian genome. *Hum. Mol. Genet.* **18**, R195–R201 (2009).
161. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. *Nature* **459**, 108–112 (2009).
162. Seligson, D. B. et al. Global levels of histone modifications predict prognosis in different cancers. *Am. J. Pathol.* **174**, 1619–1628 (2009).
163. Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. *Nat. Genet.* **37**, 391–400 (2005).
164. Di, C. V. & Schneider, R. Cancers with wrong HATs: the impact of acetylation. *Brief. Funct. Genomics.* **12**, 231–243 (2013).
165. Sadoul, K., Wang, J., Diagouraga, B. & Khochbin, S. The tale of protein lysine acetylation in the cytoplasm. *J. Biomed. Biotechnol.* **2011**, 970382 (2011).
166. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science* **325**, 834–840 (2009).
167. Kleff, S., Andrulis, E. D., Anderson, C. W. & Sternglanz, R. Identification of a gene encoding a yeast histone H4 acetyltransferase. *J. Biol. Chem.* **270**, 24674–24677 (1995).
168. Brownell, J. E. et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. *Cell* **84**, 843–851 (1996).
169. Marmorstein, R. & Zhou, M. M. Writers and readers of histone acetylation: structure, mechanism, and inhibition. *Cold Spring Harb. Perspect. Biol.* **6**, a018762 (2014).
170. Heery, D. M. & Fischer, P. M. Pharmacological targeting of lysine acetyltransferases in human disease: a progress report. *Drug Discov. Today* **12**, 88–99 (2007).
171. Yao, T. P. et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. *Cell* **93**, 361–372 (1998).
172. Oike, Y. et al. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. *Hum. Mol. Genet.* **8**, 387–396 (1999).
173. Tanner, K. G. et al. Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. *J. Biol. Chem.* **274**, 18157–18160 (1999).
174. Tanner, K. G., Langer, M. R. & Denu, J. M. Kinetic mechanism of human histone acetyltransferase P/CAF. *Biochemistry* **39**, 15652 (2000).
175. Yan, Y., Harper, S., Speicher, D. W. & Marmorstein, R. The catalytic mechanism of the ESA1 histone acetyltransferase involves a self-acetylated intermediate. *Nat. Struct. Biol.* **9**, 862–869 (2002).
176. Liu, X. et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. *Nature* **451**, 846–850 (2008).
177. Marmorstein, R. Biochemical and structural characterization of recombinant histone acetyltransferase proteins. *Methods Enzymol.* **376**, 106–119 (2004).
178. Chen, Y. F. et al. High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma. *Eur. Arch. Otorhinolaryngol.* **270**, 1009–1017 (2013).
179. Korzus, E. Rubinstein-Taybi syndrome and epigenetic alterations. *Adv. Exp. Med. Biol.* **978**, 39–62 (2017).
180. Miller, R. W. & Rubinstein, J. H. Tumors in Rubinstein-Taybi syndrome. *Am. J. Med. Genet.* **56**, 112–115 (1995).
181. Borrow, J. et al. The translocation t(8;16)(p11; p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. *Nat. Genet.* **14**, 33–41 (1996).
182. Panagopoulos, I. et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22; p13). *Hum. Mol. Genet.* **10**, 395–404 (2001).
183. Chaffanet, M. et al. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). *Genes Chromosomes Cancer* **28**, 138–144 (2000).
184. Ida, K. et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). *Blood* **90**, 4699–4704 (1997).
185. Taki, T., Sako, M., Tsuchida, M. & Hayashi, Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. *Blood* **89**, 3945–3950 (1997).
186. Muraoka, M. et al. p300 gene alterations in colorectal and gastric carcinomas. *Oncogene* **12**, 1565–1569 (1996).
187. Gayther, S. A. et al. Mutations truncating the EP300 acetylase in human cancers. *Nat. Genet.* **24**, 300–303 (2000).
188. Ozdag, H. et al. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. *Br. J. Cancer* **87**, 1162–1165 (2002).
189. Burwinkel, B. et al. Association of NCOA3 polymorphisms with breast cancer risk. *Clin. Cancer Res.* **11**, 2169–2174 (2005).
190. Wachtel, M. et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35; p23) translocation fusing PAX3 to NCOA1. *Cancer Res.* **64**, 5539–5545 (2004).
191. Dhalluin, C. et al. Structure and ligand of a histone acetyltransferase bromodomain. *Nature* **399**, 491–496 (1999).
192. Thompson, M. Polybromo-1: the chromatin targeting subunit of the PBAF complex. *Biochimie* **91**, 309–319 (2009).
193. Zhang, Q. et al. Biochemical profiling of histone binding selectivity of the yeast bromodomain family. *PLoS ONE* **5**, e8903 (2010).
194. Sanchez, R. & Zhou, M. M. The role of human bromodomains in chromatin biology and gene transcription. *Curr. Opin. Drug Discov. Devel.* **12**, 659–665 (2009).
195. Filippakopoulos, P. & Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat. Rev. Drug Discov.* **13**, 337–356 (2014).
196. Li, Y. et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. *Cell* **159**, 558–571 (2014).
197. Morin, R. D. et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. *Clin. Cancer Res.* **22**, 2290–2300 (2016).
198. Ferlman, E. J. et al. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. *Nat. Commun.* **6**, 10013 (2015).
199. Chiang, C. M. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. *F1000 Biol. Rep.* **1**, 98 (2009).
200. Zeng, L. & Zhou, M. M. Bromodomain: an acetyl-lysine binding domain. *FEBS Lett.* **513**, 124–128 (2002).
201. Pirrotta, V. The necessity of chromatin: a view in perspective. *Cold Spring Harb. Perspect. Biol.* **8**, a019547 (2016).
202. Yang, Z. et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. *Mol. Cell.* **19**, 535–545 (2005).
203. Phelps, M. A. et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. *Blood* **113**, 2637–2645 (2009).
204. Rahl, P. B. et al. c-Myc regulates transcriptional pause release. *Cell* **141**, 432–445 (2010).
205. French, C. A. et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. *Oncogene* **27**, 2237–2242 (2008).
206. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature* **478**, 524–528 (2011).
207. de Ruijter, A. J. et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. *Biochem J.* **370**, 737–749 (2003).
208. Verdin, E., Dequiedt, F. & Kasler, H. G. Class II histone deacetylases: versatile regulators. *Trends Genet.* **19**, 286–293 (2003).
209. Seto, E. & Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. *Cold Spring Harb. Perspect. Biol.* **6**, a018713 (2014).
210. Imai, S., Armstrong, C. M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature* **403**, 795–800 (2000).
211. Liszt, G., Ford, E., Kurtev, M. & Guarente, L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. *J. Biol. Chem.* **280**, 21313–21320 (2005).
212. Frye, R. A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. *Biochem Biophys. Res. Commun.* **260**, 273–279 (1999).
213. Du, J. et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. *Science* **334**, 806–809 (2011).

214. Johnson, C. A. et al. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. *J. Biol. Chem.* **277**, 9590–9597 (2002).
215. Zhang, X. et al. Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. *Mol. Cell Biol.* **24**, 5106–5118 (2004).
216. Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. *Nature* **417**, 455–458 (2002).
217. Luo, J. et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. *Nature* **408**, 377–381 (2000).
218. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell* **107**, 149–159 (2001).
219. Peng, L. et al. SIRT1 negatively regulates the activities, functions, and protein levels of hMOF and TIP60. *Mol. Cell Biol.* **32**, 2823–2836 (2012).
220. Ayer, D. E. Histone deacetylases: transcriptional repression with SINers and NuRDs. *Trends Cell Biol.* **9**, 193–198 (1999).
221. Wen, Y. D. et al. The histone deacetylase-3 complex contains nuclear receptor corepressors. *Proc. Natl Acad. Sci. USA* **97**, 7202–7207 (2000).
222. Watson, P. J., Fairall, L., Santos, G. M. & Schwabe, J. W. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. *Nature* **481**, 335–340 (2012).
223. Kang, H. et al. Peptide switch is essential for Sirt1 deacetylase activity. *Mol. Cell.* **44**, 203–213 (2011).
224. Kim, E. J., Kho, J. H., Kang, M. R. & Um, S. J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. *Mol. Cell.* **28**, 277–290 (2007).
225. Ocker, M. & Schneider-Stock, R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. *Int. J. Biochem Cell Biol.* **39**, 1367–1374 (2007).
226. Ozdağ, H. et al. Differential expression of selected histone modifier genes in human solid cancers. *BMC Genomics.* **7**, 90 (2006).
227. Xue, L. et al. RNAi screening identifies HAT1 as a potential drug target in esophageal squamous cell carcinoma. *Int. J. Clin. Exp. Pathol.* **7**, 3898–3907 (2014).
228. Fan, P. et al. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. *J. Exp. Clin. Cancer Res.* **38**, 47 (2019).
229. Miao, B. P. et al. Histone acetyltransferase 1 up regulates Bcl2L12 expression in nasopharyngeal cancer cells. *Arch. Biochem Biophys.* **646**, 72–79 (2018).
230. Jin, X., Tian, S. & Li, P. Histone acetyltransferase 1 promotes cell proliferation and induces cisplatin resistance in hepatocellular carcinoma. *Oncol. Res.* **25**, 939–946 (2017).
231. Zhang, J., Liu, M., Liu, W. & Wang, W. Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1. *Artif. Cells Nanomed. Biotechnol.* **47**, 1207–1215 (2019).
232. Han, N. et al. HAT1 induces lung cancer cell apoptosis via up regulating Fas. *Oncotarget* **8**, 89970–89977 (2017).
233. Yin, Y. W. et al. The histone acetyltransferase GCN5 expression is elevated and regulated by c-Myc and E2F1 transcription factors in human colon cancer. *Gene Expr.* **16**, 187–196 (2015).
234. Zhao, L., Pang, A. & Li, Y. Function of GCN5 in the TGF- β 1-induced epithelial-to-mesenchymal transition in breast cancer. *Oncol. Lett.* **16**, 3955–3963 (2018).
235. Zhao, C. et al. C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation. *Oncogene* **37**, 4821–4837 (2018).
236. Watts, G. S. et al. The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. *Neoplasia* **6**, 187–194 (2004).
237. Brasacchio, D. et al. Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer. *Cell Death Dis.* **9**, 442 (2018).
238. Yu, C. et al. Phenethyl isothiocyanate inhibits androgen receptor-regulated transcriptional activity in prostate cancer cells through suppressing PCAF. *Mol. Nutr. Food Res.* **57**, 1825–1833 (2013).
239. Xie, X. et al. Tip60 is associated with resistance to X-ray irradiation in prostate cancer. *FEBS Open Bio.* **8**, 271–278 (2018).
240. Wang, L. T. et al. TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer. *Oncogene* **38**, 518–532 (2019).
241. Sakuraba, K. et al. Down-regulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer. *Anticancer Res.* **29**, 3953–3955 (2009).
242. McGuire, A. et al. Quantifying Tip60 (Kat5) stratifies breast cancer. *Sci. Rep.* **9**, 3819 (2019).
243. Yang, Y. et al. Tat-interactive protein-60KDA (TIP60) regulates the tumorigenesis of lung cancer in vitro. *J. Cancer* **8**, 2277–2281 (2017).
244. Jaganathan, A. et al. Coactivator MYST1 regulates nuclear factor- κ B and androgen receptor functions during proliferation of prostate cancer cells. *Mol. Endocrinol.* **28**, 872–885 (2014).
245. Hayashi, Y. et al. NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis. *Blood Adv.* **3**, 1047–1060 (2019).
246. Quintela, M. et al. HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. *Nanomedicine* **17**, 254–265 (2019).
247. Chen, Z. et al. HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/ β -catenin signaling. *Mol. Carcinog.* **57**, 12–21 (2018).
248. Deguchi, K. et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. *Cancer Cell.* **3**, 259–271 (2003).
249. Mohammadi, K. et al. Investigation of the changes in the expression levels of MOZ gene in colorectal cancer tissues. *J. Gastrointest. Oncol.* **10**, 68–73 (2019).
250. Yu, L. et al. Identification of MYST3 as a novel epigenetic activator of ER α frequently amplified in breast cancer. *Oncogene* **36**, 2910–2918 (2017).
251. Vizmanos, J. L. et al. t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia. *Genes Chromosomes Cancer* **36**, 402–405 (2003).
252. Ono, H., Basson, M. D. & Ito, H. P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. *Oncotarget* **7**, 51301–51310 (2016).
253. Pattabiraman, D. R. et al. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. *Blood* **123**, 2682–2690 (2014).
254. Hou, X. et al. p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells. *BMC Cancer* **18**, 641 (2018).
255. Xu, B. et al. The LIM protein Ajuba recruits DBC1 and CBP/p300 to acetylate ER α and enhances ER α target gene expression in breast cancer cells. *Nucleic Acids Res.* **47**, 2322–2335 (2019).
256. Wang, Y. M. et al. Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines. *Int. J. Oncol.* **51**, 1860–1868 (2017).
257. He, H. et al. Selective p300 inhibitor C646 inhibited HPV E6-E7 genes, altered glucose metabolism and induced apoptosis in cervical cancer cells. *Eur. J. Pharmacol.* **812**, 206–215 (2017).
258. Huh, J. W. et al. Prognostic impact of p300 expression in patients with colorectal cancer. *J. Surg. Oncol.* **108**, 374–377 (2013).
259. Takeuchi, A. et al. p300 mediates cellular resistance to doxorubicin in bladder cancer. *Mol. Med Rep.* **5**, 173–176 (2012).
260. Inagaki, Y. et al. Epigenetic regulation of proliferation and invasion in hepatocellular carcinoma cells by CBP/p300 histone acetyltransferase activity. *Int. J. Oncol.* **48**, 533–540 (2016).
261. Díaz-Beyá, M. et al. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. *Leukemia* **27**, 595–603 (2013).
262. Jin, L. et al. Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer. *Cancer Res.* **77**, 5564–5575 (2017).
263. Ding, L. et al. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. *Cancer Res.* **74**, 2050–2061 (2014).
264. Jia, D. et al. Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition. *Cancer Discov.* **8**, 1422–1437 (2018).
265. Pavón, M. A. et al. CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma. *Head. Neck.* **38**(Suppl 1), E1392–E1403 (2016).
266. Qin, L. et al. NCOA1 directly targets M-CSF1 expression to promote breast cancer metastasis. *Cancer Res.* **74**, 3477–3488 (2014).
267. Ma, Y. S. et al. High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1. *Oncotarget* **8**, 11896–11905 (2017).
268. Aikawa, Y. et al. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. *Nat. Med.* **16**, 580–585 (2010). 1p following 585.
269. Fancher, A. T. et al. Reconfiguring the AR-TIF2 protein-protein interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen. *Assay. Drug Dev. Technol.* **14**, 453–477 (2016).
270. O'Donnell, K. A. et al. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. *Proc. Natl Acad. Sci. USA* **109**, E1377–E1386 (2012).
271. Yu, J. et al. Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer. *Oncogene* **35**, 187–195 (2016).
272. Kumar, S. et al. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. *Oncogene* **34**, 4879–4889 (2015).
273. Alkner, S. et al. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and

- tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1–98. *Breast Cancer Res. Treat.* **166**, 481–490 (2017).
274. Zou, J. X. et al. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. *Prostate* **66**, 1474–1486 (2006).
275. Xie, D. et al. Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. *Hum. Pathol.* **36**, 777–783 (2005).
276. Liu, W. H. & Chang, L. S. Arachidonic acid induces Fas and FasL upregulation in human leukemia U937 cells via Ca²⁺/ROS-mediated suppression of ERK/c-Fos pathway and activation of p38 MAPK/ATF-2 pathway. *Toxicol. Lett.* **191**, 140–148 (2009).
277. Desai, S., Laskar, S. & Pandey, B. N. Autocrine IL-8 and VEGF mediate epithelial-mesenchymal transition and invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer cells. *Cell Signal.* **25**, 1780–1791 (2013).
278. Sun, X., Lou, L., Zhong, K. & Wan, L. MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene. *Exp. Biol. Med.* **242**, 1299–1305 (2017).
279. Winter, A. G. et al. RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors. *Proc. Natl Acad. Sci. USA* **97**, 12619–12624 (2000).
280. Xiao, L. et al. Induction of the CLOCK gene by E2-ERα signaling promotes the proliferation of breast cancer cells. *PLoS ONE* **9**, e95878 (2014).
281. Xu, H., Wang, Z., Mo, G. & Chen, H. Association between circadian gene CLOCK and cisplatin resistance in ovarian cancer cells: a preliminary study. *Oncol. Lett.* **15**, 8945–8950 (2018).
282. Xiang, R. et al. Circadian clock gene Per2 downregulation in non-small cell lung cancer is associated with tumour progression and metastasis. *Oncol. Rep.* **40**, 3040–3048 (2018).
283. Xie, X. W. et al. Expression of CIITA-related MHCII molecules in tumors linked to prognosis in hepatocellular carcinoma. *Int. J. Oncol.* **34**, 681–688 (2009).
284. Truax, A. D., Thakkar, M. & Greer, S. F. Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells. *PLoS ONE* **7**, e36013 (2012).
285. Satoh, A. et al. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. *Oncogene* **23**, 8876–8886 (2004).
286. Starska, K. et al. Gene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancer. *Clin. Exp. Med.* **15**, 455–468 (2015).
287. Krześlak, A. et al. Gene expression of O-GlcNAc cycling enzymes in human breast cancers. *Clin. Exp. Med.* **12**, 61–65 (2012).
288. Fontanals-Cirera, B. et al. Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival gene. *Mol. Cell.* **68**, 731–744.e9 (2017).
289. Pérez-Pena, J. et al. Mapping Bromodomains in breast cancer and association with clinical outcome. *Sci. Rep.* **9**, 5734 (2019).
290. Handoko, L. et al. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states. *Epigenetics* **13**, 410–431 (2018).
291. Sherman, M. H. et al. Stromal cues regulate the pancreatic cancer epigenome and metabolome. *Proc. Natl Acad. Sci. USA* **114**, 1129–1134 (2017).
292. Zhang, Q. et al. By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. *Oncotarget* **6**, 16461–16470 (2015).
293. Dong, Z. Y., Zhou, Y. R. & Wang, L. X. HDAC1 is indirectly involved in the epigenetic regulation of p38 MAPK that drive the lung cancer progression. *Eur. Rev. Med. Pharm. Sci.* **22**, 5980–5986 (2018).
294. Zhang, N. et al. SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. *Cell Death Differ.* **26**, 843–859 (2019).
295. Li, S. Z. et al. Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1. *Cancer Lett.* **431**, 43–53 (2018).
296. von, B. J. et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. *Gastroenterology* **137**, 361–371.e1–5 (2009).
297. Tang, W. et al. The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer. *Nat. Commun.* **10**, 663 (2019).
298. Zhu, W. et al. FKBP3 promotes proliferation of non-small cell lung cancer cells through regulating Sp1/HDAC2/p27. *Theranostics* **7**, 3078–3089 (2017).
299. Roy, S. S. et al. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. *Oncogene* **33**, 3707–3716 (2014).
300. Hulsurkar, M. et al. Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1. *Oncogene* **36**, 1525–1536 (2017).
301. Miao, L. J. et al. Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in non-small cell lung cancer cells. *Tumour Biol.* **35**, 7097–7103 (2014).
302. Chen, G. et al. Long noncoding RNA SBF2-AS1 promotes colorectal cancer proliferation and invasion by inhibiting miR-619–5p activity and facilitating HDAC3 expression. *J. Cell Physiol.* **234**, 18688–18696 (2019).
303. Bayat, S. et al. Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells. *J. Cell Biochem.* **120**, 9172–9180 (2019).
304. Lucas, J. et al. Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF-κB signaling. *Int. J. Oncol.* **53**, 1469–1480 (2018).
305. Kang, Y. et al. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. *Cell Death Dis.* **5**, e1476 (2014).
306. Vanaja, G. R., Ramulu, H. G. & Kalle, A. M. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6. *Cell Commun. Signal.* **16**, 20 (2018).
307. Wang, Z. T. et al. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells. *Cell Signal.* **28**, 506–515 (2016).
308. Wu, S. et al. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. *Biol. Chem.* **397**, 75–83 (2016).
309. Halkidou, K. et al. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. *Eur. Urol.* **45**, 382–389 (2004).
310. Wang, B. et al. A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382. *Oncogenesis* **7**, 54 (2018).
311. Wei, J. Y. et al. Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. *J. Pineal Res.* **58**, 429–438 (2015).
312. Cao, C. et al. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. *Int. J. Cancer* **143**, 1388–1401 (2018).
313. Liu, C. et al. Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer. *Int. J. Oncol.* **50**, 2079–2090 (2017).
314. Sun, S. et al. HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation. *Cell Death Dis.* **9**, 929 (2018).
315. Won, H. R. et al. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells. *Mol. Carcinog.* **57**, 1383–1395 (2018).
316. Wang, Z., Hu, P., Tang, F. & Xie, C. HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells. *Med. Oncol.* **33**, 50 (2016).
317. Seidel, C. et al. 4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer. *Biochem. Pharmacol.* **99**, 31–52 (2016).
318. Witt, A. E. et al. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. *Oncogene* **36**, 1707–1720 (2017).
319. Wu, M. Y. et al. MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. *Cancer Lett.* **354**, 311–319 (2014).
320. Miremadi, A., Oestergaard, M. Z., Pharoah, P. D. & Caldas, C. Cancer genetics of epigenetic genes. *Hum. Mol. Genet.* **16**, R28–R49 (2007).
321. Salgado, E. et al. HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206. *Biochem Biophys. Res. Commun.* **503**, 1087–1091 (2018).
322. Okudela, K. et al. Expression of HDAC9 in lung cancer-potential role in lung carcinogenesis. *Int. J. Clin. Exp. Pathol.* **7**, 213–220 (2014).
323. Yang, Y. et al. HDAC10 promotes lung cancer proliferation via AKT phosphorylation. *Oncotarget* **7**, 59388–59401 (2016).
324. Islam, M. M. et al. HDAC10 as a potential therapeutic target in ovarian cancer. *Gynecol. Oncol.* **144**, 613–620 (2017).
325. Qin, J. et al. Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression. *Sci. Rep.* **7**, 10592 (2017).
326. Santolla, M. F. et al. SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. *Cell Death Dis.* **6**, e1834 (2015).
327. Sun, L. et al. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. *J. Natl Cancer Inst.* **105**, 887–898 (2013).
328. Farooqi, A. S. et al. Novel lysine-based thioureas as mechanism-based inhibitors of Sirtuin 2 (SIRT2) with anticancer activity in a colorectal cancer murine model. *J. Med. Chem.* **62**, 4131–4141 (2019).
329. Hoffmann, G., Breitenbücher, F., Schuler, M. & Ehrenhofer-Murray, A. E. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. *J. Biol. Chem.* **289**, 5208–5216 (2014).

330. Li, Y. et al. SIRT2 promotes the migration and invasion of gastric cancer through RAS/ERK/JNK/MMP-9 pathway by increasing PEPCK1-related metabolism. *Neoplasia* **20**, 745–756 (2018).
331. Li, Z. et al. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation. *Oncotarget* **7**, 18927–18939 (2016).
332. Fiskus, W. et al. SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents. *Cancer Res.* **76**, 5467–5478 (2016).
333. Damodaran, S. et al. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. *BMC Cancer* **17**, 874 (2017).
334. Xiong, Y. et al. SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer. *J. Cancer Res. Clin. Oncol.* **144**, 189–198 (2018).
335. Wang, S. et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β 4/SNAI1/SIRT3 signaling pathway. *Oncogene* **37**, 4164–4180 (2018).
336. Wu, Y. et al. SIRT3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells. *Exp. Cell Res.* **367**, 137–149 (2018).
337. Quan, Y. et al. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway. *Oncotarget* **6**, 26494–26507 (2015).
338. Lee, D. Y. et al. Regulation of SIRT3 signal related metabolic reprogramming in gastric cancer by *Helicobacter pylori* oncoprotein CagA. *Oncotarget* **8**, 78365–78378 (2017).
339. Miyo, M. et al. Tumour-suppressive function of SIRT4 in human colorectal cancer. *Br. J. Cancer* **113**, 492–499 (2015).
340. Sun, H. et al. SIRT4 acts as a tumor suppressor in gastric cancer by inhibiting cell proliferation, migration, and invasion. *Onco Targets Ther.* **11**, 3959–3968 (2018).
341. Xu, L. et al. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer. *Oncol. Rep.* **39**, 2315–2323 (2018).
342. Shi, L. et al. SIRT5-mediated deacetylation of LDHB promotes autophagy and tumorigenesis in colorectal cancer. *Mol. Oncol.* **13**, 358–375 (2019).
343. Lu, W., Zuo, Y., Feng, Y. & Zhang, M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. *Tumour Biol.* **35**, 10699–10705 (2014).
344. Tang, Z. et al. CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer. *Cancer Sci.* **109**, 2590–2598 (2018).
345. Chen, X. F. et al. SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. *EMBO Rep.* **19**, e45124 (2018).
346. Liu, Y. et al. Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. *Protein Cell.* **4**, 702–710 (2013).
347. Bauer, I. et al. The NAD⁺-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca²⁺ responses. *J. Biol. Chem.* **287**, 40924–40937 (2012).
348. Bai, L. et al. Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway. *Oncotarget* **7**, 40377–40386 (2016).
349. Min, L. et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. *Nat. Cell Biol.* **14**, 1203–1211 (2012).
350. Thirumurthi, U. et al. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. *Sci. Signal.* **7**, ra71 (2014).
351. Han, Y. et al. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long noncoding RNA MALAT1. *FEBS Lett.* **23**, 3875–3882 (2013).
352. Yu, H. et al. Overexpression of sirt7 exhibits oncogenic property and serves as a prognostic factor in colorectal cancer. *Clin. Cancer Res.* **20**, 3434–3445 (2014).
353. Tang, M. et al. Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer. *Theranostics* **7**, 1346–1359 (2017).
354. Tang, X. et al. SIRT7 antagonizes TGF- β signaling and inhibits breast cancer metastasis. *Nat. Commun.* **8**, 318 (2017).
355. Jiang, Y., Han, Z., Wang, Y. & Hao, W. Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy. *Biochem Biophys. Res. Commun.* **506**, 266–271 (2018).
356. Deubzer, H. E. et al. HDAC11 is a novel drug target in carcinomas. *Int. J. Cancer* **132**, 2200–2208 (2013).
357. Gong, D., Zeng, Z., Yi, F. & Wu, J. Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis. *Am. J. Transl. Res.* **11**, 983–990 (2019).
358. Huang, R. et al. Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma. *Anticancer Drugs* **29**, 364–370 (2018).
359. Thole, T. M. et al. Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. *Cell Death Dis.* **8**, e2635 (2017).
360. Völkel, P. & Angrand, P. O. The control of histone lysine methylation in epigenetic regulation. *Biochimie* **89**, 1–20 (2007).
361. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat. Genet.* **44**, 251–253 (2012).
362. Fang, D. et al. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. *Elife* **7**, e36696 (2018).
363. Chan, K. M. et al. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo. *Cell Cycle* **12**, 2546–2552 (2013).
364. Lu, C. et al. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. *Science* **352**, 844–849 (2016).
365. Fang, D. et al. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. *Science* **352**, 1344–1348 (2016).
366. Chuikov, S. et al. Regulation of p53 activity through lysine methylation. *Nature* **432**, 353–360 (2004).
367. Kouskouti, A. et al. Gene-specific modulation of TAF10 function by SET9-mediated methylation. *Mol. Cell.* **14**, 175–182 (2004).
368. Vagin, V. V. et al. Proteomic analysis of murine Piwi proteins reveals a role for arginine methylation in specifying interaction with Tudor family members. *Genes Dev.* **23**, 1749–1762 (2009).
369. Frederiks, F., Stulemeijer, I. J., Ovaas, H. & van Leeuwen, F. A modified epigenetics toolbox to study histone modifications on the nucleosome core. *Chembiochem* **12**, 308–313 (2011).
370. Min, J. et al. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. *Cell* **112**, 711–723 (2003).
371. Rea, S. et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature* **406**, 593–599 (2000).
372. Zhang, X. et al. Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase. *Cell* **111**, 117–127 (2002).
373. Cao, R. & Zhang, Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. *Mol. Cell.* **15**, 57–67 (2004).
374. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. *Nature* **469**, 343–349 (2011).
375. Kuzmichev, A., Jenuwein, T., Tempst, P. & Reinberg, D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. *Mol. Cell.* **14**, 183–193 (2004).
376. Spellmon, N. et al. Structure and function of SET and MYND domain-containing proteins. *Int. J. Mol. Sci.* **16**, 1406–1428 (2015).
377. Derunes, C. et al. Characterization of the PR domain of RIZ1 histone methyltransferase. *Biochem Biophys. Res. Commun.* **333**, 925–934 (2005).
378. Hayashi, K., Yoshida, K. & Matsui, Y. A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. *Nature* **438**, 374–378 (2005).
379. Davis, C. A. et al. PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells. *Mol. Cell Biol.* **26**, 2626–2636 (2006).
380. Gyory, I. et al. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. *Nat. Immunol.* **5**, 299–308 (2004).
381. Johnson, W. L. et al. RNA-dependent stabilization of SUV39H1 at constitutive heterochromatin. *Elife* **6**, e25299 (2017).
382. Hashimoto, H., Vertino, P. M. & Cheng, X. Molecular coupling of DNA methylation and histone methylation. *Epigenomics* **2**, 657–669 (2010).
383. Jurkowska, R. Z. et al. H3K14ac is linked to methylation of H3K9 by the triple Tudor domain of SETDB1. *Nat. Commun.* **8**, 2057 (2017).
384. Bantignies, F., Goodman, R. H. & Smolik, S. M. Functional interaction between the coactivator *Drosophila* CREB-binding protein and ASH1, a member of the trithorax group of chromatin modifiers. *Mol. Cell Biol.* **20**, 9317–9330 (2000).
385. Katsanis, N., Yaspo, M. L. & Fisher, E. M. Identification and mapping of a novel human gene, HRMT1L1, homologous to the rat protein arginine N-methyltransferase 1 (PRMT1) gene. *Mamm. Genome* **8**, 526–529 (1997).
386. Meyer, R., Wolf, S. S. & Obendorf, M. PRMT2, a member of the protein arginine methyltransferase family, is a coactivator of the androgen receptor. *J. Steroid Biochem. Mol. Biol.* **107**, 1–14 (2007).
387. Herrmann, F. et al. Human protein arginine methyltransferases in vivo-distinct properties of eight canonical members of the PRMT family. *J. Cell Sci.* **122**, 667–677 (2009).
388. Cook, J. R. et al. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. *Biochem Biophys. Res. Commun.* **342**, 472–481 (2006).
389. Slany, R. K. The molecular biology of mixed lineage leukemia. *Haematologica* **94**, 984–993 (2009).
390. Okada, Y. et al. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. *Nat. Cell Biol.* **8**, 1017–1024 (2006).
391. Berni, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. *Cancer Cell* **20**, 66–78 (2011).

392. Chase, A. & Cross, N. C. Aberrations of EZH2 in cancer. *Clin. Cancer Res.* **17**, 2613–2618 (2011).
393. Takawa, M. et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. *Cancer Sci.* **102**, 1298–1305 (2011).
394. Bannister, A. J. et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature* **410**, 120–124 (2001).
395. Wysocka, J. et al. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. *Cell* **121**, 859–872 (2005).
396. Shi, X. et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. *Nature* **442**, 96–99 (2006).
397. Flanagan, J. F. et al. Double chromodomains cooperate to recognize the methylated histone H3 tail. *Nature* **438**, 1181–1185 (2005).
398. Migliori, V. et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. *Nat. Struct. Mol. Biol.* **19**, 136–144 (2012).
399. Trojer, P. et al. L3MBTL1, a histone-methylation-dependent chromatin lock. *Cell* **129**, 915–928 (2007).
400. Adams-Cioaba, M. A. & Min, J. Structure and function of histone methylation binding proteins. *Biochem Cell Biol.* **87**, 93–105 (2009).
401. Lan, F. et al. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. *Nature* **448**, 718–722 (2007).
402. Ooi, S. K. et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. *Nature* **448**, 714–717 (2007).
403. Lee, J., Thompson, J. R., Botuyan, M. V. & Mer, G. Distinct binding modes specify the recognition of methylated histones H3K4 and H4K20 by JMJD2A-tudor. *Nat. Struct. Mol. Biol.* **15**, 109–111 (2008).
404. Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. *Nature* **437**, 436–439 (2005).
405. Tsukada, Y. et al. Histone demethylation by a family of JmjC domain-containing proteins. *Nature* **439**, 811–816 (2006).
406. Chang, B., Chen, Y., Zhao, Y. & Bruick, R. K. JMJD6 is a histone arginine demethylase. *Science* **318**, 444–447 (2007).
407. Wang, Y. et al. Human PAD4 regulates histone arginine methylation levels via demethyliminium. *Science* **306**, 279–283 (2004).
408. Schulte, J. H. et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. *Cancer Res.* **69**, 2065–2071 (2009).
409. Ciccone, D. N. et al. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. *Nature* **461**, 415–418 (2009).
410. Pedersen, M. T. & Helin, K. Histone demethylases in development and disease. *Trends Cell Biol.* **20**, 662–671 (2010).
411. Wagner, K. W. et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. *J. Clin. Invest.* **123**, 5231–5246 (2013).
412. Tzatsos, A. et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. *J. Clin. Invest.* **123**, 727–739 (2013).
413. Tee, A. E. et al. The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. *Oncotarget* **5**, 1793–1804 (2014).
414. Osawa, T. et al. Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor-associated macrophages. *Cancer Res.* **73**, 3019–3028 (2013).
415. Wang, J. et al. Epigenetic regulation of miR-302 by JMJD1C inhibits neural differentiation of human embryonic stem cells. *J. Biol. Chem.* **289**, 2384–2395 (2014).
416. Wang, L. et al. Novel somatic and germline mutations in intracranial germ cell tumours. *Nature* **511**, 241–245 (2014).
417. Cloos, P. A. et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. *Nature* **442**, 307–311 (2006).
418. Wang, J. K. et al. The histone demethylase UTX enables RB-dependent cell fate control. *Genes Dev.* **24**, 327–332 (2010).
419. Agger, K. et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. *Genes Dev.* **23**, 1171–1176 (2009).
420. Lee, K. H. et al. PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer. *Oncogene* **34**, 2897–2909 (2015).
421. Cai, M. et al. Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer. *J. Cell Mol. Med.* **22**, 4721–4731 (2018).
422. Yu, T. et al. Metformin inhibits Suv39H1-mediated migration of prostate cancer cells. *Oncogenesis* **6**, e324 (2017).
423. Mo, W. et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating Suv39H1 in BRCA-proficient triple-negative breast cancer. *Clin. Cancer Res.* **22**, 1699–1712 (2016).
424. Pandey, M. et al. Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control. *Toxicol. Appl. Pharmacol.* **280**, 296–304 (2014).
425. Kang, M. Y. et al. Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer. *Int J. Cancer* **121**, 2192–2197 (2007).
426. Yang, Z. et al. The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells. *Clin. Cancer Res.* **23**, 6673–6685 (2017).
427. Khanal, P. et al. Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer. *FASEB J.* **27**, 4606–4618 (2013).
428. Rodrigues, C. et al. A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells. *Exp. Cell Res.* **378**, 206–216 (2019).
429. Shuai, W. et al. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLT1 promoter. *Cancer Lett.* **422**, 56–69 (2018).
430. Yoon, K. A. et al. Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. *Carcinogenesis* **27**, 2217–2222 (2006).
431. Nishikawaji, T. et al. Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer. *Oncotarget* **7**, 67251–67265 (2016).
432. Wang, Y. F. et al. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. *Nat. Commun.* **8**, 274 (2017).
433. Tian, Y. F. et al. Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. *Am. J. Cancer Res.* **8**, 1812–1822 (2018).
434. Cui, J. et al. EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells. *Cancer Cell Int.* **15**, 4 (2015).
435. Ezponda, T. et al. The histone methyltransferase MME1/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. *Oncogene* **32**, 2882–2890 (2013).
436. Ryu, T. Y. et al. SETDB1 regulates SMAD7 expression for breast cancer metastasis. *BMB Rep.* **52**, 139–144 (2019).
437. Chen, K. et al. Histone methyltransferase SETDB1 promotes the progression of colorectal cancer by inhibiting the expression of TP53. *J. Cancer* **8**, 3318–3330 (2017).
438. Wong, C. M. et al. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. *Hepatology* **63**, 474–487 (2016).
439. Fei, Q. et al. Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. *Nat. Commun.* **6**, 8651 (2015).
440. Wu, P. C. et al. H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis. *Cancer Res.* **74**, 7333–7343 (2014).
441. Zhu, Q. et al. The Wnt-driven Mll1 epigenome regulates salivary gland and head and neck cancer. *Cell Rep.* **26**, 415–428.e5 (2019).
442. Lu, C. et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. *J. Natl Cancer Inst.* **109**, djw283 (2017).
443. Yang, Z. et al. Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells. *Eur. Urol.* **71**, 8–12 (2017).
444. Augert, A. et al. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). *J. Thorac. Oncol.* **12**, 704–713 (2017).
445. Chen, J. et al. Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion. *Mol. Cell Biol.* **30**, 5621–5635 (2010).
446. Xia, M. et al. Downregulation of MLL3 in esophageal squamous cell carcinoma is required for the growth and metastasis of cancer cells. *Tumour Biol.* **36**, 605–613 (2015).
447. Kim, J. H. et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. *Cancer Res.* **74**, 1705–1717 (2014).
448. Gallo, M. et al. MLL5 orchestrates a cancer self-renewal state by repressing the histone variant H3.3 and globally reorganizing chromatin. *Cancer Cell.* **28**, 715–729 (2015).
449. Li, T. et al. SET1A cooperates with CUDR to promote liver cancer growth and hepatocyte-like stem cell malignant transformation epigenetically. *Mol. Ther.* **24**, 261–275 (2016).
450. Karakashev, S. et al. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. *Nat. Commun.* **9**, 631 (2018).
451. Crea, F. et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. *Ann. Oncol.* **23**, 1207–1213 (2012).
452. Reijm, E. A. et al. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. *Ann. Oncol.* **25**, 2185–2190 (2014).

453. Kanu, N. et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. *Oncogene* **34**, 5699–5708 (2015).
454. Kim, I. K. et al. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. *Oncogene* **38**, 180–193 (2019).
455. Li, N. et al. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. *J. Clin. Invest.* **127**, 1284–1302 (2017).
456. Li, J. et al. MiR-2392 suppresses metastasis and epithelial-mesenchymal transition by targeting MAML3 and WHSC1 in gastric cancer. *FASEB J.* **31**, 3774–3786 (2017).
457. Saloura, V. et al. WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. *Sci. Rep.* **7**, 40664 (2017).
458. Chiou, S. H. et al. BLIMP1 induces transient metastatic heterogeneity in pancreatic cancer. *Cancer Discov.* **7**, 1184–1199 (2017).
459. Sciortino, M. et al. Dysregulation of Blimp1 transcriptional repressor unleashes p130Cas/ErbB2 breast cancer invasion. *Sci. Rep.* **7**, 1145 (2017).
460. Zhu, Z. et al. Downregulation of PRDM1 promotes cellular invasion and lung cancer metastasis. *Tumour Biol.* **39**, 1010428317695929 (2017).
461. Kang, H. B. et al. PRDM1, a tumor-suppressor gene, is induced by genkwa-daphnin in human colon cancer SW620 cells. *J. Cell Biochem.* **117**, 172–179 (2016).
462. Emterling, A., Wallin, A., Arbman, G. & Sun, X. F. Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer. *Ann. Oncol.* **15**, 242–246 (2004).
463. Abbondanza, C. et al. Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines. *J. Cell Physiol.* **227**, 964–975 (2012).
464. Nanjundan, M. et al. Amplification of MDS1/EV1 and EV11, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. *Cancer Res.* **67**, 3074–3084 (2007).
465. Lu, Y. et al. EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemo-/radioresistance in nasopharyngeal carcinoma. *J. Exp. Clin. Cancer Res.* **38**, 82 (2019).
466. Taniguchi, H. et al. Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer. *Oncotarget* **8**, 46856–46874 (2017).
467. Watanabe, Y. et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. *Clin. Cancer Res.* **13**, 4786–4794 (2007).
468. Houle, A. A. et al. Aberrant PRDM9 expression impacts the pan-cancer genomic landscape. *Genome Res.* **28**, 1611–1620 (2018).
469. Ruark, E. et al. Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. *Nat. Genet.* **45**, 686–689 (2013).
470. Moriya, C. et al. Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice. *Carcinogenesis* **38**, 638–648 (2017).
471. Takahata, M. et al. SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. *J. Biol. Chem.* **284**, 3334–3344 (2009).
472. Reynold, N. et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. *Genes Dev.* **30**, 772–785 (2016).
473. Komatsu, S. et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. *Br. J. Cancer* **112**, 357–364 (2015).
474. Sarris, M. E. et al. Smyd3 is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development. *Cancer Cell.* **29**, 354–366 (2016).
475. Cock-Rada, A. M. et al. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. *Cancer Res.* **72**, 810–820 (2012).
476. Fenizia, C. et al. SMYD3 promotes the epithelial-mesenchymal transition in breast cancer. *Nucleic Acids Res.* **47**, 1278–1293 (2018).
477. Hu, L., Zhu, Y. T., Qi, C. & Zhu, Y. J. Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. *Cancer Res.* **69**, 4067–4072 (2009).
478. Kryczek, I. et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. *Immunity* **40**, 772–784 (2014).
479. Cho, M. H. et al. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. *Nat. Commun.* **6**, 7821 (2015).
480. Liu, B. et al. MiR-502/SET8 regulatory circuit in pathobiology of breast cancer. *Cancer Lett.* **376**, 259–267 (2016).
481. Yang, S. et al. Association of miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. *Acta Biochim Biophys. Sin.* **46**, 149–154 (2014).
482. Tryndyak, V. P., Kovalchuk, O. & Pogribny, I. P. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. *Cancer Biol. Ther.* **5**, 65–70 (2006).
483. Martín-Morales, L. et al. SETD6 dominant negative mutation in familial colorectal cancer type X. *Hum. Mol. Genet.* **26**, 4481–4493 (2017).
484. Yao, R. et al. Lysines 207 and 325 methylation of WDR5 catalyzed by SETD6 promotes breast cancer cell proliferation and migration. *Oncol. Rep.* **40**, 3069–3077 (2018).
485. Shen, C. et al. SET7/9 regulates cancer cell proliferation by influencing β -catenin stability. *FASEB J.* **29**, 4313–4323 (2015).
486. Gu, Y. et al. Opposite effects of SET7/9 on apoptosis of human acute myeloid leukemia cells and lung cancer cells. *J. Cancer* **8**, 2069–2078 (2017).
487. Montenegro, M. F. et al. Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis. *Oncogene* **35**, 6143–6152 (2016).
488. Liu, L. M. et al. Methylation of C/EBP α by PRMT1 inhibits its tumor suppressive function in breast cancer. *Cancer Res.* **79**, 2865–2877 (2019).
489. Avasara, S. et al. PRMT1 is a novel regulator of epithelial-mesenchymal-transition in non-small cell lung cancer. *J. Biol. Chem.* **290**, 13479–13489 (2015).
490. Mathioudaki, K. et al. The PRMT1 gene expression pattern in colon cancer. *Br. J. Cancer* **99**, 2094–2099 (2008).
491. Lin, Z. et al. Overexpressing PRMT1 inhibits proliferation and invasion in pancreatic cancer by inverse correlation of ZEB1. *IUBMB Life.* **70**, 1032–1039 (2018).
492. Zhong, J. et al. PRMT2 β , a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells. *Oncol. Rep.* **38**, 1303–1311 (2017).
493. Al-Dhaheer, M. et al. CARM1 is an important determinant of ER α -dependent breast cancer cell differentiation and proliferation in breast cancer cells. *Cancer Res.* **71**, 2118–2128 (2011).
494. Zhong, X. Y. et al. CARM1 methylates GAPDH to regulate glucose metabolism and is suppressed in liver cancer. *Cell Rep.* **24**, 3207–3223 (2018).
495. Wang, Y. P. et al. Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. *Mol. Cell.* **64**, 673–687 (2016).
496. Rengasamy, M. et al. The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. *Nucleic Acids Res.* **45**, 11106–11120 (2017).
497. Fu, T., Lv, X., Kong, Q. & Yuan, C. A novel SHARPIN-PRMT5-H3R2me1 axis is essential for lung cancer cell invasion. *Oncotarget* **8**, 54809–54820 (2017).
498. Demetriadou, C. et al. NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression. *Cell Death Dis.* **10**, 236 (2019).
499. Huang, S. et al. CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. *Theranostics* **8**, 2549–2564 (2018).
500. Almeida-Rios, D. et al. Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. *Oncotarget* **7**, 53018–53028 (2016).
501. Okuno, K. et al. Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression. *Carcinogenesis* **40**, 15–26 (2019).
502. Chan, L. H. et al. PRMT6 regulates RAS/RAF binding and MEK/ERK-mediated cancer stemness activities in hepatocellular carcinoma through CRAF methylation. *Cell Rep.* **25**, 690–701.e8 (2018).
503. Cheng, D. et al. PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2. *Onco. Targets Ther.* **11**, 4869–4876 (2018).
504. Yao, R. et al. PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer. *Cancer Res.* **74**, 5656–5667 (2014).
505. Hernandez, S. J., Dolivo, D. M. & Dominko, T. PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancer. *Oncol. Lett.* **13**, 1983–1989 (2017).
506. Bagger, S. O. et al. Aggressiveness of non-EMT breast cancer cells relies on FBXO11 activity. *Mol. Cancer* **17**, 171 (2018).
507. Lee, Y. H. & Ann, D. K. Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: potential roles of HP1 and chromatin structure in tumorigenesis. *J. Nat. Sci.* **1**, e127 (2015).
508. Shenoy, T. R. et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. *Ann. Oncol.* **28**, 1495–1507 (2017).
509. Rodrigues, L. U. et al. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. *Cancer Res.* **75**, 1021–1034 (2015).
510. Pan, L., Tang, Z., Pan, L. & Tang, R. miR-3666 inhibits lung cancer cell proliferation, migration and invasion by targeting BPTF. *Biochem Cell Biol.* **97**, 415–422 (2018).
511. Zhao, X. et al. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits. *Redox Biol.* **20**, 427–441 (2019).
512. Zeng, H. et al. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. *Breast Cancer Res. Treat.* **133**, 127–135 (2012).

513. Kumamoto, K. et al. ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression. *Int J. Cancer* **125**, 1306–1315 (2009).
514. Okano, T. et al. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. *Oncol. Rep.* **15**, 545–549 (2006).
515. Li, Y. et al. RNA splicing of the BHC80 gene contributes to neuroendocrine prostate cancer progression. *Eur. Urol.* **76**, 157–166 (2019).
516. Li, L. et al. JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI. *Breast Cancer Res.* **16**, R56 (2014).
517. Kim, T. D. et al. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. *J. Cell Biochem.* **113**, 1368–1376 (2012).
518. Kauffman, E. C. et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. *Mol. Carcinog.* **50**, 931–944 (2011).
519. Cao, C. et al. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. *Oncogene* **36**, 133–145 (2017).
520. Stewart, C. A. & Byers, L. A. Altering the course of small cell lung cancer: targeting cancer stem cells via LSD1 inhibition. *Cancer Cell.* **28**, 4–6 (2015).
521. Liang, Y. et al. LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression. *Cancer Res.* **77**, 5479–5490 (2017).
522. Wang, Y. et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. *Cell* **138**, 660–672 (2009).
523. Chen, L. et al. Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. *Oncotarget* **8**, 81737–81753 (2017).
524. Chen, J. Y. et al. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. *Oncogenesis* **6**, e369 (2017).
525. Kong, Y. et al. RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A. *Cancer Lett.* **381**, 138–148 (2016).
526. Dhar, S. S. et al. Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. *J. Biol. Chem.* **289**, 7483–7496 (2014).
527. Zacharopoulou, N. et al. The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells. *Biochim Biophys. Acta Mol. Cell Res.* **1865**, 587–597 (2018).
528. Kottakis, F. et al. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells. *Cancer Res.* **74**, 3935–3946 (2014).
529. Peng, K. et al. Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/ β -catenin signaling. *J. Biol. Chem.* **293**, 10606–10619 (2018).
530. Ramadoss, S. et al. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. *Oncogene* **36**, 6508 (2017).
531. Wade, M. A. et al. The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. *Nucleic Acids Res.* **43**, 196–207 (2015).
532. Cai, Y., Fu, X. & Deng, Y. Histone demethylase JMJD1C regulates esophageal cancer proliferation via YAP1 signaling. *Am. J. Cancer Res.* **7**, 115–124 (2017).
533. Chen, C. et al. Downregulation of histone demethylase JMJD1C inhibits colorectal cancer metastasis through targeting ATF2. *Am. J. Cancer Res.* **8**, 852–865 (2018).
534. An, J. et al. Histone H3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372. *Oncotarget* **8**, 49093–49109 (2017).
535. Wang, W. et al. KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer. *J. Exp. Med.* **215**, 2833–2849 (2018).
536. Zhao, L. et al. JMJD2B promotes epithelial-mesenchymal transition by cooperating with β -catenin and enhances gastric cancer metastasis. *Clin. Cancer Res.* **19**, 6419–6429 (2013).
537. Fu, L. N. et al. Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms. *Oncogene* **37**, 389–402 (2018).
538. Luo, W. et al. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. *Proc. Natl Acad. Sci. USA* **109**, E3367–E3376 (2012).
539. An, Y. et al. circZMYM2 competed endogenously with miR-335-5p to regulate JMJD2C in pancreatic cancer. *Cell Physiol. Biochem.* **51**, 2224–2236 (2018).
540. Peng, K. et al. Histone demethylase JMJD2D interacts with β -catenin to induce transcription and activate colorectal cancer cell proliferation and tumor growth in mice. *Gastroenterology* **156**, 1112–1126 (2019).
541. Yang, G. J. et al. Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a Rhodium(III) complex for triple-negative breast cancer therapy. *Angew. Chem. Int. Ed. Engl.* **57**, 13091–13095 (2018).
542. Uemura, M. et al. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. *Clin. Cancer Res.* **16**, 4636–4646 (2010).
543. Hayami, S. et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. *Mol. Cancer* **9**, 59 (2010).
544. Li, N. & Jiang, D. Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer. *Biomed. Pharmacother.* **89**, 305–315 (2017).
545. Lin, H. et al. KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABC1. *Biomed. Pharmacother.* **107**, 1205–1209 (2018).
546. Shen, X. et al. KDM5D inhibit epithelial-mesenchymal transition of gastric cancer through demethylation in the promoter of Cul4A in male. *J. Cell Biochem.* **120**, 12247–12258 (2019).
547. Komura, K. et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. *Proc. Natl Acad. Sci. USA* **113**, 6259–6264 (2016).
548. Zhu, X. X. et al. Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer. *Oncotarget* **8**, 24483–24490 (2017).
549. Tange, S. et al. JARID2 is involved in transforming growth factor-beta-induced epithelial-mesenchymal transition of lung and colon cancer cell lines. *PLoS ONE* **9**, e115684 (2014).
550. Paccet, J. D. et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl. *Oncogenesis* **8**, 14 (2019).
551. Ler, L. D. et al. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. *Sci. Transl. Med* **9**, eaai8312 (2017).
552. Andricovich, J. et al. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. *Cancer Cell.* **33**, 512–526.e8 (2018).
553. Mo, J. et al. Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis. *Nanoscale* **9**, 13142–13152 (2017).
554. Wang, W. et al. KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K/AKT inhibitor treatment in breast cancer. *Mol. Cancer Ther.* **17**, 1973–1983 (2018).
555. Ahn, J. et al. Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer. *Oncotarget* **7**, 63252–63260 (2016).
556. Lee, K. H. et al. Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer. *Int J. Cancer* **143**, 2849–2861 (2018).
557. Björkman, M. et al. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. *Oncogene* **31**, 3444–3456 (2012).
558. Li, S. et al. Histone demethylase PHF8 promotes progression and metastasis of gastric cancer. *Am. J. Cancer Res.* **7**, 448–461 (2017).
559. Shen, Y., Pan, X. & Zhao, H. The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer. *Biochem Biophys. Res. Commun.* **451**, 119–125 (2014).
560. Zhao, Z. et al. Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer. *Int J. Clin. Exp. Pathol.* **8**, 10325–10334 (2015).
561. Hsia, D. A. et al. KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. *Proc. Natl Acad. Sci. USA* **107**, 9671–9676 (2010).
562. Abu-Jamous, B., Buffa, F. M., Harris, A. L. & Nandi, A. K. In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer. *Mol. Cancer* **16**, 105 (2017).
563. Liu, Y. et al. JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity. *Oncogene* **38**, 980–997 (2019).
564. Lee, Y. F. et al. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. *Breast Cancer Res.* **14**, R85 (2012).
565. Zhang, Z., Yang, Y. & Zhang, X. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/ β -catenin pathway in non-small cell lung cancer. *Life Sci.* **188**, 163–171 (2017).
566. Chang, X. et al. Investigating the pathogenic role of PADI4 in oesophageal cancer. *Int J. Biol. Sci.* **7**, 769–781 (2011).
567. Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc. Natl Acad. Sci. USA* **101**, 2999–3004 (2004).
568. Kasinski, A. L. & Slack, F. J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. *Nat. Rev. Cancer* **11**, 849–864 (2011).
569. García, A. I. et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. *EMBO Mol. Med.* **3**, 279–290 (2011).

570. Friedman, J. M. et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. *Cancer Res.* **69**, 2623–2629 (2009).
571. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. *Science* **322**, 1695–1699 (2008).
572. Fabbri, M. et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proc. Natl Acad. Sci. USA* **104**, 15805–15810 (2007).
573. Yang, L. et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. *Nature* **500**, 598–602 (2013).
574. He, Y. et al. Long noncoding RNAs: Novel insights into hepatocellular carcinoma. *Cancer Lett.* **344**, 20–27 (2014).
575. Kim, K. et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. *Oncogene* **32**, 1616–1625 (2013).
576. Kogo, R. et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. *Cancer Res.* **71**, 6320–6326 (2011).
577. Nakagawa, T. et al. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. *Biochem Biophys. Res. Commun.* **436**, 319–324 (2013).
578. Gius, D. et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. *Cancer Cell.* **6**, 361–371 (2004).
579. Li, E., Bestor, T. H. & Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* **69**, 915–926 (1992).
580. Jackson-Grusby, L. et al. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. *Nat. Genet.* **27**, 31–39 (2001).
581. Carr, B. I. et al. The tumorigenicity of 5-azacytidine in the male Fischer rat. *Carcinogenesis* **5**, 1583–1590 (1984).
582. Christman, J. K. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. *Oncogene* **21**, 5483–5495 (2002).
583. Jones, P. A. & Laird, P. W. Cancer epigenetics comes of age. *Nat. Genet.* **21**, 163–167 (1999).
584. Rosen, M. B., House, H. S., Francis, B. M. & Chernoff, N. Teratogenicity of 5-azacytidine in the Sprague-Dawley rat. *J. Toxicol. Environ. Health* **29**, 201–210 (1990).
585. Doerksen, T. & Trasler, J. M. Developmental exposure of male germ cells to 5-azacytidine results in abnormal preimplantation development in rats. *Biol. Reprod.* **55**, 1155–1162 (1996).
586. Chik, F. & Szyf, M. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. *Carcinogenesis* **32**, 224–232 (2011).
587. Issa, J. P. et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood* **103**, 1635–1640 (2004).
588. Beisler, J. A., Abbasi, M. M., Kelley, J. A. & Driscoll, J. S. Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine. *J. Med. Chem.* **20**, 806–812 (1977).
589. Present, C. A., Coulter, D., Valeriote, F. & Vietti, T. J. Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice. *J. Natl Cancer Inst.* **66**, 1151–1154 (1981).
590. Curt, G. A. et al. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). *Cancer Res.* **45**, 3359–3363 (1985).
591. Cheng, J. C. et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. *J. Natl Cancer Inst.* **95**, 399–409 (2003).
592. Holleran, J. L. et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. *Clin. Cancer Res.* **11**, 3862–3868 (2005).
593. Kaminskas, E. et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. *Clin. Cancer Res.* **11**, 3604–3608 (2005).
594. Steensma, D. P. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. *Leuk. Res.* **33**(Suppl 2), S12–S17 (2009).
595. Liang, G. et al. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. *Cancer Res.* **62**, 961–966 (2002).
596. Brueckner, B. et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. *Cancer Res.* **65**, 6305–6311 (2005).
597. Piña, I. C. et al. Psammoplins from the sponge *Pseudoceratina purpurea*: inhibition of both histone deacetylase and DNA methyltransferase. *J. Org. Chem.* **68**, 3866–3873 (2003).
598. Fang, M. Z. et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res.* **63**, 7563–7570 (2003).
599. Cornacchia, E. et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. *J. Immunol.* **140**, 2197–2200 (1988).
600. Segura-Pacheco, B. et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. *Clin. Cancer Res.* **9**, 1596–1603 (2003).
601. Villar-Garea, A., Fraga, M. F., Espada, J. & Esteller, M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. *Cancer Res.* **63**, 4984–4989 (2003).
602. Davis, A. J. et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. *Invest N. Drugs* **21**, 85–97 (2003).
603. Amato, R. J. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. *Clin. Genitourin. Cancer* **5**, 422–426 (2007).
604. Plummer, R. et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. *Clin. Cancer Res.* **15**, 3177–3183 (2009).
605. Chuang, J. C. et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. *Mol. Cancer Ther.* **4**, 1515–1520 (2005).
606. Mutskov, V. & Felsenfeld, G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. *EMBO J.* **23**, 138–149 (2004).
607. Lau, O. D. et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. *Mol. Cell.* **5**, 589–595 (2000).
608. Yang, C., Ngo, L. & Zheng, Y. G. Rational design of substrate-based multivalent inhibitors of the histone acetyltransferase Tip60. *ChemMedChem* **9**, 537–541 (2014).
609. Balasubramanyam, K., Swaminathan, V., Ranganathan, A. & Kundu, T. K. Small molecule modulators of histone acetyltransferase p300. *J. Biol. Chem.* **278**, 19134–19140 (2003).
610. Balasubramanyam, K. et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. *J. Biol. Chem.* **279**, 51163–51171 (2004).
611. Balasubramanyam, K. et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. *J. Biol. Chem.* **279**, 33716–33726 (2004).
612. Biel, M. et al. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. *Angew. Chem. Int. Ed. Engl.* **43**, 3974–3976 (2004).
613. Stimson, L. et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. *Mol. Cancer Ther.* **4**, 1521–1532 (2005).
614. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. *Nature* **468**, 1067–1073 (2010).
615. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. *Nature* **468**, 1119–1123 (2010).
616. Brand, M. et al. Small molecule inhibitors of bromodomain-acetyl-lysine interactions. *ACS Chem. Biol.* **10**, 22–39 (2015).
617. Romero, F. A. et al. Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors. *J. Med. Chem.* **59**, 1271–1298 (2016).
618. Xiang, Q. et al. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. *Eur. J. Med. Chem.* **147**, 238–252 (2018).
619. Theodoulou, N. H. et al. Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. *J. Med. Chem.* **59**, 1425–1439 (2016).
620. Vangamudi, B. et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. *Cancer Res.* **75**, 3865–3878 (2015).
621. Palmer, W. S. et al. Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor. *J. Med. Chem.* **59**, 1440–1454 (2016).
622. Picaud, S. et al. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. *Sci. Adv.* **2**, e1600760 (2016).
623. Riggs, M. G., Whittaker, R. G., Neumann, J. R. & Ingram, V. M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. *Nature* **268**, 462–464 (1977).
624. Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. *J. Biol. Chem.* **265**, 17174–17179 (1990).
625. Van Lint, C., Emiliani, S. & Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. *Gene Expr.* **5**, 245–253 (1996).

626. Fandy, T. E. et al. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. *Neoplasia* **7**, 646–657 (2005).
627. Fang, J. Y. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers. *J. Gastroenterol. Hepatol.* **20**, 988–994 (2005).
628. Singh, T. R., Shankar, S. & Srivastava, R. K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. *Oncogene* **24**, 4609–4623 (2005).
629. Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. *Nature* **401**, 188–193 (1999).
630. Richon, V. M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. *Proc. Natl Acad. Sci. USA* **95**, 3003–3007 (1998).
631. Jung, M. et al. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. *J. Med. Chem.* **42**, 4669–4679 (1999).
632. Kim, Y. B. et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. *Oncogene* **18**, 2461–2470 (1999).
633. Su, G. H., Sohn, T. A., Ryu, B. & Kern, S. E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. *Cancer Res.* **60**, 3137–3142 (2000).
634. Bressi, J. C. et al. Benzimidazole and imidazole inhibitors of histone deacetylases: synthesis and biological activity. *Bioorg. Med. Chem. Lett.* **20**, 3138–3141 (2010).
635. Ito, T. et al. Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. *Chem. Biol.* **18**, 495–507 (2011).
636. Suzuki, T. et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. *J. Med. Chem.* **42**, 3001–3003 (1999).
637. Kijima, M. et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. *J. Biol. Chem.* **268**, 22429–22435 (1993).
638. Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. *Cancer Res.* **62**, 4916–4921 (2002).
639. Lea, M. A., Randolph, V. M. & Patel, M. Increased acetylation of histones induced by diallyl disulfide and structurally related molecules. *Int J. Oncol.* **15**, 347–352 (1999).
640. Haggarty, S. J. et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc. Natl Acad. Sci. USA* **100**, 4389–4394 (2003).
641. Balasubramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. *Leukemia* **22**, 1026–1034 (2008).
642. Methot, J. L. et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). *Bioorg. Med. Chem. Lett.* **18**, 973–978 (2008).
643. Mann, B. S. et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. *Oncologist* **12**, 1247–1252 (2007).
644. Ropero, S. et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. *Nat. Genet.* **38**, 566–569 (2006).
645. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. *Cancer Cell.* **20**, 53–65 (2011).
646. Daigle, S. R. et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. *Blood* **122**, 1017–1025 (2013).
647. Basavapathruni, A. et al. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. *Biopharm. Drug Dispos.* **35**, 237–252 (2014).
648. Miranda, T. B. et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. *Mol. Cancer Ther.* **8**, 1579–1588 (2009).
649. Glazer, R. I. et al. 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. *Biochem Biophys. Res. Commun.* **135**, 688–694 (1986).
650. Qi, W. et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. *Proc. Natl Acad. Sci. USA* **109**, 21360–21365 (2012).
651. Verma, S. K. et al. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. *ACS Med. Chem. Lett.* **3**, 1091–1096 (2012).
652. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* **492**, 108–112 (2012).
653. Knutson, S. K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. *Nat. Chem. Biol.* **8**, 890–896 (2012).
654. Knutson, S. K. et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. *Mol. Cancer Ther.* **13**, 842–854 (2014).
655. Fiedorowicz, J. G. & Swartz, K. L. The role of monoamine oxidase inhibitors in current psychiatric practice. *J. Psychiatr. Pract.* **10**, 239–248 (2004).
656. Harris, W. J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. *Cancer Cell.* **21**, 473–487 (2012).
657. Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat. Med.* **18**, 605–611 (2012).
658. Liang, Y. et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. *MBio* **4**, e00558–00512 (2013).
659. Neelamegam, R. et al. Brain-penetrant LSD1 inhibitors can block memory consolidation. *ACS Chem. Neurosci.* **3**, 120–128 (2012).
660. Fiskus, W. et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. *Leukemia* **28**, 2155–2164 (2014).
661. Maes, T. et al. Advances in the development of histone lysine demethylase inhibitors. *Curr. Opin. Pharmacol.* **23**, 52–60 (2015).
662. Rose, N. R. et al. Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. *J. Med. Chem.* **55**, 6639–6643 (2012).
663. Tan, Y. et al. Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression. *Nat. Commun.* **5**, 4619 (2014).
664. Kruidenier, L. et al. A selective jumoni H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. *Nature* **488**, 404–408 (2012).
665. Heinemann, B. et al. Inhibition of demethylases by GSK-J1/J4. *Nature* **514**, E1–E2 (2014).



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019